US8008313B2 - Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases - Google Patents
Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases Download PDFInfo
- Publication number
- US8008313B2 US8008313B2 US11/509,921 US50992106A US8008313B2 US 8008313 B2 US8008313 B2 US 8008313B2 US 50992106 A US50992106 A US 50992106A US 8008313 B2 US8008313 B2 US 8008313B2
- Authority
- US
- United States
- Prior art keywords
- isopropyl
- methoxy
- phenoxy
- pyrimidine
- diamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 0 [1*]C1=C(CC2=C([6*])N([2H])=C([Y])N=C2C)C([5*])=C([4*])C([3*])=C1[2*] Chemical compound [1*]C1=C(CC2=C([6*])N([2H])=C([Y])N=C2C)C([5*])=C([4*])C([3*])=C1[2*] 0.000 description 17
- GAMDKVQHJGJOGM-UHFFFAOYSA-N CCC1=C(OC2=CN=C(N)N=C2N)C=C(C)C2=C1C=CS2 Chemical compound CCC1=C(OC2=CN=C(N)N=C2N)C=C(C)C2=C1C=CS2 GAMDKVQHJGJOGM-UHFFFAOYSA-N 0.000 description 3
- DFJFBWTXZLXBHA-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)(C)O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)(C)O DFJFBWTXZLXBHA-UHFFFAOYSA-N 0.000 description 3
- ZGFNLWIITGKBCO-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CN=CS1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CN=CS1 ZGFNLWIITGKBCO-UHFFFAOYSA-N 0.000 description 3
- AATPYXMXFBBKFO-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I AATPYXMXFBBKFO-UHFFFAOYSA-N 0.000 description 3
- VMBHTTKTCLZHQC-UHFFFAOYSA-N C=CC1=C(OC2=CN=C(N)N=C2N)C=C(OC)C(OC)=C1 Chemical compound C=CC1=C(OC2=CN=C(N)N=C2N)C=C(OC)C(OC)=C1 VMBHTTKTCLZHQC-UHFFFAOYSA-N 0.000 description 2
- OFPNUNGBABGIRX-UHFFFAOYSA-N CC(C)C1=C(CC2=CN=C(N)N=C2N)C=C(I)C(O)=C1 Chemical compound CC(C)C1=C(CC2=CN=C(N)N=C2N)C=C(I)C(O)=C1 OFPNUNGBABGIRX-UHFFFAOYSA-N 0.000 description 2
- DEWIBCJPHDNXTN-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=NC=CN=C2)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=NC=CN=C2)=C1 DEWIBCJPHDNXTN-UHFFFAOYSA-N 0.000 description 2
- XLGVLDCHNUEHJB-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C2C=CN(C)C2=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C2C=CN(C)C2=C1 XLGVLDCHNUEHJB-UHFFFAOYSA-N 0.000 description 2
- RUDQRCYUIAWNMY-LLVKDONJSA-N CCC1=C(OC2=CN=C(N[C@H](CC)CO)N=C2N)C=C(Cl)C(OC)=C1 Chemical compound CCC1=C(OC2=CN=C(N[C@H](CC)CO)N=C2N)C=C(Cl)C(OC)=C1 RUDQRCYUIAWNMY-LLVKDONJSA-N 0.000 description 2
- LXJOHWMGBARELU-UHFFFAOYSA-N CCNC(=O)NC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC Chemical compound CCNC(=O)NC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC LXJOHWMGBARELU-UHFFFAOYSA-N 0.000 description 2
- ZOFIPWPNFRQPJV-UHFFFAOYSA-N CCNC1=NC(NC(C)C)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1 Chemical compound CCNC1=NC(NC(C)C)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1 ZOFIPWPNFRQPJV-UHFFFAOYSA-N 0.000 description 2
- ULKPZOGEOWYWTI-UHFFFAOYSA-N CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(S(C)(=O)=O)=C2)C(N)=N1 Chemical compound CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(S(C)(=O)=O)=C2)C(N)=N1 ULKPZOGEOWYWTI-UHFFFAOYSA-N 0.000 description 2
- JXJXAABDQFTWOZ-NSHDSACASA-N CC[C@@H](CO)NC1=NC=C(OC2=C(C(C)C)C=C(OC)C(Br)=C2)C(N)=N1.Cl Chemical compound CC[C@@H](CO)NC1=NC=C(OC2=C(C(C)C)C=C(OC)C(Br)=C2)C(N)=N1.Cl JXJXAABDQFTWOZ-NSHDSACASA-N 0.000 description 2
- QMXWNJHFAYUIIW-LLVKDONJSA-N CNC(=O)OC[C@@H](C)NC1=NC=C(OC2=C(C(C)C)C=C(OC)C(Cl)=C2)C(N)=N1 Chemical compound CNC(=O)OC[C@@H](C)NC1=NC=C(OC2=C(C(C)C)C=C(OC)C(Cl)=C2)C(N)=N1 QMXWNJHFAYUIIW-LLVKDONJSA-N 0.000 description 2
- RMAGLOCZEPSYPM-UHFFFAOYSA-N COC1=C(C2=CC=C(Cl)S2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 Chemical compound COC1=C(C2=CC=C(Cl)S2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 RMAGLOCZEPSYPM-UHFFFAOYSA-N 0.000 description 2
- QMSUJJCLMIEGAR-UHFFFAOYSA-N COC1=C(C2=COC=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 Chemical compound COC1=C(C2=COC=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 QMSUJJCLMIEGAR-UHFFFAOYSA-N 0.000 description 2
- BXDKERQVHSVAEI-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1Br Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1Br BXDKERQVHSVAEI-UHFFFAOYSA-N 0.000 description 2
- JUEODSQEJGVBBZ-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(=O)N(C)C Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(=O)N(C)C JUEODSQEJGVBBZ-UHFFFAOYSA-N 0.000 description 2
- HSPKZHMIHXRIOT-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)=O HSPKZHMIHXRIOT-UHFFFAOYSA-N 0.000 description 2
- SXAAXDVCLIWUTC-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)C Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)C SXAAXDVCLIWUTC-UHFFFAOYSA-N 0.000 description 2
- QRFLXLOCJNJKEJ-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(N)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(N)=O QRFLXLOCJNJKEJ-UHFFFAOYSA-N 0.000 description 2
- XRCWMLVPRKTAQG-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NN=NN1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NN=NN1 XRCWMLVPRKTAQG-UHFFFAOYSA-N 0.000 description 2
- DKTXNZOXBDKCFO-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NOC=N1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NOC=N1 DKTXNZOXBDKCFO-UHFFFAOYSA-N 0.000 description 2
- OMPGYSFGCUXAEG-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N OMPGYSFGCUXAEG-UHFFFAOYSA-N 0.000 description 2
- KPZZADILSSDURZ-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1[N+](=O)[O-] Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1[N+](=O)[O-] KPZZADILSSDURZ-UHFFFAOYSA-N 0.000 description 2
- FKYPXQCVZVCRCL-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1[N+](=O)[O-] Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1[N+](=O)[O-] FKYPXQCVZVCRCL-UHFFFAOYSA-N 0.000 description 2
- CXZIPUMIEJQOQR-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC3=CC=C(F)C=C3)N=C2N)C=C1S(C)(=O)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC3=CC=C(F)C=C3)N=C2N)C=C1S(C)(=O)=O CXZIPUMIEJQOQR-UHFFFAOYSA-N 0.000 description 2
- MFYZPUDYTHXHNH-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC3CCS(=O)(=O)CC3)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC3CCS(=O)(=O)CC3)N=C2N)C=C1Cl MFYZPUDYTHXHNH-UHFFFAOYSA-N 0.000 description 2
- KYQZRTKJMCQWID-MFBUALDNSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N[C@@H](C)C34OCC(C)(CO3)CO4)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N[C@@H](C)C34OCC(C)(CO3)CO4)N=C2N)C=C1Cl KYQZRTKJMCQWID-MFBUALDNSA-N 0.000 description 2
- LJFVCFSJZYTGMT-SNVBAGLBSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N[C@H](C)CO)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N[C@H](C)CO)N=C2N)C=C1Cl LJFVCFSJZYTGMT-SNVBAGLBSA-N 0.000 description 2
- CQDMORXFTLGVHI-UHFFFAOYSA-N COC1=CC(C2CC2)=C(OC2=CN=C(N)N=C2N)C=C1Cl Chemical compound COC1=CC(C2CC2)=C(OC2=CN=C(N)N=C2N)C=C1Cl CQDMORXFTLGVHI-UHFFFAOYSA-N 0.000 description 2
- OFQRWHMOWMNXJA-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2N)=C(C(C)C)C=C1Cl Chemical compound COC1=CC(CC2=CN=C(N)N=C2N)=C(C(C)C)C=C1Cl OFQRWHMOWMNXJA-UHFFFAOYSA-N 0.000 description 2
- PYNPWUIBJMVRIG-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC PYNPWUIBJMVRIG-UHFFFAOYSA-N 0.000 description 2
- ABXCQRYAHHXQJS-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2NC2CCN(C)CC2)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2NC2CCN(C)CC2)=C(C(C)C)C=C1OC ABXCQRYAHHXQJS-UHFFFAOYSA-N 0.000 description 2
- BGKHLFYQGBXUAX-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2NCCO)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2NCCO)=C(C(C)C)C=C1OC BGKHLFYQGBXUAX-UHFFFAOYSA-N 0.000 description 2
- VCCLRENKLBEAQM-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC3=CC=CC=C3)N=C2NC2=CC=CC=C2)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC3=CC=CC=C3)N=C2NC2=CC=CC=C2)=C(C(C)C)C=C1OC VCCLRENKLBEAQM-UHFFFAOYSA-N 0.000 description 2
- KUBFILAHCWEJDB-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC3=NC=CC=N3)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC3=NC=CC=N3)N=C2N)=C(C(C)C)C=C1OC KUBFILAHCWEJDB-UHFFFAOYSA-N 0.000 description 2
- SMOCHEVFJLEVGL-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NCC(F)(F)F)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NCC(F)(F)F)N=C2N)=C(C(C)C)C=C1OC SMOCHEVFJLEVGL-UHFFFAOYSA-N 0.000 description 2
- KQJIFBXQLQMOHU-UHFFFAOYSA-N COC1=CC(CC2=CN=CN=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=CN=C2N)=C(C(C)C)C=C1OC KQJIFBXQLQMOHU-UHFFFAOYSA-N 0.000 description 2
- AQGFKKRQECIMDJ-UHFFFAOYSA-N COC1=CC(OC2=CN=C(NCC(F)(F)F)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(OC2=CN=C(NCC(F)(F)F)N=C2N)=C(C(C)C)C=C1OC AQGFKKRQECIMDJ-UHFFFAOYSA-N 0.000 description 2
- YEFZSBGKFAKVJU-UHFFFAOYSA-N COC1=CC=C(CNC2=NC(N)=NC=C2CC2=C(C(C)C)C=C(OC)C(OC)=C2)C=C1 Chemical compound COC1=CC=C(CNC2=NC(N)=NC=C2CC2=C(C(C)C)C=C(OC)C(OC)=C2)C=C1 YEFZSBGKFAKVJU-UHFFFAOYSA-N 0.000 description 2
- SQXXHAAEHMZGHD-UHFFFAOYSA-N COC1=CC=CC=C1COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I Chemical compound COC1=CC=CC=C1COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I SQXXHAAEHMZGHD-UHFFFAOYSA-N 0.000 description 2
- KSIDPKYHLJUIET-UHFFFAOYSA-N COCCNC1=NC(N)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1 Chemical compound COCCNC1=NC(N)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1 KSIDPKYHLJUIET-UHFFFAOYSA-N 0.000 description 2
- KOOXTXLDIPLJET-UHFFFAOYSA-N COCCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(OC)=C2)C(N)=N1 Chemical compound COCCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(OC)=C2)C(N)=N1 KOOXTXLDIPLJET-UHFFFAOYSA-N 0.000 description 2
- CVBKWCYQORDHBI-UHFFFAOYSA-N B.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)=O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)O.[NaH] Chemical compound B.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)=O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)O.[NaH] CVBKWCYQORDHBI-UHFFFAOYSA-N 0.000 description 1
- QOTSKLGCJIAWKH-YWUYNLNCSA-N BrBr.BrC1=CC(/C=N/C2CCCCC2)=CC2=C1OCCO2.BrC1=CC(/C=N/C2CCCCC2)=CC2=C1OCCO2.BrCCBr.CCC1=C(/C=N/C2CCCCC2)C=C(Br)C2=C1OCCO2.CCC1=C(C=O)C=C(Br)C2=C1OCCO2.CCC1=C(O)C=C(Br)C2=C1OCCO2.CCI.NC1CCCCC1.O=CC1=CC(O)=C(O)C(Br)=C1.O=CC1=CC(O)=C(O)C=C1.O=CC1=CC2=C(OCCO2)C(Br)=C1.[3H]S(=O)CC#N Chemical compound BrBr.BrC1=CC(/C=N/C2CCCCC2)=CC2=C1OCCO2.BrC1=CC(/C=N/C2CCCCC2)=CC2=C1OCCO2.BrCCBr.CCC1=C(/C=N/C2CCCCC2)C=C(Br)C2=C1OCCO2.CCC1=C(C=O)C=C(Br)C2=C1OCCO2.CCC1=C(O)C=C(Br)C2=C1OCCO2.CCI.NC1CCCCC1.O=CC1=CC(O)=C(O)C(Br)=C1.O=CC1=CC(O)=C(O)C=C1.O=CC1=CC2=C(OCCO2)C(Br)=C1.[3H]S(=O)CC#N QOTSKLGCJIAWKH-YWUYNLNCSA-N 0.000 description 1
- HOAUUXZRBIDGKR-UHFFFAOYSA-N BrBr.BrC1=CSC=C1.C.C.C.C.CCC(Br)C(=O)C1=CSC=C1.CCC(C(=O)CC(C)=O)C1=CSC=C1.CCC1=C(O)C=C(C)C2=C1C=CS2.CCC1=C(OC(C#N)C(N(C)C)N(C)C)C=C(C)C2=C1C=CS2.CCC1=C(OCC#N)C=C(C)C2=C1C=CS2.CCCC(=O)C1=CSC=C1.CCCC(=O)Cl.CCCC(=O)N(C)OC.CNOC.N#CCBr.[NaH] Chemical compound BrBr.BrC1=CSC=C1.C.C.C.C.CCC(Br)C(=O)C1=CSC=C1.CCC(C(=O)CC(C)=O)C1=CSC=C1.CCC1=C(O)C=C(C)C2=C1C=CS2.CCC1=C(OC(C#N)C(N(C)C)N(C)C)C=C(C)C2=C1C=CS2.CCC1=C(OCC#N)C=C(C)C2=C1C=CS2.CCCC(=O)C1=CSC=C1.CCCC(=O)Cl.CCCC(=O)N(C)OC.CNOC.N#CCBr.[NaH] HOAUUXZRBIDGKR-UHFFFAOYSA-N 0.000 description 1
- FUCSWBQFLSASRY-GYLCKTPQSA-N BrBr.CC(C)C1=C(Br)C=CC(O)=C1.CC(C)C1=CC=C(Br)C(O)=C1.CC(C)C1=CC=CC(O)=C1.CI.CO/C=C(\C#N)OC1=C(C(C)C)C=C(OC)C(Br)=C1.COC1=CC(C(C)C)=C(Br)C=C1.COC1=CC(C(C)C)=C(Br)C=C1C=O.COC1=CC(C(C)C)=C(Br)C=C1O.COC1=CC(C(C)C)=C(C=O)C=C1Br.COC1=CC(C(C)C)=C(O)C=C1Br.COC1=CC(C(C)C)=C(O)C=C1Br.COC1=CC(C(C)C)=C(OCC#N)C=C1Br.COC1=CC(C(C)C)=CC=C1Br Chemical compound BrBr.CC(C)C1=C(Br)C=CC(O)=C1.CC(C)C1=CC=C(Br)C(O)=C1.CC(C)C1=CC=CC(O)=C1.CI.CO/C=C(\C#N)OC1=C(C(C)C)C=C(OC)C(Br)=C1.COC1=CC(C(C)C)=C(Br)C=C1.COC1=CC(C(C)C)=C(Br)C=C1C=O.COC1=CC(C(C)C)=C(Br)C=C1O.COC1=CC(C(C)C)=C(C=O)C=C1Br.COC1=CC(C(C)C)=C(O)C=C1Br.COC1=CC(C(C)C)=C(O)C=C1Br.COC1=CC(C(C)C)=C(OCC#N)C=C1Br.COC1=CC(C(C)C)=CC=C1Br FUCSWBQFLSASRY-GYLCKTPQSA-N 0.000 description 1
- RVMVQUIZOIUFCC-UHFFFAOYSA-K Br[Mg]C1CC1.C1CCOC1.CCCCC1=CC=CC=C1.COC1=CC(Br)=CC=C1Cl.COC1=CC(C2CC2)=CC=C1Cl.Cl[Ni]Cl.PC1=CC=CC=C1 Chemical compound Br[Mg]C1CC1.C1CCOC1.CCCCC1=CC=CC=C1.COC1=CC(Br)=CC=C1Cl.COC1=CC(C2CC2)=CC=C1Cl.Cl[Ni]Cl.PC1=CC=CC=C1 RVMVQUIZOIUFCC-UHFFFAOYSA-K 0.000 description 1
- KWIATTRZEXMRJP-UHFFFAOYSA-N C#CCOC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I Chemical compound C#CCOC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I KWIATTRZEXMRJP-UHFFFAOYSA-N 0.000 description 1
- IAZXZBINKUWTGP-UHFFFAOYSA-N C#CCOC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I.CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(O)=C1 Chemical compound C#CCOC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I.CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(O)=C1 IAZXZBINKUWTGP-UHFFFAOYSA-N 0.000 description 1
- OOWYIWUNOPMXEF-UHFFFAOYSA-L C.C.C.C.C.C.C.C.C.COC1=C([N+](=O)[O-])C(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1.COC1=CC(C(C)(C)O)=C(O)C=C1.COC1=CC(C(C)=O)=C(O)C=C1.COC1=CC(C(C)C)=C(O)C=C1.COC1=CC(C(C)C)=C(O)C=C1[N+](=O)[O-].COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1[N+](=O)[O-].COC1=CC(C(C)C)=C(OCC#N)C=C1[N+](=O)[O-].COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1[N+](=O)[O-].C[Mg]Br.O=[N+]([O-])O.O[K].[C-]#[N+]COS(=O)(=O)C1=CC=C(C)C=C1 Chemical compound C.C.C.C.C.C.C.C.C.COC1=C([N+](=O)[O-])C(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1.COC1=CC(C(C)(C)O)=C(O)C=C1.COC1=CC(C(C)=O)=C(O)C=C1.COC1=CC(C(C)C)=C(O)C=C1.COC1=CC(C(C)C)=C(O)C=C1[N+](=O)[O-].COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1[N+](=O)[O-].COC1=CC(C(C)C)=C(OCC#N)C=C1[N+](=O)[O-].COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1[N+](=O)[O-].C[Mg]Br.O=[N+]([O-])O.O[K].[C-]#[N+]COS(=O)(=O)C1=CC=C(C)C=C1 OOWYIWUNOPMXEF-UHFFFAOYSA-L 0.000 description 1
- ACAOXMJHZLZDRR-UHFFFAOYSA-N C.C.C.C.C.C.C.CCOC(=O)C(C)C(C)=O.CCOC(=O)C1=C(C)C2=CC(OC)=C(C(F)(F)F)C=C2N1.COC1=C(C(F)(F)F)C=C(N)C=C1.COC1=C(C(F)(F)F)C=C([N+](=O)[O-])C=C1.COC1=C(C(F)(F)F)C=C2C(=C1)C(C)=CN2C.COC1=C(C(F)(F)F)C=C2NC(C(=O)O)=C(C)C2=C1.COC1=C(C(F)(F)F)C=C2NC=C(C)C2=C1 Chemical compound C.C.C.C.C.C.C.CCOC(=O)C(C)C(C)=O.CCOC(=O)C1=C(C)C2=CC(OC)=C(C(F)(F)F)C=C2N1.COC1=C(C(F)(F)F)C=C(N)C=C1.COC1=C(C(F)(F)F)C=C([N+](=O)[O-])C=C1.COC1=C(C(F)(F)F)C=C2C(=C1)C(C)=CN2C.COC1=C(C(F)(F)F)C=C2NC(C(=O)O)=C(C)C2=C1.COC1=C(C(F)(F)F)C=C2NC=C(C)C2=C1 ACAOXMJHZLZDRR-UHFFFAOYSA-N 0.000 description 1
- PZKUMQYNTOYIKW-UHFFFAOYSA-N C.C.C.C.C.C.CCOC(=O)C(C)C(C)=O.CCOC(=O)C1=C(C)C2=CC(C(C)C)=C(OC)C=C2N1.CCOC(=O)C1=C(C)C2=CC(C(C)C)=C(OC3=CN=C(N)N=C3N)C=C2N1.CI.COC1=C(C(C)(C)O)C=CC(NC(C)=O)=C1.COC1=C(C(C)=O)C=CC(NC(C)=O)=C1.COC1=C(C(C)C)C=CC(N)=C1.COC1=C(C(C)C)C=CC(NC(C)=O)=C1.COC1=CC=CC(NC(C)=O)=C1 Chemical compound C.C.C.C.C.C.CCOC(=O)C(C)C(C)=O.CCOC(=O)C1=C(C)C2=CC(C(C)C)=C(OC)C=C2N1.CCOC(=O)C1=C(C)C2=CC(C(C)C)=C(OC3=CN=C(N)N=C3N)C=C2N1.CI.COC1=C(C(C)(C)O)C=CC(NC(C)=O)=C1.COC1=C(C(C)=O)C=CC(NC(C)=O)=C1.COC1=C(C(C)C)C=CC(N)=C1.COC1=C(C(C)C)C=CC(NC(C)=O)=C1.COC1=CC=CC(NC(C)=O)=C1 PZKUMQYNTOYIKW-UHFFFAOYSA-N 0.000 description 1
- BJQKODLBZWZWIE-UHFFFAOYSA-M C.C.C.CC(=O)Cl.CI.COC1=C(C(C)=O)C=C2C(=C1)OCCN2C.COC1=C(C(C)C)C=C2C(=C1)OCCN2C.COC1=CC=C(N)C(OC)=C1.COC1=CC=C(NC(=O)CCl)C(O)=C1.COC1=CC=C(NC(=O)CCl)C(OC)=C1.COC1=CC=C2C(=C1)OCC(=O)N2C.COC1=CC=C2C(=C1)OCCN2C.COC1=CC=C2NC(=O)COC2=C1.O=C(Cl)CCl.O=COO[K].[KH] Chemical compound C.C.C.CC(=O)Cl.CI.COC1=C(C(C)=O)C=C2C(=C1)OCCN2C.COC1=C(C(C)C)C=C2C(=C1)OCCN2C.COC1=CC=C(N)C(OC)=C1.COC1=CC=C(NC(=O)CCl)C(O)=C1.COC1=CC=C(NC(=O)CCl)C(OC)=C1.COC1=CC=C2C(=C1)OCC(=O)N2C.COC1=CC=C2C(=C1)OCCN2C.COC1=CC=C2NC(=O)COC2=C1.O=C(Cl)CCl.O=COO[K].[KH] BJQKODLBZWZWIE-UHFFFAOYSA-M 0.000 description 1
- XMJFBMPNGBLQCW-UHFFFAOYSA-N C.C.C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C#N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NCCN1.NCCN Chemical compound C.C.C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C#N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NCCN1.NCCN XMJFBMPNGBLQCW-UHFFFAOYSA-N 0.000 description 1
- GNARUUOKOULRRP-UHFFFAOYSA-N C.C.C.COC1=CC=C(C2CC2)C=C1OC.[H]C(=O)C1=CC=C(OC)C(OC)=C1 Chemical compound C.C.C.COC1=CC=C(C2CC2)C=C1OC.[H]C(=O)C1=CC=C(OC)C(OC)=C1 GNARUUOKOULRRP-UHFFFAOYSA-N 0.000 description 1
- QVHJWOHFJLXCLM-KPOMWBFQSA-N C.C/N=C(\NC)N1C=CC=N1.C/N=C(\NC)N[C@H](C)CO.C[C@@H](N)CO Chemical compound C.C/N=C(\NC)N1C=CC=N1.C/N=C(\NC)N[C@H](C)CO.C[C@@H](N)CO QVHJWOHFJLXCLM-KPOMWBFQSA-N 0.000 description 1
- FKWAVNPBVWKFFW-UHFFFAOYSA-N C.C=CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)OC Chemical compound C.C=CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)OC FKWAVNPBVWKFFW-UHFFFAOYSA-N 0.000 description 1
- BYBYSRMAGFDAIW-UHFFFAOYSA-N C.CC(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)=O Chemical compound C.CC(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)=O BYBYSRMAGFDAIW-UHFFFAOYSA-N 0.000 description 1
- TUTDQDPPDQBURI-UHFFFAOYSA-N C.CC1=CC(O)=C(C(C)C)C2=C1N=CO2.CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C2=C1N=CO2 Chemical compound C.CC1=CC(O)=C(C(C)C)C2=C1N=CO2.CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C2=C1N=CO2 TUTDQDPPDQBURI-UHFFFAOYSA-N 0.000 description 1
- HYCPRGNADLULGB-UHFFFAOYSA-N C.CC1=CN(C)C2=CC(C(F)(F)F)=C(O)C=C12.CC1=CN(C)C2=CC(C(F)(F)F)=C(OC3=CN=C(N)N=C3N)C=C12 Chemical compound C.CC1=CN(C)C2=CC(C(F)(F)F)=C(O)C=C12.CC1=CN(C)C2=CC(C(F)(F)F)=C(OC3=CN=C(N)N=C3N)C=C12 HYCPRGNADLULGB-UHFFFAOYSA-N 0.000 description 1
- IZRMWPSZRZYRMG-UHFFFAOYSA-N C.CCC1=C(OC(C#N)CNC2=CC=CC=C2)C=C(C)C2=C1C=CS2.CCC1=C(OC2=CN=C(N)N=C2N)C=C(C)C2=C1C=CS2 Chemical compound C.CCC1=C(OC(C#N)CNC2=CC=CC=C2)C=C(C)C2=C1C=CS2.CCC1=C(OC2=CN=C(N)N=C2N)C=C(C)C2=C1C=CS2 IZRMWPSZRZYRMG-UHFFFAOYSA-N 0.000 description 1
- ANIGVHFTLJDVHG-UHFFFAOYSA-N C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NC=CN1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NCCN1 Chemical compound C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NC=CN1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NCCN1 ANIGVHFTLJDVHG-UHFFFAOYSA-N 0.000 description 1
- IKRXCVDYGNEUMM-UHFFFAOYSA-N C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1NC(=O)CCCCl.O=C(Cl)CCCCl Chemical compound C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1NC(=O)CCCCl.O=C(Cl)CCCCl IKRXCVDYGNEUMM-UHFFFAOYSA-N 0.000 description 1
- PWUKIPSRILJRQN-UHFFFAOYSA-N C.COC1=CC=CC(O)=C1C(C)(C)O.COC1=CC=CC(O)=C1C(C)=O.COC1=CC=CC(O)=C1C(C)C.COC1=CC=CC(OC2=CN=C(N)N=C2N)=C1C(C)C.C[MgH] Chemical compound C.COC1=CC=CC(O)=C1C(C)(C)O.COC1=CC=CC(O)=C1C(C)=O.COC1=CC=CC(O)=C1C(C)C.COC1=CC=CC(OC2=CN=C(N)N=C2N)=C1C(C)C.C[MgH] PWUKIPSRILJRQN-UHFFFAOYSA-N 0.000 description 1
- LKNFQNWTVDONLU-FWNNTFJKSA-N C/N=C(\NC)N[C@H](C)CO.C[C@H](CO)NC(=N)N Chemical compound C/N=C(\NC)N[C@H](C)CO.C[C@H](CO)NC(=N)N LKNFQNWTVDONLU-FWNNTFJKSA-N 0.000 description 1
- TVKSWCXTDKCDMP-UHFFFAOYSA-M C1=CNC=N1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CN=C1.[Cu]I Chemical compound C1=CNC=N1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CN=C1.[Cu]I TVKSWCXTDKCDMP-UHFFFAOYSA-M 0.000 description 1
- URCDHTQMLNBGEB-UHFFFAOYSA-N C1=CSC=N1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CN=CS1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I Chemical compound C1=CSC=N1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CN=CS1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I URCDHTQMLNBGEB-UHFFFAOYSA-N 0.000 description 1
- GAIVVIZBQOLSJN-UHFFFAOYSA-N C=C(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OC)=C1 Chemical compound C=C(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OC)=C1 GAIVVIZBQOLSJN-UHFFFAOYSA-N 0.000 description 1
- RDJSKZZZQVGVNG-UHFFFAOYSA-N C=C(C)C1=C(OCOC)C=C(I)C(OC)=C1.CC1=CC=C(S(=O)(=O)OCC#N)C=C1.COC1=CC(C(C)=O)=C(O)C=C1I.COC1=CC(C(C)CO)=C(O)C=C1I.COC1=CC(C(C)CO)=C(OC2=CN=C(N)N=C2N)C=C1I.COC1=CC(C(C)CO)=C(OCC#N)C=C1I.COCCl.COCOC1=C(C(C)=O)C=C(OC)C(I)=C1 Chemical compound C=C(C)C1=C(OCOC)C=C(I)C(OC)=C1.CC1=CC=C(S(=O)(=O)OCC#N)C=C1.COC1=CC(C(C)=O)=C(O)C=C1I.COC1=CC(C(C)CO)=C(O)C=C1I.COC1=CC(C(C)CO)=C(OC2=CN=C(N)N=C2N)C=C1I.COC1=CC(C(C)CO)=C(OCC#N)C=C1I.COCCl.COCOC1=C(C(C)=O)C=C(OC)C(I)=C1 RDJSKZZZQVGVNG-UHFFFAOYSA-N 0.000 description 1
- NCUSLLQQJJLXAB-PTJXWQCLSA-N C=CC#N.COC/C(C#N)=C/C1=C(C)C=C(OC)C(OC)=C1.COC1=C(OC)C=C(C=O)C(C)=C1.COC1=CC(C)=C(CC2=CN=C(N)N=C2N)C=C1OC.CO[Na].N=C(N)N Chemical compound C=CC#N.COC/C(C#N)=C/C1=C(C)C=C(OC)C(OC)=C1.COC1=C(OC)C=C(C=O)C(C)=C1.COC1=CC(C)=C(CC2=CN=C(N)N=C2N)C=C1OC.CO[Na].N=C(N)N NCUSLLQQJJLXAB-PTJXWQCLSA-N 0.000 description 1
- HWOXEFDCDKPLIL-UHFFFAOYSA-N C=CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC Chemical compound C=CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC HWOXEFDCDKPLIL-UHFFFAOYSA-N 0.000 description 1
- SPLFKVYTKLMYQR-UHFFFAOYSA-N C=FC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(Cl)C(OC)=C1 Chemical compound C=FC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(Cl)C(OC)=C1 SPLFKVYTKLMYQR-UHFFFAOYSA-N 0.000 description 1
- LVXCCGGMWXAAQM-UHFFFAOYSA-N CC(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1O Chemical compound CC(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1O LVXCCGGMWXAAQM-UHFFFAOYSA-N 0.000 description 1
- XQDAUHISFBFRKE-UHFFFAOYSA-N CC(Br)CC1=CC=CC=C1.CI.COC(=O)C1=C(C(C)CC2=CC=CC=C2)C=C(OC)C(OC)=C1.COC1=CC(C2=N(C)C(C)(C)CO2)=C(C(C)CC2=CC=CC=C2)C=C1OC.COC1=CC(C2=NC(C)(C)CO2)=C(C(C)CC2=CC=CC=C2)C=C1OC.COC1=CC(CO)=C(C(C)CC2=CC=CC=C2)C=C1OC.COC1=CC(OC)=C(C2=NC(C)(C)CO2)C=C1OC.CPC Chemical compound CC(Br)CC1=CC=CC=C1.CI.COC(=O)C1=C(C(C)CC2=CC=CC=C2)C=C(OC)C(OC)=C1.COC1=CC(C2=N(C)C(C)(C)CO2)=C(C(C)CC2=CC=CC=C2)C=C1OC.COC1=CC(C2=NC(C)(C)CO2)=C(C(C)CC2=CC=CC=C2)C=C1OC.COC1=CC(CO)=C(C(C)CC2=CC=CC=C2)C=C1OC.COC1=CC(OC)=C(C2=NC(C)(C)CO2)C=C1OC.CPC XQDAUHISFBFRKE-UHFFFAOYSA-N 0.000 description 1
- OWAWCGZTRLVOBB-XTFPODMKSA-N CC(C)C(N)C(C)C.CCN.CCNC1=NC(SC)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1.COC1=C(OC)C=C(C(C)C)C(/C=N/C(C(C)C)C(C)C)=C1.COC1=C(OC)C=C(C(C)C)C(C=O)=C1.COC1=CC(C(C)C)=C(C(O)C2=CN=C(SC)N=C2Cl)C=C1OC.COC1=CC(CC2=CN=C(SC)N=C2Cl)=C(C(C)C)C=C1OC.COC1=CC(OC)=C(OC)C=C1/C=N/C(C(C)C)C(C)C.COC1=CC(OC)=C(OC)C=C1C=O.CSC1=NC=C(I)C(Cl)=N1.Cl.[Li]C(C)C Chemical compound CC(C)C(N)C(C)C.CCN.CCNC1=NC(SC)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1.COC1=C(OC)C=C(C(C)C)C(/C=N/C(C(C)C)C(C)C)=C1.COC1=C(OC)C=C(C(C)C)C(C=O)=C1.COC1=CC(C(C)C)=C(C(O)C2=CN=C(SC)N=C2Cl)C=C1OC.COC1=CC(CC2=CN=C(SC)N=C2Cl)=C(C(C)C)C=C1OC.COC1=CC(OC)=C(OC)C=C1/C=N/C(C(C)C)C(C)C.COC1=CC(OC)=C(OC)C=C1C=O.CSC1=NC=C(I)C(Cl)=N1.Cl.[Li]C(C)C OWAWCGZTRLVOBB-XTFPODMKSA-N 0.000 description 1
- NACYWOCBVAWAST-UHFFFAOYSA-N CC(C)C1=C(CC2=CN=C(N)N=C2N)C=C(Cl)C(Cl)=C1 Chemical compound CC(C)C1=C(CC2=CN=C(N)N=C2N)C=C(Cl)C(Cl)=C1 NACYWOCBVAWAST-UHFFFAOYSA-N 0.000 description 1
- AYJQOICIAYIGIT-UHFFFAOYSA-N CC(C)C1=C(CC2=CN=C(N)N=C2N)C=C(I)C(OCCO)=C1 Chemical compound CC(C)C1=C(CC2=CN=C(N)N=C2N)C=C(I)C(OCCO)=C1 AYJQOICIAYIGIT-UHFFFAOYSA-N 0.000 description 1
- ANGVRWNVDAPUSJ-SCYGSPGNSA-N CC(C)C1=C(Cl)C=CC(O)=C1.CC(C)C1=CC=C(Cl)C(O)=C1.CC(C)C1=CC=CC(O)=C1.CI.CO/C=C(\C#N)OC1=C(C(C)C)C=C(OC)C(Cl)=C1.COC1=CC(C(C)C)=C(C=O)C=C1Cl.COC1=CC(C(C)C)=C(C=O)C=C1Cl.COC1=CC(C(C)C)=C(Cl)C=C1.COC1=CC(C(C)C)=C(Cl)C=C1C=O.COC1=CC(C(C)C)=C(O)C=C1Cl.COC1=CC(C(C)C)=C(OCC#N)C=C1Cl.COC1=CC(C(C)C)=CC=C1Cl.C[C@H](CO)NC(=N)N Chemical compound CC(C)C1=C(Cl)C=CC(O)=C1.CC(C)C1=CC=C(Cl)C(O)=C1.CC(C)C1=CC=CC(O)=C1.CI.CO/C=C(\C#N)OC1=C(C(C)C)C=C(OC)C(Cl)=C1.COC1=CC(C(C)C)=C(C=O)C=C1Cl.COC1=CC(C(C)C)=C(C=O)C=C1Cl.COC1=CC(C(C)C)=C(Cl)C=C1.COC1=CC(C(C)C)=C(Cl)C=C1C=O.COC1=CC(C(C)C)=C(O)C=C1Cl.COC1=CC(C(C)C)=C(OCC#N)C=C1Cl.COC1=CC(C(C)C)=CC=C1Cl.C[C@H](CO)NC(=N)N ANGVRWNVDAPUSJ-SCYGSPGNSA-N 0.000 description 1
- GDYKHVHFVTUEBS-UHFFFAOYSA-N CC(C)C1=C(O)C=C2OCCN(C)C2=C1.CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C2OCCN(C)C2=C1 Chemical compound CC(C)C1=C(O)C=C2OCCN(C)C2=C1.CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C2OCCN(C)C2=C1 GDYKHVHFVTUEBS-UHFFFAOYSA-N 0.000 description 1
- ZUTXDVLGIYWBIV-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C(I)=C(I)C2=C1OCCO2 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C(I)=C(I)C2=C1OCCO2 ZUTXDVLGIYWBIV-UHFFFAOYSA-N 0.000 description 1
- FJNRSOLKUCMHQT-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C(I)=C(I)C2=C1OCCO2.CC(C)C1=C(OC2=CN=C(N)N=C2N)C(I)=CC2=C1OCCO2 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C(I)=C(I)C2=C1OCCO2.CC(C)C1=C(OC2=CN=C(N)N=C2N)C(I)=CC2=C1OCCO2 FJNRSOLKUCMHQT-UHFFFAOYSA-N 0.000 description 1
- FBQPRXSDRQQCLK-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C(I)=CC2=C1OCCO2 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C(I)=CC2=C1OCCO2 FBQPRXSDRQQCLK-UHFFFAOYSA-N 0.000 description 1
- RTVQKVNHHHKBSP-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(Cl)C(OC(F)F)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(Cl)C(OC(F)F)=C1 RTVQKVNHHHKBSP-UHFFFAOYSA-N 0.000 description 1
- QHEAZCABDDLXHC-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(O)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(O)=C1 QHEAZCABDDLXHC-UHFFFAOYSA-N 0.000 description 1
- GWOYIFMIIVNPTJ-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(O)=C1.CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCCO[Si](C)(C)C)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(O)=C1.CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCCO[Si](C)(C)C)=C1 GWOYIFMIIVNPTJ-UHFFFAOYSA-N 0.000 description 1
- YEQHXHYKIWZQNW-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(O)=C1.CCOC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(O)=C1.CCOC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I YEQHXHYKIWZQNW-UHFFFAOYSA-N 0.000 description 1
- UNFRZWOUCFZPNA-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(O)=C1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(O)=C1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I UNFRZWOUCFZPNA-UHFFFAOYSA-N 0.000 description 1
- JOZZLVWUUKVHKK-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC#N)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC#N)=C1 JOZZLVWUUKVHKK-UHFFFAOYSA-N 0.000 description 1
- KUWZULYJEJQBJG-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=C(F)C=CC=C2F)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=C(F)C=CC=C2F)=C1 KUWZULYJEJQBJG-UHFFFAOYSA-N 0.000 description 1
- NAVGRSYAMQNJPZ-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=CC(F)=CC=C2)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=CC(F)=CC=C2)=C1 NAVGRSYAMQNJPZ-UHFFFAOYSA-N 0.000 description 1
- QUWOCYVCBJJVGH-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=CC=CC=C2)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=CC=CC=C2)=C1 QUWOCYVCBJJVGH-UHFFFAOYSA-N 0.000 description 1
- CWNSFTZFKNWNJJ-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=CC=CC=C2F)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=CC=CC=C2F)=C1 CWNSFTZFKNWNJJ-UHFFFAOYSA-N 0.000 description 1
- BDVKWPUMUDKEGN-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=CC=CN=C2)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=CC=CN=C2)=C1 BDVKWPUMUDKEGN-UHFFFAOYSA-N 0.000 description 1
- PFLUSUBJHNYBEH-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=CC=NC=C2)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=CC=NC=C2)=C1 PFLUSUBJHNYBEH-UHFFFAOYSA-N 0.000 description 1
- ZHRMYFGDDVWNQE-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=NC=CC=C2)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=NC=CC=C2)=C1 ZHRMYFGDDVWNQE-UHFFFAOYSA-N 0.000 description 1
- UJBYLRNOZGFZKM-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=NC=CC=N2)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2=NC=CC=N2)=C1 UJBYLRNOZGFZKM-UHFFFAOYSA-N 0.000 description 1
- VFHBQHHVTBJOJD-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2CCCCO2)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCC2CCCCO2)=C1 VFHBQHHVTBJOJD-UHFFFAOYSA-N 0.000 description 1
- BOWYOYNCENTSAK-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCCC2=CC=CC=C2)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCCC2=CC=CC=C2)=C1 BOWYOYNCENTSAK-UHFFFAOYSA-N 0.000 description 1
- NJPBHEGFVSZBBY-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCCO)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCCO)=C1 NJPBHEGFVSZBBY-UHFFFAOYSA-N 0.000 description 1
- BOIBMZDLEHKVEZ-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCCO)=C1.CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCCO[Si](C)(C)C)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCCO)=C1.CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OCCO[Si](C)(C)C)=C1 BOIBMZDLEHKVEZ-UHFFFAOYSA-N 0.000 description 1
- MKHVSLALYHSEGI-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C(I)C=C1 MKHVSLALYHSEGI-UHFFFAOYSA-N 0.000 description 1
- JZWJNQOOMXUXCO-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C2C(C(=O)O)=CN(C)C2=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C2C(C(=O)O)=CN(C)C2=C1 JZWJNQOOMXUXCO-UHFFFAOYSA-N 0.000 description 1
- UEVWXASYNWFYEU-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C2OCCN(C)C2=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=C2OCCN(C)C2=C1 UEVWXASYNWFYEU-UHFFFAOYSA-N 0.000 description 1
- BAYPKKLKCSWUPN-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=CC(Br)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=CC(Br)=C1 BAYPKKLKCSWUPN-UHFFFAOYSA-N 0.000 description 1
- BJCXHFPJBNUYBN-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=CC(I)=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=CC(I)=C1 BJCXHFPJBNUYBN-UHFFFAOYSA-N 0.000 description 1
- YILCHFFZMXESIM-UHFFFAOYSA-N CC(C)C1=C(OC2=CN=C(N)N=C2N)C=CC=C1 Chemical compound CC(C)C1=C(OC2=CN=C(N)N=C2N)C=CC=C1 YILCHFFZMXESIM-UHFFFAOYSA-N 0.000 description 1
- JAYJHOJDRLIOPN-XKYJCVGQSA-N CC(C)C1=C(OCC2=CC=CC=C2)C=C2C=CNC2=C1.CC1=CN(C)C2=CC(C(C)C)=C(O)C=C12.CC1=CN(C)C2=CC(C(C)C)=C(OC3=CN=C(N)N=C3N)C=C12.CC1=CN(C)C2=CC(C(C)C)=C(OCC#N)C=C12.CC1=CN(C)C2=CC(C(C)C)=C(OCC3=CC=CC=C3)C=C12.CC1=CNC2=CC(C(C)C)=C(OCC3=CC=CC=C3)C=C12.CO/C=C(\C#N)OC1=C(C(C)C)C=C2C(=C1)C(C)=CN2C Chemical compound CC(C)C1=C(OCC2=CC=CC=C2)C=C2C=CNC2=C1.CC1=CN(C)C2=CC(C(C)C)=C(O)C=C12.CC1=CN(C)C2=CC(C(C)C)=C(OC3=CN=C(N)N=C3N)C=C12.CC1=CN(C)C2=CC(C(C)C)=C(OCC#N)C=C12.CC1=CN(C)C2=CC(C(C)C)=C(OCC3=CC=CC=C3)C=C12.CC1=CNC2=CC(C(C)C)=C(OCC3=CC=CC=C3)C=C12.CO/C=C(\C#N)OC1=C(C(C)C)C=C2C(=C1)C(C)=CN2C JAYJHOJDRLIOPN-XKYJCVGQSA-N 0.000 description 1
- DNSXZPBZBKFWIV-UHFFFAOYSA-N CC(C)C1=CC(OCC(F)(F)F)=C(I)C=C1OC1=CN=C(N)N=C1N Chemical compound CC(C)C1=CC(OCC(F)(F)F)=C(I)C=C1OC1=CN=C(N)N=C1N DNSXZPBZBKFWIV-UHFFFAOYSA-N 0.000 description 1
- DYYBWNKJJRZRCU-UHFFFAOYSA-N CC(C)C1=CC(OCC(N)=O)=C(I)C=C1OC1=CN=C(N)N=C1N Chemical compound CC(C)C1=CC(OCC(N)=O)=C(I)C=C1OC1=CN=C(N)N=C1N DYYBWNKJJRZRCU-UHFFFAOYSA-N 0.000 description 1
- ZKJXZVUFEMWMQW-UHFFFAOYSA-N CC(C)C1=CC2=C(C=NN2C)C=C1OC1=CN=C(N)N=C1N Chemical compound CC(C)C1=CC2=C(C=NN2C)C=C1OC1=CN=C(N)N=C1N ZKJXZVUFEMWMQW-UHFFFAOYSA-N 0.000 description 1
- URUAPNQYDOMUPB-UHFFFAOYSA-N CC(C)C1=CC2=NN(C)C=C2C=C1OC1=CN=C(N)N=C1N Chemical compound CC(C)C1=CC2=NN(C)C=C2C=C1OC1=CN=C(N)N=C1N URUAPNQYDOMUPB-UHFFFAOYSA-N 0.000 description 1
- ONPWUNMIUPAOJN-YQLNASGTSA-N CC(C)c(c(Oc1c(N)nc(N)nc1)c1)cc(OC/C=N\C)c1I Chemical compound CC(C)c(c(Oc1c(N)nc(N)nc1)c1)cc(OC/C=N\C)c1I ONPWUNMIUPAOJN-YQLNASGTSA-N 0.000 description 1
- KBFSAAZSPYWRFE-UHFFFAOYSA-N CC(C)c(cc(c(C(N)=S)c1)OC)c1Oc1cnc(N)nc1N Chemical compound CC(C)c(cc(c(C(N)=S)c1)OC)c1Oc1cnc(N)nc1N KBFSAAZSPYWRFE-UHFFFAOYSA-N 0.000 description 1
- SBZGXAOQBIPTPZ-UHFFFAOYSA-N CC1=C(C(=O)O)NC2=CC(OC3=CN=C(N)N=C3N)=C(C(C)C)C=C21 Chemical compound CC1=C(C(=O)O)NC2=CC(OC3=CN=C(N)N=C3N)=C(C(C)C)C=C21 SBZGXAOQBIPTPZ-UHFFFAOYSA-N 0.000 description 1
- MHYYNVSQTPIWHW-UHFFFAOYSA-N CC1=CC(O)=C(C(C)C)C2=C1N=C(C)O2.CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C2=C1N=C(C)O2 Chemical compound CC1=CC(O)=C(C(C)C)C2=C1N=C(C)O2.CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C2=C1N=C(C)O2 MHYYNVSQTPIWHW-UHFFFAOYSA-N 0.000 description 1
- YVVGBYWPZSPOKH-UHFFFAOYSA-N CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C2=C1N=C(C)O2 Chemical compound CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C2=C1N=C(C)O2 YVVGBYWPZSPOKH-UHFFFAOYSA-N 0.000 description 1
- GVCSWXWOMCFXNF-UHFFFAOYSA-N CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C2=C1N=CO2 Chemical compound CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C2=C1N=CO2 GVCSWXWOMCFXNF-UHFFFAOYSA-N 0.000 description 1
- RAKSAPLZNJXYRB-UHFFFAOYSA-N CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1 Chemical compound CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1 RAKSAPLZNJXYRB-UHFFFAOYSA-N 0.000 description 1
- JMFUWSWXXSOWHE-UHFFFAOYSA-N CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1Cl Chemical compound CC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1Cl JMFUWSWXXSOWHE-UHFFFAOYSA-N 0.000 description 1
- NLGHTQBRHZXOON-WPGPNXFZSA-N CC1=CC=C(S(=O)(=O)N/N=C/C(Cl)Cl)C=C1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CN=N1 Chemical compound CC1=CC=C(S(=O)(=O)N/N=C/C(Cl)Cl)C=C1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CN=N1 NLGHTQBRHZXOON-WPGPNXFZSA-N 0.000 description 1
- MWTNBFNIEZEGCR-UHFFFAOYSA-N CC1=CN(C)C2=CC(C(C)C)=C(OC3=CN=C(N)N=C3N)C=C12 Chemical compound CC1=CN(C)C2=CC(C(C)C)=C(OC3=CN=C(N)N=C3N)C=C12 MWTNBFNIEZEGCR-UHFFFAOYSA-N 0.000 description 1
- SLRWVYSDJNDBEM-UHFFFAOYSA-N CC1=CN(C)C2=CC(C(F)(F)F)=C(OC3=CN=C(N)N=C3N)C=C12 Chemical compound CC1=CN(C)C2=CC(C(F)(F)F)=C(OC3=CN=C(N)N=C3N)C=C12 SLRWVYSDJNDBEM-UHFFFAOYSA-N 0.000 description 1
- BZFLUWWCGKAANQ-UHFFFAOYSA-N CCC(C)C1=C(CC2=CN=C(N)N=C2N)C=C(OC)C(OC)=C1 Chemical compound CCC(C)C1=C(CC2=CN=C(N)N=C2N)C=C(OC)C(OC)=C1 BZFLUWWCGKAANQ-UHFFFAOYSA-N 0.000 description 1
- USFMKSGNOOVMSV-MCQOVQOZSA-N CCC1=C(C=O)C=CC=C1OC.CCC1=C(CC2=CN=C(N)N=C2N)C=CC=C1OC.CCI.COC1=CC=CC(/C=N/C2CCCCC2)=C1.COC1=CC=CC(C=O)=C1.NC1CCCCC1 Chemical compound CCC1=C(C=O)C=CC=C1OC.CCC1=C(CC2=CN=C(N)N=C2N)C=CC=C1OC.CCI.COC1=CC=CC(/C=N/C2CCCCC2)=C1.COC1=CC=CC(C=O)=C1.NC1CCCCC1 USFMKSGNOOVMSV-MCQOVQOZSA-N 0.000 description 1
- YKIDBUSAQFWTBZ-UHFFFAOYSA-N CCC1=C(CC2=CN=C(N)N=C2N)C=CC(OC)=C1OC Chemical compound CCC1=C(CC2=CN=C(N)N=C2N)C=CC(OC)=C1OC YKIDBUSAQFWTBZ-UHFFFAOYSA-N 0.000 description 1
- WQKDFGPJAJJOMC-UHFFFAOYSA-N CCC1=C(CC2=CN=C(N)N=C2N)C=CC=C1OC Chemical compound CCC1=C(CC2=CN=C(N)N=C2N)C=CC=C1OC WQKDFGPJAJJOMC-UHFFFAOYSA-N 0.000 description 1
- GIOLOUPMDFKIPT-UHFFFAOYSA-N CCC1=C(OC2=CN=C(N)N=C2N)C=C(Br)C(OC)=C1 Chemical compound CCC1=C(OC2=CN=C(N)N=C2N)C=C(Br)C(OC)=C1 GIOLOUPMDFKIPT-UHFFFAOYSA-N 0.000 description 1
- LXHREPOYANQVJR-UHFFFAOYSA-N CCC1=C(OC2=CN=C(N)N=C2N)C=C(Br)C2=C1OCCO2 Chemical compound CCC1=C(OC2=CN=C(N)N=C2N)C=C(Br)C2=C1OCCO2 LXHREPOYANQVJR-UHFFFAOYSA-N 0.000 description 1
- AQYVKGFIKOGPSP-UHFFFAOYSA-N CCC1=C(OC2=CN=C(N)N=C2N)C=C(Br)C2=C1OCCO2.CCC1=C(OCC#N)C=C(Br)C2=C1OCCO2 Chemical compound CCC1=C(OC2=CN=C(N)N=C2N)C=C(Br)C2=C1OCCO2.CCC1=C(OCC#N)C=C(Br)C2=C1OCCO2 AQYVKGFIKOGPSP-UHFFFAOYSA-N 0.000 description 1
- PRHAVBNUFHROMN-UHFFFAOYSA-N CCC1=C(OC2=CN=C(N)N=C2N)C=C(C(F)(F)F)C(OC)=C1 Chemical compound CCC1=C(OC2=CN=C(N)N=C2N)C=C(C(F)(F)F)C(OC)=C1 PRHAVBNUFHROMN-UHFFFAOYSA-N 0.000 description 1
- WLTKUZZDYPUYQC-UHFFFAOYSA-N CCC1=C(OC2=CN=C(N)N=C2N)C=C(Cl)C(OC)=C1 Chemical compound CCC1=C(OC2=CN=C(N)N=C2N)C=C(Cl)C(OC)=C1 WLTKUZZDYPUYQC-UHFFFAOYSA-N 0.000 description 1
- XPSPDZPZSCPYSC-UHFFFAOYSA-N CCC1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OC)=C1.Cl Chemical compound CCC1=C(OC2=CN=C(N)N=C2N)C=C(I)C(OC)=C1.Cl XPSPDZPZSCPYSC-UHFFFAOYSA-N 0.000 description 1
- MBTYOTQEKJWDNT-UHFFFAOYSA-N CCC1=C(OC2=CN=C(N)N=C2N)C=C(I)C=C1 Chemical compound CCC1=C(OC2=CN=C(N)N=C2N)C=C(I)C=C1 MBTYOTQEKJWDNT-UHFFFAOYSA-N 0.000 description 1
- LPTNABSKOFMFNP-UHFFFAOYSA-N CCC1=C(OC2=CN=C(N)N=C2N)C=C(OC)C(OC)=C1 Chemical compound CCC1=C(OC2=CN=C(N)N=C2N)C=C(OC)C(OC)=C1 LPTNABSKOFMFNP-UHFFFAOYSA-N 0.000 description 1
- HHPFIAMNRLFUEO-UHFFFAOYSA-N CCC1=C(OC2=CN=C(N)N=C2N)C=C(S(C)(=O)=O)C(OC)=C1 Chemical compound CCC1=C(OC2=CN=C(N)N=C2N)C=C(S(C)(=O)=O)C(OC)=C1 HHPFIAMNRLFUEO-UHFFFAOYSA-N 0.000 description 1
- OVZONLAHJJOKKF-UHFFFAOYSA-N CCNC(=O)NC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N Chemical compound CCNC(=O)NC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N OVZONLAHJJOKKF-UHFFFAOYSA-N 0.000 description 1
- MCBMHLVAURZALR-UHFFFAOYSA-N CCNC1=NC(N)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1 Chemical compound CCNC1=NC(N)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1 MCBMHLVAURZALR-UHFFFAOYSA-N 0.000 description 1
- KKGAUCQHDXKWLK-UHFFFAOYSA-N CCNC1=NC(N)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1.CCNC1=NC(S(C)(=O)=O)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1.N.O Chemical compound CCNC1=NC(N)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1.CCNC1=NC(S(C)(=O)=O)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1.N.O KKGAUCQHDXKWLK-UHFFFAOYSA-N 0.000 description 1
- XPUALKMZEPZUJW-UHFFFAOYSA-N CCNC1=NC=C(CC2=C(C(C)C)C=C(OC)C(Cl)=C2)C(N)=N1 Chemical compound CCNC1=NC=C(CC2=C(C(C)C)C=C(OC)C(Cl)=C2)C(N)=N1 XPUALKMZEPZUJW-UHFFFAOYSA-N 0.000 description 1
- JFPCGLRXHUAHLZ-UHFFFAOYSA-N CCNC1=NC=C(CC2=C(C(C)C)C=C(OC)C(OC)=C2)C(N)=N1 Chemical compound CCNC1=NC=C(CC2=C(C(C)C)C=C(OC)C(OC)=C2)C(N)=N1 JFPCGLRXHUAHLZ-UHFFFAOYSA-N 0.000 description 1
- WXZBSPKPIYAJTE-UHFFFAOYSA-N CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(C#N)=C2)C(N)=N1.CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(C(N)=O)=C2)C(N)=N1 Chemical compound CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(C#N)=C2)C(N)=N1.CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(C(N)=O)=C2)C(N)=N1 WXZBSPKPIYAJTE-UHFFFAOYSA-N 0.000 description 1
- MYSPVSAGXGEEAC-UHFFFAOYSA-N CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(C#N)=C2)C(N)=N1.CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(I)=C2)C(N)=N1 Chemical compound CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(C#N)=C2)C(N)=N1.CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(I)=C2)C(N)=N1 MYSPVSAGXGEEAC-UHFFFAOYSA-N 0.000 description 1
- SBZRZYPOYBGMDN-UHFFFAOYSA-N CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(C(N)=O)=C2)C(N)=N1 Chemical compound CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(C(N)=O)=C2)C(N)=N1 SBZRZYPOYBGMDN-UHFFFAOYSA-N 0.000 description 1
- NMVWKJDBVHEMMR-UHFFFAOYSA-N CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(S(C)(=O)=O)=C2)C(N)=N1.CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C=C2)C(N)=N1 Chemical compound CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(S(C)(=O)=O)=C2)C(N)=N1.CCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C=C2)C(N)=N1 NMVWKJDBVHEMMR-UHFFFAOYSA-N 0.000 description 1
- KPBGGTLGTLDIFQ-UHFFFAOYSA-N CCNS(=O)(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC Chemical compound CCNS(=O)(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC KPBGGTLGTLDIFQ-UHFFFAOYSA-N 0.000 description 1
- NFPBJQYCASCLMV-WIWZYDELSA-N CCOC(=O)/C(=C\OC)OC1=C(C(C)C)C=C(OC)C(C)=C1.CCOC(=O)CBr.CCOC(=O)COC1=C(C(C)C)C=C(OC)C(C)=C1.CI.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2Cl)C=C1C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2NC2=CC=CC=C2)C=C1C.COC1=CC(C(C)C)=C(OC2=CN=C(N)NC2=O)C=C1C.COCCOC.NC1=CC=CC=C1.O=P(Cl)(Cl)Cl.[H]OC1=C(C(C)C)C=C(OC)C(C)=C1 Chemical compound CCOC(=O)/C(=C\OC)OC1=C(C(C)C)C=C(OC)C(C)=C1.CCOC(=O)CBr.CCOC(=O)COC1=C(C(C)C)C=C(OC)C(C)=C1.CI.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2Cl)C=C1C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2NC2=CC=CC=C2)C=C1C.COC1=CC(C(C)C)=C(OC2=CN=C(N)NC2=O)C=C1C.COCCOC.NC1=CC=CC=C1.O=P(Cl)(Cl)Cl.[H]OC1=C(C(C)C)C=C(OC)C(C)=C1 NFPBJQYCASCLMV-WIWZYDELSA-N 0.000 description 1
- UQPNKQFNOCNPKB-UHFFFAOYSA-N CCOC(=O)C1=C(C)C2=CC(C(C)C)=C(OC3=CN=C(N)N=C3N)C=C2N1 Chemical compound CCOC(=O)C1=C(C)C2=CC(C(C)C)=C(OC3=CN=C(N)N=C3N)C=C2N1 UQPNKQFNOCNPKB-UHFFFAOYSA-N 0.000 description 1
- LIZGQIFEXMCNPZ-UHFFFAOYSA-N CCOC(=O)C1=CN(C)C2=CC(C(C)C)=C(OC3=CN=C(N)N=C3N)C=C12 Chemical compound CCOC(=O)C1=CN(C)C2=CC(C(C)C)=C(OC3=CN=C(N)N=C3N)C=C12 LIZGQIFEXMCNPZ-UHFFFAOYSA-N 0.000 description 1
- WZIYCRZAOFWDKL-UHFFFAOYSA-N CCOC(=O)N1CCC(NC2=NC=C(OC3=C(C(C)C)C=C(OC)C(Cl)=C3)C(N)=N2)CC1 Chemical compound CCOC(=O)N1CCC(NC2=NC=C(OC3=C(C(C)C)C=C(OC)C(Cl)=C3)C(N)=N2)CC1 WZIYCRZAOFWDKL-UHFFFAOYSA-N 0.000 description 1
- LWUNICOSKAFDRD-UHFFFAOYSA-N CCOC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I Chemical compound CCOC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I LWUNICOSKAFDRD-UHFFFAOYSA-N 0.000 description 1
- HIQGXHBXBQGAQT-UHFFFAOYSA-N CCS(=O)(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC Chemical compound CCS(=O)(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC HIQGXHBXBQGAQT-UHFFFAOYSA-N 0.000 description 1
- VYMDFVNOXVACHL-UHFFFAOYSA-N CCS(=O)(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1S(=O)(=O)Cl Chemical compound CCS(=O)(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1S(=O)(=O)Cl VYMDFVNOXVACHL-UHFFFAOYSA-N 0.000 description 1
- GLBCIFWPDGFVBC-UHFFFAOYSA-N CCS(=O)(=O)CCC(C)NC1=NC=C(OC2=C(C(C)C)C=C(OC)C(Cl)=C2)C(N)=N1 Chemical compound CCS(=O)(=O)CCC(C)NC1=NC=C(OC2=C(C(C)C)C=C(OC)C(Cl)=C2)C(N)=N1 GLBCIFWPDGFVBC-UHFFFAOYSA-N 0.000 description 1
- JPQGTYZNLLVGRE-LLVKDONJSA-N CC[C@H](CO)NC1=NC=C(OC2=C(C(C)C)C=C(OC)C(Cl)=C2)C(N)=N1 Chemical compound CC[C@H](CO)NC1=NC=C(OC2=C(C(C)C)C=C(OC)C(Cl)=C2)C(N)=N1 JPQGTYZNLLVGRE-LLVKDONJSA-N 0.000 description 1
- INSQJBFXNDKDQG-GFCCVEGCSA-N CC[C@H](CO)NC1=NC=C(OC2=C(C(C)C)C=C(OC)C(S(C)(=O)=O)=C2)C(N)=N1 Chemical compound CC[C@H](CO)NC1=NC=C(OC2=C(C(C)C)C=C(OC)C(S(C)(=O)=O)=C2)C(N)=N1 INSQJBFXNDKDQG-GFCCVEGCSA-N 0.000 description 1
- IEVJOQVWAGEXPD-UHFFFAOYSA-N CI.COC1=CC(C(C)C)=C(OC2=CN=C(N)NC2N)C=C1C1=NC=CN1.COC1=CC(C(C)C)=C(OC2=CN=C(N)NC2N)C=C1C1=NC=CN1C Chemical compound CI.COC1=CC(C(C)C)=C(OC2=CN=C(N)NC2N)C=C1C1=NC=CN1.COC1=CC(C(C)C)=C(OC2=CN=C(N)NC2N)C=C1C1=NC=CN1C IEVJOQVWAGEXPD-UHFFFAOYSA-N 0.000 description 1
- AIJOAWGMFGWGSG-UHFFFAOYSA-N CN.CNS(=O)(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1S(=O)(=O)Cl Chemical compound CN.CNS(=O)(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1S(=O)(=O)Cl AIJOAWGMFGWGSG-UHFFFAOYSA-N 0.000 description 1
- VYJJKVHKWJBNBN-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC Chemical compound CNC(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC VYJJKVHKWJBNBN-UHFFFAOYSA-N 0.000 description 1
- QOWNGKCHRBRGBT-UHFFFAOYSA-N CNC1=NC(N)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1 Chemical compound CNC1=NC(N)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1 QOWNGKCHRBRGBT-UHFFFAOYSA-N 0.000 description 1
- YYLNLWPWMJKKGN-UHFFFAOYSA-N CNC1=NC(NC(C)C)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1 Chemical compound CNC1=NC(NC(C)C)=NC=C1CC1=C(C(C)C)C=C(OC)C(OC)=C1 YYLNLWPWMJKKGN-UHFFFAOYSA-N 0.000 description 1
- DRAGEURBXZQOCP-UHFFFAOYSA-N CNC1=NC=C(CC2=C(C(C)C)C=C(OC)C(Cl)=C2)C(N)=N1 Chemical compound CNC1=NC=C(CC2=C(C(C)C)C=C(OC)C(Cl)=C2)C(N)=N1 DRAGEURBXZQOCP-UHFFFAOYSA-N 0.000 description 1
- PRQRMPLWIHANDE-UHFFFAOYSA-N CNC1=NC=C(CC2=C(C(C)C)C=C(OC)C(OC)=C2)C(N)=N1 Chemical compound CNC1=NC=C(CC2=C(C(C)C)C=C(OC)C(OC)=C2)C(N)=N1 PRQRMPLWIHANDE-UHFFFAOYSA-N 0.000 description 1
- HHGQXRUYIBMPBQ-UHFFFAOYSA-N CNC1=NC=C(CC2=C(C(C)C)C=C(OC)C(OC)=C2)C(NC(C)C)=N1 Chemical compound CNC1=NC=C(CC2=C(C(C)C)C=C(OC)C(OC)=C2)C(NC(C)C)=N1 HHGQXRUYIBMPBQ-UHFFFAOYSA-N 0.000 description 1
- VJYSXRLBVZWKMH-UHFFFAOYSA-N CNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(S(C)(=O)=O)=C2)C(N)=N1 Chemical compound CNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(S(C)(=O)=O)=C2)C(N)=N1 VJYSXRLBVZWKMH-UHFFFAOYSA-N 0.000 description 1
- KDDGQNVJYJDNOU-UHFFFAOYSA-N CNS(=O)(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC Chemical compound CNS(=O)(=O)C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC KDDGQNVJYJDNOU-UHFFFAOYSA-N 0.000 description 1
- YKPIESJBEINRBY-GWBIRJHYSA-N COC(OC)N(C)C.COC1=CC(C(C)C)=C(OC2=CN=C(/N=C\N(C)C)N=C2/N=C\N(C)C)C=C1C(=O)/C=C/N(C)C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(=O)/C=C/N(C)C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)=O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CC=NO1.N.NO.O Chemical compound COC(OC)N(C)C.COC1=CC(C(C)C)=C(OC2=CN=C(/N=C\N(C)C)N=C2/N=C\N(C)C)C=C1C(=O)/C=C/N(C)C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(=O)/C=C/N(C)C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)=O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CC=NO1.N.NO.O YKPIESJBEINRBY-GWBIRJHYSA-N 0.000 description 1
- DKZAQOBJKLOOHW-UHFFFAOYSA-N COC1=C(C2=CC(C)=CS2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 Chemical compound COC1=C(C2=CC(C)=CS2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 DKZAQOBJKLOOHW-UHFFFAOYSA-N 0.000 description 1
- GPQLUQVDNKMFQO-UHFFFAOYSA-N COC1=C(C2=CC=C(F)C=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 Chemical compound COC1=C(C2=CC=C(F)C=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 GPQLUQVDNKMFQO-UHFFFAOYSA-N 0.000 description 1
- NRYHHPIQGZTIBK-UHFFFAOYSA-N COC1=C(C2=CC=CC(C#N)=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 Chemical compound COC1=C(C2=CC=CC(C#N)=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 NRYHHPIQGZTIBK-UHFFFAOYSA-N 0.000 description 1
- HWWMBMTVBODZCC-UHFFFAOYSA-N COC1=C(C2=CC=CC=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 Chemical compound COC1=C(C2=CC=CC=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 HWWMBMTVBODZCC-UHFFFAOYSA-N 0.000 description 1
- XODNCRHNYXDKOU-UHFFFAOYSA-N COC1=C(C2=CC=CN=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 Chemical compound COC1=C(C2=CC=CN=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 XODNCRHNYXDKOU-UHFFFAOYSA-N 0.000 description 1
- QMYQAOZSHZKFRP-UHFFFAOYSA-N COC1=C(C2=CC=CO2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 Chemical compound COC1=C(C2=CC=CO2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 QMYQAOZSHZKFRP-UHFFFAOYSA-N 0.000 description 1
- YSEGJHAHYJWESO-UHFFFAOYSA-N COC1=C(C2=CC=CS2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 Chemical compound COC1=C(C2=CC=CS2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 YSEGJHAHYJWESO-UHFFFAOYSA-N 0.000 description 1
- KYSHZXQFFAZQIZ-UHFFFAOYSA-N COC1=C(C2=CC=NC=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 Chemical compound COC1=C(C2=CC=NC=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 KYSHZXQFFAZQIZ-UHFFFAOYSA-N 0.000 description 1
- MXIDGJNPHOETTK-UHFFFAOYSA-N COC1=C(C2=CN(C)N=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 Chemical compound COC1=C(C2=CN(C)N=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 MXIDGJNPHOETTK-UHFFFAOYSA-N 0.000 description 1
- FGCRSMAFADBDQV-UHFFFAOYSA-N COC1=C(C2=CSC3=C2C=CC=C3)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 Chemical compound COC1=C(C2=CSC3=C2C=CC=C3)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 FGCRSMAFADBDQV-UHFFFAOYSA-N 0.000 description 1
- SCJRALDXZLVVGF-UHFFFAOYSA-N COC1=C(C2=CSC=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 Chemical compound COC1=C(C2=CSC=C2)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 SCJRALDXZLVVGF-UHFFFAOYSA-N 0.000 description 1
- QNLNUTYQPUPYKI-UHFFFAOYSA-N COC1=C(C2=CSC=C2C)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 Chemical compound COC1=C(C2=CSC=C2C)C=C(OC2=CN=C(N)N=C2N)C(C(C)C)=C1 QNLNUTYQPUPYKI-UHFFFAOYSA-N 0.000 description 1
- RKNTUTGBUHVAPY-UHFFFAOYSA-N COC1=CC(Br)=C(OC2=CN=C(N)N=C2N)C=C1OC Chemical compound COC1=CC(Br)=C(OC2=CN=C(N)N=C2N)C=C1OC RKNTUTGBUHVAPY-UHFFFAOYSA-N 0.000 description 1
- VGJUGXQWCVQARR-UHFFFAOYSA-N COC1=CC(C(=O)C2=CN=C(N)N=C2N)=C(C(C)CC2=CC=CC=C2)C=C1OC.COC1=CC(C(=O)C2=CN=C(OC)N=C2OC)=C(C(C)CC2=CC=CC=C2)C=C1OC.COC1=CC(C(C)CC2=CC=CC=C2)=C(C(O)C2=CN=C(OC)N=C2OC)C=C1OC.COC1=CC(C=O)=C(C(C)CC2=CC=CC=C2)C=C1OC.COC1=CC(CC2=CN=C(N)N=C2N)=C(C(C)CC2=CC=CC=C2)C=C1OC.N.O=[Mn]=O Chemical compound COC1=CC(C(=O)C2=CN=C(N)N=C2N)=C(C(C)CC2=CC=CC=C2)C=C1OC.COC1=CC(C(=O)C2=CN=C(OC)N=C2OC)=C(C(C)CC2=CC=CC=C2)C=C1OC.COC1=CC(C(C)CC2=CC=CC=C2)=C(C(O)C2=CN=C(OC)N=C2OC)C=C1OC.COC1=CC(C=O)=C(C(C)CC2=CC=CC=C2)C=C1OC.COC1=CC(CC2=CN=C(N)N=C2N)=C(C(C)CC2=CC=CC=C2)C=C1OC.N.O=[Mn]=O VGJUGXQWCVQARR-UHFFFAOYSA-N 0.000 description 1
- OOSJUUYSPPBJFG-UHFFFAOYSA-N COC1=CC(C(C)(C)F)=C(OC2=CN=C(N)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)(C)F)=C(OC2=CN=C(N)N=C2N)C=C1Cl OOSJUUYSPPBJFG-UHFFFAOYSA-N 0.000 description 1
- DIIGYQOFPKWZBS-UHFFFAOYSA-N COC1=CC(C(C)(C)O)=C(OC2=CN=C(N)N=C2N)C=C1I Chemical compound COC1=CC(C(C)(C)O)=C(OC2=CN=C(N)N=C2N)C=C1I DIIGYQOFPKWZBS-UHFFFAOYSA-N 0.000 description 1
- OEJAPEQZAPUOTQ-UHFFFAOYSA-N COC1=CC(C(C)C)=C(C(O)C2=CN=C(N)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(C(O)C2=CN=C(N)N=C2N)C=C1Cl OEJAPEQZAPUOTQ-UHFFFAOYSA-N 0.000 description 1
- MXKBJDXIQUUHLJ-UHFFFAOYSA-N COC1=CC(C(C)C)=C(C(O)C2=CN=C(N)N=C2N)C=C1OC Chemical compound COC1=CC(C(C)C)=C(C(O)C2=CN=C(N)N=C2N)C=C1OC MXKBJDXIQUUHLJ-UHFFFAOYSA-N 0.000 description 1
- OAMUFGVRTFLZJQ-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C OAMUFGVRTFLZJQ-UHFFFAOYSA-N 0.000 description 1
- XJTHSJOUPAEYDS-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C#N Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C#N XJTHSJOUPAEYDS-UHFFFAOYSA-N 0.000 description 1
- NJXRXWKKPVLLHA-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C.COC1=CC(C(C)C)=C(CC2=CN=C(NC(C)=O)N=C2NC(C)=O)C=C1C Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C.COC1=CC(C(C)C)=C(CC2=CN=C(NC(C)=O)N=C2NC(C)=O)C=C1C NJXRXWKKPVLLHA-UHFFFAOYSA-N 0.000 description 1
- UJXRUJFHNDWNBD-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C1=CC=C(Cl)S1 Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C1=CC=C(Cl)S1 UJXRUJFHNDWNBD-UHFFFAOYSA-N 0.000 description 1
- NXPZKWTUXSRBAE-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C1=CC=CO1 Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C1=CC=CO1 NXPZKWTUXSRBAE-UHFFFAOYSA-N 0.000 description 1
- OMEXFBSDKBQVAB-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C1=CN=CS1 Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C1=CN=CS1 OMEXFBSDKBQVAB-UHFFFAOYSA-N 0.000 description 1
- QAWCCOFKSRGWDX-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C1=CSC=C1 Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C1=CSC=C1 QAWCCOFKSRGWDX-UHFFFAOYSA-N 0.000 description 1
- JNHYCVUBRIWAHW-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C1=NCCO1 Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1C1=NCCO1 JNHYCVUBRIWAHW-UHFFFAOYSA-N 0.000 description 1
- HWELVAUMWCZRBN-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1Cl HWELVAUMWCZRBN-UHFFFAOYSA-N 0.000 description 1
- OQYKEEGOIJGLLD-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1OC1=CC=CC=C1 Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1OC1=CC=CC=C1 OQYKEEGOIJGLLD-UHFFFAOYSA-N 0.000 description 1
- QOYOOOIFBJZJJM-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1S(C)(=O)=O Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(N)N=C2N)C=C1S(C)(=O)=O QOYOOOIFBJZJJM-UHFFFAOYSA-N 0.000 description 1
- PNVSPZCNHOHAKW-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(NC(C)(C)C)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(NC(C)(C)C)N=C2N)C=C1Cl PNVSPZCNHOHAKW-UHFFFAOYSA-N 0.000 description 1
- VNDRBBOXAUBRLF-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(NC(C)=O)N=C2NC(C)=O)C=C1C Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(NC(C)=O)N=C2NC(C)=O)C=C1C VNDRBBOXAUBRLF-UHFFFAOYSA-N 0.000 description 1
- KOVIVHFKBVBTMU-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(NC(C)C)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(NC(C)C)N=C2N)C=C1Cl KOVIVHFKBVBTMU-UHFFFAOYSA-N 0.000 description 1
- AHQDNLOUUNWLKB-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(NC3=CC=CC=C3)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(NC3=CC=CC=C3)N=C2N)C=C1Cl AHQDNLOUUNWLKB-UHFFFAOYSA-N 0.000 description 1
- RNCIILHWBKUMNX-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(NC3CC3)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(NC3CC3)N=C2N)C=C1Cl RNCIILHWBKUMNX-UHFFFAOYSA-N 0.000 description 1
- UQFGHWCWVKZWOY-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(NC3CCCCC3)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(NC3CCCCC3)N=C2N)C=C1Cl UQFGHWCWVKZWOY-UHFFFAOYSA-N 0.000 description 1
- IKZHEGKWWUUEEF-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(NCC(C)C)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(NCC(C)C)N=C2N)C=C1Cl IKZHEGKWWUUEEF-UHFFFAOYSA-N 0.000 description 1
- ZQWXTFMQUDCGQX-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(NCC(F)(F)F)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(NCC(F)(F)F)N=C2N)C=C1Cl ZQWXTFMQUDCGQX-UHFFFAOYSA-N 0.000 description 1
- MQDMHWFNFGXTSX-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(NCC(F)(F)F)N=C2N)C=C1Cl.COC1=CC(C(C)C)=C(CC2=CN=C(S(C)(=O)=O)N=C2N)C=C1Cl.COC1=CC(C(C)C)=C(CC2=CN=C(SC)N=C2Cl)C=C1Cl.COC1=CC(C(C)C)=C(CC2=CN=C(SC)N=C2N)C=C1Cl.N.NCC(F)(F)F Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(NCC(F)(F)F)N=C2N)C=C1Cl.COC1=CC(C(C)C)=C(CC2=CN=C(S(C)(=O)=O)N=C2N)C=C1Cl.COC1=CC(C(C)C)=C(CC2=CN=C(SC)N=C2Cl)C=C1Cl.COC1=CC(C(C)C)=C(CC2=CN=C(SC)N=C2N)C=C1Cl.N.NCC(F)(F)F MQDMHWFNFGXTSX-UHFFFAOYSA-N 0.000 description 1
- QRTIBDIRCPGNMX-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(NCC3=CC=CC=C3)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(NCC3=CC=CC=C3)N=C2N)C=C1Cl QRTIBDIRCPGNMX-UHFFFAOYSA-N 0.000 description 1
- SLRACLCMOIJHDO-UHFFFAOYSA-N COC1=CC(C(C)C)=C(CC2=CN=C(NCCC3=CC=CC=C3)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(CC2=CN=C(NCCC3=CC=CC=C3)N=C2N)C=C1Cl SLRACLCMOIJHDO-UHFFFAOYSA-N 0.000 description 1
- QDJZBKIYYCUBMI-UHFFFAOYSA-N COC1=CC(C(C)C)=C(I)C=C1CC1=C(N)N=C(N)N=C1 Chemical compound COC1=CC(C(C)C)=C(I)C=C1CC1=C(N)N=C(N)N=C1 QDJZBKIYYCUBMI-UHFFFAOYSA-N 0.000 description 1
- UWNGZPCGBCETPF-UHFFFAOYSA-N COC1=CC(C(C)C)=C(O)C=C1C(F)(F)F.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(F)(F)F.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C(F)(F)F.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1I Chemical compound COC1=CC(C(C)C)=C(O)C=C1C(F)(F)F.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(F)(F)F.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C(F)(F)F.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1I UWNGZPCGBCETPF-UHFFFAOYSA-N 0.000 description 1
- SQROKVCEISNVIY-UHFFFAOYSA-N COC1=CC(C(C)C)=C(O)C=C1C1=CSC=N1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CSC=N1.COC1=CC(C(C)C)=C(OCC#N)C=C1C1=CSC=N1.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C(=O)CBr.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C(C)=O.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C1=CSC=N1 Chemical compound COC1=CC(C(C)C)=C(O)C=C1C1=CSC=N1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CSC=N1.COC1=CC(C(C)C)=C(OCC#N)C=C1C1=CSC=N1.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C(=O)CBr.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C(C)=O.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C1=CSC=N1 SQROKVCEISNVIY-UHFFFAOYSA-N 0.000 description 1
- ORPGEZJCBATACM-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C(C)=C1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C(C)=C1 ORPGEZJCBATACM-UHFFFAOYSA-N 0.000 description 1
- HIKYTWIVLKHYIM-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1 HIKYTWIVLKHYIM-UHFFFAOYSA-N 0.000 description 1
- SVUGYFCYJQPKBH-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I SVUGYFCYJQPKBH-UHFFFAOYSA-N 0.000 description 1
- SJSQTTWUMQMMQA-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1S(=O)(=O)Cl.O=S(=O)(O)Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1S(=O)(=O)Cl.O=S(=O)(O)Cl SJSQTTWUMQMMQA-UHFFFAOYSA-N 0.000 description 1
- SSUVBQJENVJJHP-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1S(C)(=O)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1S(C)(=O)=O SSUVBQJENVJJHP-UHFFFAOYSA-N 0.000 description 1
- CVDIQNLSSMDPKP-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1/C(N)=N/O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C#N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NOC=N1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2NC=O)C=C1C1=NOC=N1.COC1=CC(C(C)C)=C(OC2=CN=C(NC=O)N=C2N)C=C1C1=NOC=N1.COC1=CC(C(C)C)=C(OC2=CN=C(NC=O)N=C2NC=O)C=C1C1=NOC=N1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1/C(N)=N/O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C#N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NOC=N1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2NC=O)C=C1C1=NOC=N1.COC1=CC(C(C)C)=C(OC2=CN=C(NC=O)N=C2N)C=C1C1=NOC=N1.COC1=CC(C(C)C)=C(OC2=CN=C(NC=O)N=C2NC=O)C=C1C1=NOC=N1 CVDIQNLSSMDPKP-UHFFFAOYSA-N 0.000 description 1
- IBCZHROKDLOJJF-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C IBCZHROKDLOJJF-UHFFFAOYSA-N 0.000 description 1
- WZTGXCZSRLRAEO-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C#N Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C#N WZTGXCZSRLRAEO-UHFFFAOYSA-N 0.000 description 1
- CMRHNFRUSNIDAQ-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C#N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(=O)O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C#N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(=O)O CMRHNFRUSNIDAQ-UHFFFAOYSA-N 0.000 description 1
- MYDVOSRQZSBCTI-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C#N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(N)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C#N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(N)=O MYDVOSRQZSBCTI-UHFFFAOYSA-N 0.000 description 1
- HFCUVRSHPFEABS-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C#N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NN=NN1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C#N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NN=NN1 HFCUVRSHPFEABS-UHFFFAOYSA-N 0.000 description 1
- PJBWYOJNXUMQLP-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C#N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C#N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I PJBWYOJNXUMQLP-UHFFFAOYSA-N 0.000 description 1
- JLVYCMCKJDODHX-UHDJGPCESA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(=O)/C=C/N(C)C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CC=NN1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(=O)/C=C/N(C)C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CC=NN1 JLVYCMCKJDODHX-UHDJGPCESA-N 0.000 description 1
- XITZIVGLZZPBER-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(=O)N(C)C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(=O)O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(=O)N(C)C.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(=O)O XITZIVGLZZPBER-UHFFFAOYSA-N 0.000 description 1
- UMZMQINYOLOMAX-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(=O)O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(=O)O UMZMQINYOLOMAX-UHFFFAOYSA-N 0.000 description 1
- KUIRMDWCTDPADD-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)(C)O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)(C)O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)=O KUIRMDWCTDPADD-UHFFFAOYSA-N 0.000 description 1
- PCXSWYJALVNVSD-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)(C)O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)C Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)(C)O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)C PCXSWYJALVNVSD-UHFFFAOYSA-N 0.000 description 1
- MZODADHVCMQGRL-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)O MZODADHVCMQGRL-UHFFFAOYSA-N 0.000 description 1
- RYUXAHQPQCTTRU-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)OC Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(C)OC RYUXAHQPQCTTRU-UHFFFAOYSA-N 0.000 description 1
- NJYCBTLQFMHCJD-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(F)(F)F Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(F)(F)F NJYCBTLQFMHCJD-UHFFFAOYSA-N 0.000 description 1
- FSKLGMRCJAORMX-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(N)=O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(N)=S Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(N)=O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(N)=S FSKLGMRCJAORMX-UHFFFAOYSA-N 0.000 description 1
- MWOGVIOGNFCYHB-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(N)=S.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NC=CS1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C(N)=S.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NC=CS1 MWOGVIOGNFCYHB-UHFFFAOYSA-N 0.000 description 1
- HRZAWWDEMNDIAT-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CC=CO1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I.OB(O)C1=CC=CO1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CC=CO1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I.OB(O)C1=CC=CO1 HRZAWWDEMNDIAT-UHFFFAOYSA-N 0.000 description 1
- DTTHQXFQTVSJBU-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CC=NN1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CC=NN1 DTTHQXFQTVSJBU-UHFFFAOYSA-N 0.000 description 1
- RZZPCOLMJOTYKV-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CC=NO1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CC=NO1 RZZPCOLMJOTYKV-UHFFFAOYSA-N 0.000 description 1
- NAGAZGOOWQMNOR-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CN=C(C)S1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CN=C(C)S1 NAGAZGOOWQMNOR-UHFFFAOYSA-N 0.000 description 1
- WHFZJVOOWMVKQP-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CN=CO1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CN=CO1 WHFZJVOOWMVKQP-UHFFFAOYSA-N 0.000 description 1
- DUFUYWGJEAVLMT-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CN=CS1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CN=CS1.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I DUFUYWGJEAVLMT-UHFFFAOYSA-N 0.000 description 1
- AGLXNSDTIKVFQB-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=COC=N1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=COC=N1 AGLXNSDTIKVFQB-UHFFFAOYSA-N 0.000 description 1
- OBJWMYJVNXRZMP-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=COC=N1.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C1=COC=N1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=COC=N1.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C1=COC=N1 OBJWMYJVNXRZMP-UHFFFAOYSA-N 0.000 description 1
- WVHYGDXPLVWLRJ-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CSC(C)=N1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CSC(C)=N1 WVHYGDXPLVWLRJ-UHFFFAOYSA-N 0.000 description 1
- UNRDQHBKUNHXTN-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CSC=N1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=CSC=N1 UNRDQHBKUNHXTN-UHFFFAOYSA-N 0.000 description 1
- BMGSNGSJUJYWRK-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NC=CN1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NC=CN1 BMGSNGSJUJYWRK-UHFFFAOYSA-N 0.000 description 1
- SSHWUEVOFPNHJD-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NC=CN1C Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NC=CN1C SSHWUEVOFPNHJD-UHFFFAOYSA-N 0.000 description 1
- OUDDDTOHZCJBJR-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NC=CO1.Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NC=CO1.Cl OUDDDTOHZCJBJR-UHFFFAOYSA-N 0.000 description 1
- DUCLZJBAXVTLTN-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NC=CS1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NC=CS1 DUCLZJBAXVTLTN-UHFFFAOYSA-N 0.000 description 1
- YQVZTFRYKTVAKW-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NCCO1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1C1=NCCO1 YQVZTFRYKTVAKW-UHFFFAOYSA-N 0.000 description 1
- HGARQXXUVFFGNI-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1Cl HGARQXXUVFFGNI-UHFFFAOYSA-N 0.000 description 1
- VOSYPTXKTNWRPD-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1F Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1F VOSYPTXKTNWRPD-UHFFFAOYSA-N 0.000 description 1
- XRMWJMDMTXTHGX-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I.COC1=CC(C(C)C)=C(OC2=C[N+]([O-])=C(N)N=C2N)C=C1I Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I.COC1=CC(C(C)C)=C(OC2=C[N+]([O-])=C(N)N=C2N)C=C1I XRMWJMDMTXTHGX-UHFFFAOYSA-N 0.000 description 1
- KVSHBEIGMAZHTM-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CC=C1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CC=C1 KVSHBEIGMAZHTM-UHFFFAOYSA-N 0.000 description 1
- UZUZFOKJFSAQFX-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1NC(C)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1NC(C)=O UZUZFOKJFSAQFX-UHFFFAOYSA-N 0.000 description 1
- DFVFLQJXNYQMSU-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1NC(N)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1NC(N)=O DFVFLQJXNYQMSU-UHFFFAOYSA-N 0.000 description 1
- HLQMTDPVPHAIDD-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C(C)=CC=C1C Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C(C)=CC=C1C HLQMTDPVPHAIDD-UHFFFAOYSA-N 0.000 description 1
- DALUMQXLIITJKY-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CC(C)=N1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CC(C)=N1 DALUMQXLIITJKY-UHFFFAOYSA-N 0.000 description 1
- GWEDPMOXSLFNBL-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CC=C1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CC=C1 GWEDPMOXSLFNBL-UHFFFAOYSA-N 0.000 description 1
- DGUSHQKTAKWJKH-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CC=N1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CC=N1 DGUSHQKTAKWJKH-UHFFFAOYSA-N 0.000 description 1
- IOIAZYJMQXLFOM-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CN=C1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CN=C1 IOIAZYJMQXLFOM-UHFFFAOYSA-N 0.000 description 1
- ZYMVMYWQZRKAHP-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CN=C1S Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CN=C1S ZYMVMYWQZRKAHP-UHFFFAOYSA-N 0.000 description 1
- NOIVMUMHAPAJDG-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CN=N1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=CN=N1 NOIVMUMHAPAJDG-UHFFFAOYSA-N 0.000 description 1
- CBYRACOKTJYKGE-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=NC=N1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=NC=N1 CBYRACOKTJYKGE-UHFFFAOYSA-N 0.000 description 1
- MWNMCRJSHZGOHJ-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=NN=N1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1C=NN=N1 MWNMCRJSHZGOHJ-UHFFFAOYSA-N 0.000 description 1
- XNDNRBZJORLXGV-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1CCCC1=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1CCCC1=O XNDNRBZJORLXGV-UHFFFAOYSA-N 0.000 description 1
- AIJCSOFUWUNOGX-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1CCCC1=O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1NC(=O)CCCCl.CO[Na] Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1CCCC1=O.COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1NC(=O)CCCCl.CO[Na] AIJCSOFUWUNOGX-UHFFFAOYSA-N 0.000 description 1
- XAIQGZFHIDGGHH-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1CCN(S(C)(=O)=O)CC1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1CCN(S(C)(=O)=O)CC1 XAIQGZFHIDGGHH-UHFFFAOYSA-N 0.000 description 1
- ZTPKUTURUMNCSF-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1N=C(C)C=C1C Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1N1N=C(C)C=C1C ZTPKUTURUMNCSF-UHFFFAOYSA-N 0.000 description 1
- OHXYLIUHLBLYIQ-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1NC(=O)NC1=CC=CC=C1 Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1NC(=O)NC1=CC=CC=C1 OHXYLIUHLBLYIQ-UHFFFAOYSA-N 0.000 description 1
- POSMYBDNNRVPDA-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1NC(C)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1NC(C)=O POSMYBDNNRVPDA-UHFFFAOYSA-N 0.000 description 1
- LAJYCADRXKLNFL-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1NC(N)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1NC(N)=O LAJYCADRXKLNFL-UHFFFAOYSA-N 0.000 description 1
- KGMGEZRXBPHRRH-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1OC(F)(F)F Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1OC(F)(F)F KGMGEZRXBPHRRH-UHFFFAOYSA-N 0.000 description 1
- OUQUOVKPHMOXRY-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1S(C)(=O)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1S(C)(=O)=O OUQUOVKPHMOXRY-UHFFFAOYSA-N 0.000 description 1
- HLWURFKMDLAKOD-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1S(N)(=O)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1S(N)(=O)=O HLWURFKMDLAKOD-UHFFFAOYSA-N 0.000 description 1
- AHUCEGVZPVBZJP-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2NC2=CC=CC=C2)C=C1C Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2NC2=CC=CC=C2)C=C1C AHUCEGVZPVBZJP-UHFFFAOYSA-N 0.000 description 1
- GXJQMZHURMGBDH-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC(C)C)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC(C)C)N=C2N)C=C1Cl GXJQMZHURMGBDH-UHFFFAOYSA-N 0.000 description 1
- PSZTTZXFBYNLRE-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC(C)C)N=C2N)C=C1S(C)(=O)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC(C)C)N=C2N)C=C1S(C)(=O)=O PSZTTZXFBYNLRE-UHFFFAOYSA-N 0.000 description 1
- MQBXVKHZIDJALF-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC(C)C3CC3)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC(C)C3CC3)N=C2N)C=C1Cl MQBXVKHZIDJALF-UHFFFAOYSA-N 0.000 description 1
- DSOCGRPPDQJTDM-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC(C)CN3CCN(C(C)=O)CC3)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC(C)CN3CCN(C(C)=O)CC3)N=C2N)C=C1Cl DSOCGRPPDQJTDM-UHFFFAOYSA-N 0.000 description 1
- HFVXVGOJTPJLSH-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC(CCO)CCO)N=C2N)C=C1Br.Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC(CCO)CCO)N=C2N)C=C1Br.Cl HFVXVGOJTPJLSH-UHFFFAOYSA-N 0.000 description 1
- WOOPGMBOAAAYRE-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC(CCO)CCO)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC(CCO)CCO)N=C2N)C=C1Cl WOOPGMBOAAAYRE-UHFFFAOYSA-N 0.000 description 1
- GAEUBZWYLISMLN-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC3=CC=CC=C3)N=C2N)C=C1S(C)(=O)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC3=CC=CC=C3)N=C2N)C=C1S(C)(=O)=O GAEUBZWYLISMLN-UHFFFAOYSA-N 0.000 description 1
- BQORNIDWLWBQQF-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC3CC3)N=C2N)C=C1S(C)(=O)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC3CC3)N=C2N)C=C1S(C)(=O)=O BQORNIDWLWBQQF-UHFFFAOYSA-N 0.000 description 1
- HSLJCGPSCBNJAP-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC3CCN(S(C)(=O)=O)CC3)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC3CCN(S(C)(=O)=O)CC3)N=C2N)C=C1Cl HSLJCGPSCBNJAP-UHFFFAOYSA-N 0.000 description 1
- ADFFGVLKEURHJD-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC3CCN(S(C)(=O)=O)CC3)N=C2N)C=C1S(C)(=O)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC3CCN(S(C)(=O)=O)CC3)N=C2N)C=C1S(C)(=O)=O ADFFGVLKEURHJD-UHFFFAOYSA-N 0.000 description 1
- WBNMEAGWTWLBKZ-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC3CCOCC3)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC3CCOCC3)N=C2N)C=C1Cl WBNMEAGWTWLBKZ-UHFFFAOYSA-N 0.000 description 1
- WZPFHHHVCIENNZ-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC3CCOCC3)N=C2N)C=C1S(C)(=O)=O.Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC3CCOCC3)N=C2N)C=C1S(C)(=O)=O.Cl WZPFHHHVCIENNZ-UHFFFAOYSA-N 0.000 description 1
- WLSFYZNHIWKXQI-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NC3CCSCC3)N=C2N)C=C1S(C)(=O)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NC3CCSCC3)N=C2N)C=C1S(C)(=O)=O WLSFYZNHIWKXQI-UHFFFAOYSA-N 0.000 description 1
- BSCYIAHFCIWPKM-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NCC(C)C)N=C2N)C=C1S(C)(=O)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NCC(C)C)N=C2N)C=C1S(C)(=O)=O BSCYIAHFCIWPKM-UHFFFAOYSA-N 0.000 description 1
- HMVMRUHGJLHILP-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NCC(F)(F)F)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NCC(F)(F)F)N=C2N)C=C1Cl HMVMRUHGJLHILP-UHFFFAOYSA-N 0.000 description 1
- CKRNTIBSCVRKKK-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NCC(F)(F)F)N=C2N)C=C1S(C)(=O)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NCC(F)(F)F)N=C2N)C=C1S(C)(=O)=O CKRNTIBSCVRKKK-UHFFFAOYSA-N 0.000 description 1
- MTFHVLNOWDUCHF-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NCC3=CC=CC=C3)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NCC3=CC=CC=C3)N=C2N)C=C1Cl MTFHVLNOWDUCHF-UHFFFAOYSA-N 0.000 description 1
- SNVUVBLKOVSHMF-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NCC3=CC=CC=C3)N=C2N)C=C1S(C)(=O)=O Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NCC3=CC=CC=C3)N=C2N)C=C1S(C)(=O)=O SNVUVBLKOVSHMF-UHFFFAOYSA-N 0.000 description 1
- CLHAXDYJHQPNKE-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=CN=C(NCCO)N=C2N)C=C1S(C)(=O)=O.Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(NCCO)N=C2N)C=C1S(C)(=O)=O.Cl CLHAXDYJHQPNKE-UHFFFAOYSA-N 0.000 description 1
- YEKQWJLPEIDRNQ-VIFPVBQESA-N COC1=CC(C(C)C)=C(OC2=CN=C(N[C@@H](C)C(=O)O)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N[C@@H](C)C(=O)O)N=C2N)C=C1Cl YEKQWJLPEIDRNQ-VIFPVBQESA-N 0.000 description 1
- ZGBYWYHFSQTCQA-ZDUSSCGKSA-N COC1=CC(C(C)C)=C(OC2=CN=C(N[C@@H](C)C(=O)OCC(C)(CO)CO)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)C)=C(OC2=CN=C(N[C@@H](C)C(=O)OCC(C)(CO)CO)N=C2N)C=C1Cl ZGBYWYHFSQTCQA-ZDUSSCGKSA-N 0.000 description 1
- HNMQNTSAMJVPHG-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OC2=C[N+]([O-])=C(N)N=C2N)C=C1I Chemical compound COC1=CC(C(C)C)=C(OC2=C[N+]([O-])=C(N)N=C2N)C=C1I HNMQNTSAMJVPHG-UHFFFAOYSA-N 0.000 description 1
- MGODLUYIEWRTPI-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C(=O)CBr.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C(=O)COC=O Chemical compound COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C(=O)CBr.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C(=O)COC=O MGODLUYIEWRTPI-UHFFFAOYSA-N 0.000 description 1
- DYAONJCGXSTWIV-UHFFFAOYSA-N COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C(=O)COC=O.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C1=COC=N1 Chemical compound COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C(=O)COC=O.COC1=CC(C(C)C)=C(OS(=O)(=O)C2=CC=C(C)C=C2)C=C1C1=COC=N1 DYAONJCGXSTWIV-UHFFFAOYSA-N 0.000 description 1
- ICERBHMIZNLYJG-UHFFFAOYSA-N COC1=CC(C(C)CO)=C(OC2=CN=C(N)N=C2N)C=C1I Chemical compound COC1=CC(C(C)CO)=C(OC2=CN=C(N)N=C2N)C=C1I ICERBHMIZNLYJG-UHFFFAOYSA-N 0.000 description 1
- YKGPEIIPMTYPPO-UHFFFAOYSA-N COC1=CC(C(C)O)=C(OC2=CN=C(N)N=C2N)C=C1Cl Chemical compound COC1=CC(C(C)O)=C(OC2=CN=C(N)N=C2N)C=C1Cl YKGPEIIPMTYPPO-UHFFFAOYSA-N 0.000 description 1
- NQQUYTBHSILUEC-UHFFFAOYSA-N COC1=CC(C2CC2)=C(OC2=CN=C(N)N=C2N)C=C1Br Chemical compound COC1=CC(C2CC2)=C(OC2=CN=C(N)N=C2N)C=C1Br NQQUYTBHSILUEC-UHFFFAOYSA-N 0.000 description 1
- PDJNQUFPFIGBLK-UHFFFAOYSA-N COC1=CC(C2CC2)=C(OC2=CN=C(N)N=C2N)C=C1Cl.COC1=CC(C2CC2)=CC=C1Cl Chemical compound COC1=CC(C2CC2)=C(OC2=CN=C(N)N=C2N)C=C1Cl.COC1=CC(C2CC2)=CC=C1Cl PDJNQUFPFIGBLK-UHFFFAOYSA-N 0.000 description 1
- BOIPSMBURQLWPD-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2N)=C(C2CC2)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2N)=C(C2CC2)C=C1OC BOIPSMBURQLWPD-UHFFFAOYSA-N 0.000 description 1
- KUCONWGMZBHMNG-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2NC(C)C)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2NC(C)C)=C(C(C)C)C=C1OC KUCONWGMZBHMNG-UHFFFAOYSA-N 0.000 description 1
- LTGMAPCMEXWDIS-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2NC2=CC=CC=C2)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2NC2=CC=CC=C2)=C(C(C)C)C=C1OC LTGMAPCMEXWDIS-UHFFFAOYSA-N 0.000 description 1
- IUIVDVVNSYHQOA-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2NC2CC2)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2NC2CC2)=C(C(C)C)C=C1OC IUIVDVVNSYHQOA-UHFFFAOYSA-N 0.000 description 1
- HRTQORPJSNKNFU-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2NC2CCC(S(C)(=O)=O)CC2)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2NC2CCC(S(C)(=O)=O)CC2)=C(C(C)C)C=C1OC HRTQORPJSNKNFU-UHFFFAOYSA-N 0.000 description 1
- GVBIMWXHIHVUKV-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2NC2CCOCC2)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2NC2CCOCC2)=C(C(C)C)C=C1OC GVBIMWXHIHVUKV-UHFFFAOYSA-N 0.000 description 1
- OUMFGWDQNIMDKE-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2NCC(C)C)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2NCC(C)C)=C(C(C)C)C=C1OC OUMFGWDQNIMDKE-UHFFFAOYSA-N 0.000 description 1
- QYUPWOZVNUJIHI-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2NCC(F)(F)F)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2NCC(F)(F)F)=C(C(C)C)C=C1OC QYUPWOZVNUJIHI-UHFFFAOYSA-N 0.000 description 1
- AGOXVVDJKUPMNH-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2NCC(O)CO)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2NCC(O)CO)=C(C(C)C)C=C1OC AGOXVVDJKUPMNH-UHFFFAOYSA-N 0.000 description 1
- WNXAMIXFQODHDW-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2NCC2=C(OC)C=CC=C2)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2NCC2=C(OC)C=CC=C2)=C(C(C)C)C=C1OC WNXAMIXFQODHDW-UHFFFAOYSA-N 0.000 description 1
- BKIGRPKGZLSAJB-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2NCC2=CC=CC=C2)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2NCC2=CC=CC=C2)=C(C(C)C)C=C1OC BKIGRPKGZLSAJB-UHFFFAOYSA-N 0.000 description 1
- CBIIEYHIRAZYQF-UHFFFAOYSA-N COC1=CC(CC2=CN=C(N)N=C2NCC2=CC=NO2)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(N)N=C2NCC2=CC=NO2)=C(C(C)C)C=C1OC CBIIEYHIRAZYQF-UHFFFAOYSA-N 0.000 description 1
- KETOQGMCVKVQOJ-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC(C)(C)C)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC(C)(C)C)N=C2N)=C(C(C)C)C=C1OC KETOQGMCVKVQOJ-UHFFFAOYSA-N 0.000 description 1
- VWVMTIFGROHJIA-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC(C)=O)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC(C)=O)N=C2N)=C(C(C)C)C=C1OC VWVMTIFGROHJIA-UHFFFAOYSA-N 0.000 description 1
- UZYYCCZEGJKDDD-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC(C)C)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC(C)C)N=C2N)=C(C(C)C)C=C1OC UZYYCCZEGJKDDD-UHFFFAOYSA-N 0.000 description 1
- NEVVPQHYRBRHBV-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC(C)C)N=C2NC(C)C)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC(C)C)N=C2NC(C)C)=C(C(C)C)C=C1OC NEVVPQHYRBRHBV-UHFFFAOYSA-N 0.000 description 1
- VJAQMFIKRHKZGB-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC(C)C)N=C2NC2=CC=CC=C2)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC(C)C)N=C2NC2=CC=CC=C2)=C(C(C)C)C=C1OC VJAQMFIKRHKZGB-UHFFFAOYSA-N 0.000 description 1
- NBRRXVXJIGZXSS-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC(C)C)N=C2NCC(C)C)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC(C)C)N=C2NCC(C)C)=C(C(C)C)C=C1OC NBRRXVXJIGZXSS-UHFFFAOYSA-N 0.000 description 1
- WPAAWTXGNDCGEA-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC(C)C)N=C2NCC2=CC=CC=C2)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC(C)C)N=C2NCC2=CC=CC=C2)=C(C(C)C)C=C1OC WPAAWTXGNDCGEA-UHFFFAOYSA-N 0.000 description 1
- TYVIAWYJCWQIRD-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC(C)C)N=C2NCCO)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC(C)C)N=C2NCCO)=C(C(C)C)C=C1OC TYVIAWYJCWQIRD-UHFFFAOYSA-N 0.000 description 1
- AMMBWCBACNHIPE-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC(C)CN3CCN(C(C)=O)CC3)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC(C)CN3CCN(C(C)=O)CC3)N=C2N)=C(C(C)C)C=C1OC AMMBWCBACNHIPE-UHFFFAOYSA-N 0.000 description 1
- SEDXJNHJRKZWSV-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC3=C(Cl)C=CC=C3)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC3=C(Cl)C=CC=C3)N=C2N)=C(C(C)C)C=C1OC SEDXJNHJRKZWSV-UHFFFAOYSA-N 0.000 description 1
- RKRIZLQWBZOGHE-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC3=C(OC)C=CC=C3)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC3=C(OC)C=CC=C3)N=C2N)=C(C(C)C)C=C1OC RKRIZLQWBZOGHE-UHFFFAOYSA-N 0.000 description 1
- YKLLIBIJYFUZFL-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC3=CC=C(Cl)C=C3)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC3=CC=C(Cl)C=C3)N=C2N)=C(C(C)C)C=C1OC YKLLIBIJYFUZFL-UHFFFAOYSA-N 0.000 description 1
- ZJHIYGHAIYGMBH-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC3=CC=CC=C3)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC3=CC=CC=C3)N=C2N)=C(C(C)C)C=C1OC ZJHIYGHAIYGMBH-UHFFFAOYSA-N 0.000 description 1
- BRQXPKOBCKLDMF-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC3=CC=CC=N3)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC3=CC=CC=N3)N=C2N)=C(C(C)C)C=C1OC BRQXPKOBCKLDMF-UHFFFAOYSA-N 0.000 description 1
- MQHKLCWEKIVTBQ-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC3CC3)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC3CC3)N=C2N)=C(C(C)C)C=C1OC MQHKLCWEKIVTBQ-UHFFFAOYSA-N 0.000 description 1
- SKEDOVGNBCICFH-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC3CCC3)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC3CCC3)N=C2N)=C(C(C)C)C=C1OC SKEDOVGNBCICFH-UHFFFAOYSA-N 0.000 description 1
- JXLFYSVTVRHJAQ-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NC3CCN(C)CC3)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NC3CCN(C)CC3)N=C2N)=C(C(C)C)C=C1OC JXLFYSVTVRHJAQ-UHFFFAOYSA-N 0.000 description 1
- LNCLTFUBPRVPDS-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NCC(C)(C)O)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NCC(C)(C)O)N=C2N)=C(C(C)C)C=C1OC LNCLTFUBPRVPDS-UHFFFAOYSA-N 0.000 description 1
- ZTOZIBGMYWVXRQ-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NCC(C)C)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NCC(C)C)N=C2N)=C(C(C)C)C=C1OC ZTOZIBGMYWVXRQ-UHFFFAOYSA-N 0.000 description 1
- WREUETVJCDCZSE-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NCC3=CC=CC=C3)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NCC3=CC=CC=C3)N=C2N)=C(C(C)C)C=C1OC WREUETVJCDCZSE-UHFFFAOYSA-N 0.000 description 1
- SGVMJKNVTUPTRL-UHFFFAOYSA-N COC1=CC(CC2=CN=C(NCCO)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(CC2=CN=C(NCCO)N=C2N)=C(C(C)C)C=C1OC SGVMJKNVTUPTRL-UHFFFAOYSA-N 0.000 description 1
- XXNQJVXRPWJYJZ-UHFFFAOYSA-N COC1=CC(CCNC2=NC(N)=NC=C2CC2=C(C(C)C)C=C(OC)C(OC)=C2)=CC=C1 Chemical compound COC1=CC(CCNC2=NC(N)=NC=C2CC2=C(C(C)C)C=C(OC)C(OC)=C2)=CC=C1 XXNQJVXRPWJYJZ-UHFFFAOYSA-N 0.000 description 1
- QGRJAHKOSDVINI-UHFFFAOYSA-N COC1=CC(COC2=CC(C(C)C)=C(OC3=CN=C(N)N=C3N)C=C2I)=CC(OC)=C1OC Chemical compound COC1=CC(COC2=CC(C(C)C)=C(OC3=CN=C(N)N=C3N)C=C2I)=CC(OC)=C1OC QGRJAHKOSDVINI-UHFFFAOYSA-N 0.000 description 1
- KPHOCHXJNSHHRW-UHFFFAOYSA-N COC1=CC(I)=C(OC)C=C1I.COC1=CC(I)=C(OCC#N)C=C1I Chemical compound COC1=CC(I)=C(OC)C=C1I.COC1=CC(I)=C(OCC#N)C=C1I KPHOCHXJNSHHRW-UHFFFAOYSA-N 0.000 description 1
- RXDZATRBZIFUNL-UHFFFAOYSA-N COC1=CC(I)=C(OC2=CN=C(N)N=C2N)C=C1I Chemical compound COC1=CC(I)=C(OC2=CN=C(N)N=C2N)C=C1I RXDZATRBZIFUNL-UHFFFAOYSA-N 0.000 description 1
- UVGWFUFJPOVMMP-UHFFFAOYSA-N COC1=CC(I)=C(OC2=CN=C(N)N=C2N)C=C1I.COC1=CC(I)=C(OCC#N)C=C1I Chemical compound COC1=CC(I)=C(OC2=CN=C(N)N=C2N)C=C1I.COC1=CC(I)=C(OCC#N)C=C1I UVGWFUFJPOVMMP-UHFFFAOYSA-N 0.000 description 1
- DZESLGCIBKNAER-UHFFFAOYSA-N COC1=CC(I)=C(OC2=CN=C(N)N=C2N)C=C1OC Chemical compound COC1=CC(I)=C(OC2=CN=C(N)N=C2N)C=C1OC DZESLGCIBKNAER-UHFFFAOYSA-N 0.000 description 1
- GZWGDKZICQOPHY-UHFFFAOYSA-N COC1=CC(NC2=NC=C(CC3=C(C(C)C)C=C(OC)C(Cl)=C3)C(N)=N2)=CC=C1 Chemical compound COC1=CC(NC2=NC=C(CC3=C(C(C)C)C=C(OC)C(Cl)=C3)C(N)=N2)=CC=C1 GZWGDKZICQOPHY-UHFFFAOYSA-N 0.000 description 1
- FQWBGNBRPGPUNQ-UHFFFAOYSA-N COC1=CC(OC)=C(NC2=NC=C(CC3=C(C(C)C)C=C(OC)C(OC)=C3)C(N)=N2)C=C1 Chemical compound COC1=CC(OC)=C(NC2=NC=C(CC3=C(C(C)C)C=C(OC)C(OC)=C3)C(N)=N2)C=C1 FQWBGNBRPGPUNQ-UHFFFAOYSA-N 0.000 description 1
- AUDWTEBRWMRRKC-UHFFFAOYSA-N COC1=CC(OC2=C(C)N=C(N)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(OC2=C(C)N=C(N)N=C2N)=C(C(C)C)C=C1OC AUDWTEBRWMRRKC-UHFFFAOYSA-N 0.000 description 1
- JIAVFCRYYYAQPY-UHFFFAOYSA-N COC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1 Chemical compound COC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1 JIAVFCRYYYAQPY-UHFFFAOYSA-N 0.000 description 1
- UXZIOQCGIFBABV-UHFFFAOYSA-N COC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1Br Chemical compound COC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1Br UXZIOQCGIFBABV-UHFFFAOYSA-N 0.000 description 1
- WRLPRSJDJPPCQU-UHFFFAOYSA-N COC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1C1=CC=C(F)C=C1 Chemical compound COC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1C1=CC=C(F)C=C1 WRLPRSJDJPPCQU-UHFFFAOYSA-N 0.000 description 1
- OMFSHRXJXVUIJY-UHFFFAOYSA-N COC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1C1=CC=CO1 Chemical compound COC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1C1=CC=CO1 OMFSHRXJXVUIJY-UHFFFAOYSA-N 0.000 description 1
- DUWZFANLTWXYCX-UHFFFAOYSA-N COC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1I Chemical compound COC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1I DUWZFANLTWXYCX-UHFFFAOYSA-N 0.000 description 1
- QVZLKMLKJOKUHQ-UHFFFAOYSA-N COC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC QVZLKMLKJOKUHQ-UHFFFAOYSA-N 0.000 description 1
- ZRQRQLNPALEPSG-UHFFFAOYSA-N COC1=CC(OC2=CN=C(N)N=C2N)=C(C2CC2)C=C1OC Chemical compound COC1=CC(OC2=CN=C(N)N=C2N)=C(C2CC2)C=C1OC ZRQRQLNPALEPSG-UHFFFAOYSA-N 0.000 description 1
- VVIOOYXTAFWDHU-UHFFFAOYSA-N COC1=CC(OC2=CN=C(NC(C)=O)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(OC2=CN=C(NC(C)=O)N=C2N)=C(C(C)C)C=C1OC VVIOOYXTAFWDHU-UHFFFAOYSA-N 0.000 description 1
- LIUHEUHCZWARPH-UHFFFAOYSA-N COC1=CC(OC2=CN=C(NC(C)C)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(OC2=CN=C(NC(C)C)N=C2N)=C(C(C)C)C=C1OC LIUHEUHCZWARPH-UHFFFAOYSA-N 0.000 description 1
- QKMJKBZHMFHKTI-UHFFFAOYSA-N COC1=CC(OC2=CN=C(NC3=CC=CC=C3)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(OC2=CN=C(NC3=CC=CC=C3)N=C2N)=C(C(C)C)C=C1OC QKMJKBZHMFHKTI-UHFFFAOYSA-N 0.000 description 1
- RCGJEHLJDSVEQY-UHFFFAOYSA-N COC1=CC(OC2=CN=C(NC3CCS(=O)(=O)CC3)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(OC2=CN=C(NC3CCS(=O)(=O)CC3)N=C2N)=C(C(C)C)C=C1OC RCGJEHLJDSVEQY-UHFFFAOYSA-N 0.000 description 1
- IQOHNAHDSJMKGD-UHFFFAOYSA-N COC1=CC(OC2=CN=C(NCC3=CC=CC=C3)N=C2N)=C(C(C)C)C=C1OC Chemical compound COC1=CC(OC2=CN=C(NCC3=CC=CC=C3)N=C2N)=C(C(C)C)C=C1OC IQOHNAHDSJMKGD-UHFFFAOYSA-N 0.000 description 1
- LQFBUUBKHQVNDW-UHFFFAOYSA-N COC1=CC=C(CCNC2=NC(N)=NC=C2CC2=C(C(C)C)C=C(OC)C(OC)=C2)C=C1 Chemical compound COC1=CC=C(CCNC2=NC(N)=NC=C2CC2=C(C(C)C)C=C(OC)C(OC)=C2)C=C1 LQFBUUBKHQVNDW-UHFFFAOYSA-N 0.000 description 1
- SWGCKVKJXBMZLO-UHFFFAOYSA-N COC1=CC=C(NC2=NC=C(CC3=C(C(C)C)C=C(OC)C(OC)=C3)C(N)=N2)C=C1 Chemical compound COC1=CC=C(NC2=NC=C(CC3=C(C(C)C)C=C(OC)C(OC)=C3)C(N)=N2)C=C1 SWGCKVKJXBMZLO-UHFFFAOYSA-N 0.000 description 1
- RDZSRXUCTCEXPF-UHFFFAOYSA-N COC1=CC=CC(OC2=CN=C(N)N=C2N)=C1C(C)C Chemical compound COC1=CC=CC(OC2=CN=C(N)N=C2N)=C1C(C)C RDZSRXUCTCEXPF-UHFFFAOYSA-N 0.000 description 1
- KEFFTCUKEKKMGH-UHFFFAOYSA-N COCCNC1=NC=C(CC2=C(C(C)C)C=C(OC)C(Cl)=C2)C(N)=N1 Chemical compound COCCNC1=NC=C(CC2=C(C(C)C)C=C(OC)C(Cl)=C2)C(N)=N1 KEFFTCUKEKKMGH-UHFFFAOYSA-N 0.000 description 1
- GMDXZHNHDKNPIK-UHFFFAOYSA-N COCCNC1=NC=C(CC2=C(C(C)C)C=C(OC)C(OC)=C2)C(N)=N1 Chemical compound COCCNC1=NC=C(CC2=C(C(C)C)C=C(OC)C(OC)=C2)C(N)=N1 GMDXZHNHDKNPIK-UHFFFAOYSA-N 0.000 description 1
- LXZSPHNWRMYSJB-UHFFFAOYSA-N COCCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(S(C)(=O)=O)=C2)C(N)=N1 Chemical compound COCCNC1=NC=C(OC2=C(C(C)C)C=C(OC)C(S(C)(=O)=O)=C2)C(N)=N1 LXZSPHNWRMYSJB-UHFFFAOYSA-N 0.000 description 1
- PAEJRWDFYROELD-UHFFFAOYSA-N COCCOC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I Chemical compound COCCOC1=CC(C(C)C)=C(OC2=CN=C(N)N=C2N)C=C1I PAEJRWDFYROELD-UHFFFAOYSA-N 0.000 description 1
- GLVOXVCTGAISRY-UHFFFAOYSA-N COc(cc(c(OC)c1)I)c1I Chemical compound COc(cc(c(OC)c1)I)c1I GLVOXVCTGAISRY-UHFFFAOYSA-N 0.000 description 1
- IVAPDIRFTBTTKK-UHFFFAOYSA-N COc(cc(c(OCC#N)c1)I)c1I Chemical compound COc(cc(c(OCC#N)c1)I)c1I IVAPDIRFTBTTKK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention pertains to compounds and methods for treatment of diseases associated with P2X purinergic receptors, and more particularly to methods of using P2X 3 and/or P2X 2/3 antagonists for treatment of genitourinary, gastrointestinal, respiratory, and pain-related diseases, conditions and disorders.
- the urinary bladder is responsible for two important physiological functions: urine storage and urine emptying. This process involves two main steps: (1) the bladder fills progressively until the tension in its walls rises above a threshold level; and (2) a nervous reflex, called the micturition reflex, occurs that empties the bladder or, if this fails, at least causes a conscious desire to urinate.
- the micturition reflex is an autonomic spinal cord reflex, it can also be inhibited or mediated by centers in the cerebral cortex or brain.
- ATP ATP receptors
- P2Y- and P2X-purinoreceptors are G-protein coupled receptors
- P2X-purinoreceptors are a family of ATP-gated cation channels.
- Purinergic receptors in particular, P2X receptors
- P2X receptors are known to form homomultimers or heteromultimers.
- cDNAs for several P2X receptors subtypes have been cloned, including: six homomeric receptors, P2X 1 ; P2X 2 ; P2X 3 ; P2X 4 ; P2X 5 ; and P2X 7 ; and three heteromeric receptors P2X 2/3 , P2X 4/6 , P2X 1/5 (See, e.g., Chen, et al. (1995) Nature 377:428-431; Lewis, et al. (1995) Nature 377:432-435; and Burnstock (1997) Neurophamacol. 36:1127-1139).
- P2X receptor subunits are found on afferents in rodent and human bladder urothelium. Data exists suggesting that ATP may be released from epithelial/endothelial cells of the urinary bladder or other hollow organs as a result of distention (Burnstock (1999) J. Anatomy 194:335-342; and Ferguson et al. (1997) J. Physiol. 505:503-511). ATP released in this manner may serve a role in conveying information to sensory neurons located in subepithelial components, e.g., suburothelial lamina limba (Namasivayam, et al. (1999) BJU Intl. 84:854-860).
- the P2X receptors have been studied in a number of neurons, including sensory, sympathetic, parasympathetic, mesenteric, and central neurons (Zhong, et al. (1998) Br. J. Pharmacol. 125:771-781). These studies indicate that purinergic receptors play a role in afferent neurotransmission from the bladder, and that modulators of P2X receptors are potentially useful in the treatment of bladder disorders and other genitourinary diseases or conditions.
- ATP released from damaged cells may thus lead to pain by activating P2X 3 and/or P2X 2/3 containing receptors on nociceptive sensory nerve endings. This is consistent with the induction of pain by intradermally applied ATP in the human blister-base model (Bleehen, Br J Pharmacol 62:573-577 (1978)).
- P2X antagonists have been shown to be analgesic in animal models (Driessen and Starke, Naunyn Schmiedebergs Arch Pharmacol 350:618-625 (1994)). This evidence suggests that P2X 2 and P2X 3 are involved in nociception, and that modulators of P2X receptors are potentially useful as analgesics.
- P2X 3 receptors are expressed in human colon, and are expressed at higher levels in inflamed colon than in normal colon (Y. Yiangou et al, Neurogastroenterol Mot (2001) 13:365-69).
- Other researchers have implicated the P2X 3 receptor in detection of distension or intraluminal pressure in the intestine, and initiation of reflex contractions (X. Bian et al., J Physiol (2003) 551.1:309-22), and have linked this to colitis (G. Wynn et al., Am J Physiol Gastrointest Liver Physiol (2004) 287:G647-57). Inge Brouns et al.
- P2X 3 receptors are expressed in pulmonary neuroepithelial bodies (NEBs), implicating the receptor in pain transmission in the lung. More recently, others have implicated P2X 2 and P2X 3 receptors in pO 2 detection in pulmonary NEBs (W. Rong et al., J Neurosci (2003) 23(36):11315-21).
- the invention provides methods for treating a respiratory disease mediated by a P2X 3 or P2X 2/3 receptor antagonist, said method comprising administering to a subject in need thereof an effective amount of a compound of formula (I):
- X is: —CH 2 —; —O—; —C(O)—; —CHOH—; —S(O) n —; or —NR c — wherein n is from 0 to 2 and R c is hydrogen or alkyl;
- Y is: hydrogen; or —NR d R e wherein one of R d and R e is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalky; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl;
- D is an optional oxygen
- R 1 is: alkyl; alkenyl; cycloalkyl; cycloalkenyl; halo; haloalkyl; hydroxyalkyl; or alkoxy;
- R 2 , R 3 , R 4 and R 5 each independently is: hydrogen; alkyl; alkenyl; amino; aminosulfonyl; halo; amido; haloalkyl; alkoxy; hydroxy; haloalkoxy; nitro; hydroxyalkyl; alkoxyalkyl; hydroxyalkoxy; alkynylalkoxy; alkylsulfonyl; arylsulfonyl; cyano; aryl; heteroaryl; heterocyclyl; heterocyclylalkoxy; aryloxy; heteroaryloxy; aralkyloxy; heteroaralkyloxy; optionally substituted phenoxy; —(CH 2 ) m —(Z) n —(CO)—R f or —(CH 2 ) m —(Z) n —SO 2 —(NR g ) n —R f where m and n each independently is 0 or 1, Z is O or NR
- R 6 is: hydrogen; alkyl; halo; haloalkyl; amino; or alkoxy; and
- R 7 and R 8 is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalky; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- Exemplary respiratory diseases treatable with the invention include chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, and the like.
- COPD chronic obstructive pulmonary disease
- the invention also provides and pharmaceutical compositions and methods of preparing the same.
- Exemplary gastrointestinal diseases include Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), biliary colic and other biliary disorders, renal colic, diarrhea-dominant IBS, pain associated with GI distension, and the like.
- IBS Irritable Bowel Syndrome
- IBD Inflammatory Bowel Disease
- biliary colic and other biliary disorders renal colic
- renal colic diarrhea-dominant IBS
- pain associated with GI distension and the like.
- Antagonist refers to a compound that enhances the activity of another compound or receptor site.
- Alkyl means the monovalent linear or branched saturated hydrocarbon moiety, consisting solely of carbon and hydrogen atoms, having from one to twelve carbon atoms. “Lower alkyl” refers to an alkyl group of one to six carbon atoms, i.e. C 1 -C 6 alkyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl, n-hexyl, octyl, dodecyl, and the like.
- Alkenyl means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms, containing at least one double bond, e.g., ethenyl, propenyl, and the like.
- Alkynyl means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms, containing at least one triple bond, e.g., ethynyl, propynyl, and the like.
- Alkylene means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, e.g., methylene, ethylene, 2,2-dimethylethylene, propylene, 2-methylpropylene, butylene, pentylene, and the like.
- Alkoxy means a moiety of the formula —OR, wherein R is an alkyl moiety as defined herein.
- alkoxy moieties include, but are not limited to, methoxy, ethoxy, isopropoxy, and the like.
- Alkoxyalkyl means a moiety of the formula R a —O—R b —, where R a is alkyl and R b is alkylene as defined herein.
- exemplary alkoxyalkyl groups include, by way of example, 2-methoxyethyl, 3-methoxypropyl, 1-methyl-2-methoxyethyl, 1-(2-methoxyethyl)-3-methoxypropyl, and 1-(2-methoxyethyl)-3-methoxypropyl.
- Alkylcarbonyl means a moiety of the formula —R′-R′′, where R′ is oxo and R′′ is alkyl as defined herein.
- Alkylsulfonyl means a moiety of the formula —R′-R′′, where R′ is —SO 2 — and R′′ is alkyl as defined herein.
- Alkylsulfonylalkyl means a moiety of the formula —R′-R′′-R′′′ where where R′ is alkylene, R′′ is —SO 2 — and R′′′ is alkyl as defined herein.
- Alkylamino means a moiety of the formula —NR—OR′ wherein R is hyrdogen or alkyl and R′ is alkyl as defined herein.
- Alkoxyamino means a moiety of the formula —NR—OR′ wherein R is hydrogen or alkyl and R′ is alkyl as defined herein.
- Alkylsulfanyl means a moiety of the formula —SR wherein R is alkyl as defined herein.
- Aminoalkyl means a group —R—R′ wherein R′ is amino and R is alkylene as defined herein.
- Aminoalkyl includes aminomethyl, aminoethyl, 1-aminopropyl, 2-aminopropyl, and the like. The amino moiety of “aminoalkyl” may be substituted once or twice with alkyl to provide “alkylaminoalkyl” and “dialkylaminoalkyl” respectively.
- Alkylaminoalkyl includes methylaminomethyl, methylaminoethyl, methylaminopropyl, ethylaminoethyl and the like.
- Dialkylaminoalkyl includes dimethylaminomethyl, dimethylaminoethyl, dimethylaminopropyl, N-methyl-N-ethylaminoethyl, and the like.
- Aminoalkoxy means a group —OR—R′ wherein R′ is amino and R is alkylene as defined herein.
- Aminosulfonyl means a group —SO 2 —NRR′ wherein R and R′ each independently is hydrogen or alkyl as defined herein.
- Alkylsulfonylamido means a moiety of the formula —NR′SO 2 —R wherein R is alkyl and R′ is hydrogen or alkyl.
- Aminocarbonyloxyalkyl or “carbamylalkyl” means a group of the formula —R—O—C(O)—NR′R′′ wherein R is alkylene and R′, R′′ each independently is hydrogen or alkyl as defined herein.
- Alkynylalkoxy means a group of the formula —O—R—R′ wherein R is alkylene and R′ is alkynyl as defined herein.
- Antagonist refers to a compound that diminishes or prevents the action of another compound or receptor site.
- Aryl means a monovalent cyclic aromatic hydrocarbon moiety consisting of a mono-, bi- or tricyclic aromatic ring.
- the aryl group can be optionally substituted as defined herein.
- aryl moieties include, but are not limited to, optionally substituted phenyl, naphthyl, phenanthryl, fluorenyl, indenyl, pentalenyl, azulenyl, oxydiphenyl, biphenyl, methylenediphenyl, aminodiphenyl, diphenylsulfidyl, diphenylsulfonyl, diphenylisopropylidenyl, benzodioxanyl, benzofuranyl, benzodioxylyl, benzopyranyl, benzoxazinyl, benzoxazinonyl, benzopiperadinyl, benzopiperazinyl, benzopyrrolidinyl, benzomorpholinyl,
- Arylalkyl means a group of the formula —R—R′ wherein R is alkylene and R′ is aryl as defined herein.
- Arylsulfonyl means a group of the formula —SO 2 —R wherein R is aryl as defined herein.
- Aryloxy means a group of the formula —O—R wherein R is aryl as defined herein.
- Alkyloxy means a group of the formula —O—R—R′′ wherein R is alkylene and R′ is aryl as defined herein.
- Cyanoalkyl means a moiety of the formula —R′-R′′, where R′ is alkylene as defined herein and R′′ is cyano or nitrile.
- Cycloalkyl means a monovalent saturated carbocyclic moiety consisting of mono- or bicyclic rings. Cycloalkyl can optionally be substituted with one or more substituents, wherein each substituent is independently hydroxy, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino, unless otherwise specifically indicated. Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like, including partially unsaturated derivatives thereof.
- Cycloalkylalkyl means a moiety of the formula —R′-R′′, where R′ is alkylene and R′′ is cycloalkyl as defined herein.
- Heteroalkyl means an alkyl radical as defined herein wherein one, two or three hydrogen atoms have been replaced with a substituent independently selected from the group consisting of —OR a , —NR b R c , and —S(O) n R d (where n is an integer from 0 to 2), with the understanding that the point of attachment of the heteroalkyl radical is through a carbon atom, wherein R a is hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylalkyl; R b and R c are independently of each other hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylalkyl; and when n is 0, R d is hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl, and when n is 1 or 2, R d is alkyl, cycloalkyl, cycloalkylalkyl, amino, acyl
- Representative examples include, but are not limited to, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxy-1-hydroxymethylethyl, 2,3-dihydroxypropyl, 1-hydroxymethylethyl, 3-hydroxybutyl, 2,3-dihydroxybutyl, 2-hydroxy-1-methylpropyl, 2-aminoethyl, 3-aminopropyl, 2-methylsulfonylethyl, aminosulfonylmethyl, aminosulfonylethyl, aminosulfonylpropyl, methylaminosulfonylmethyl, methylaminosulfonylethyl, methylaminosulfonylpropyl, and the like.
- Heteroaryl means a monocyclic or bicyclic radical of 5 to 12 ring atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, with the understanding that the attachment point of the heteroaryl radical will be on an aromatic ring.
- the heteroaryl ring may be optionally substituted as defined herein.
- heteroaryl moieties include, but are not limited to, optionally substituted imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, thienyl, benzothienyl, thiophenyl, furanyl, pyranyl, pyridyl, pyrrolyl, pyrazolyl, pyrimidyl, quinolinyl, isoquinolinyl, benzofuryl, benzothiophenyl, benzothiopyranyl, benzimidazolyl, benzooxazolyl, benzooxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzopyranyl, indolyl, isoindolyl, triazolyl, triazinyl, quinoxalinyl, purinyl, quinazolinyl
- Heteroarylalkyl or “heteroaralkyl” means a group of the formula —R—R′ wherein R is alkylene and R′ is heteroaryl as defined herein.
- Heteroarylsulfonyl means a group of the formula —SO 2 —R wherein R is heteroaryl as defined herein.
- Heteroaryloxy means a group of the formula —O—R wherein R is heteroaryl as defined herein.
- Heteroaralkyloxy means a group of the formula —O—R—R′′ wherein R is alkylene and R′ is heteroaryl as defined herein.
- halo refers to a substituent fluoro, chloro, bromo, or iodo.
- Haloalkyl means alkyl as defined herein in which one or more hydrogen has been replaced with same or different halogen.
- exemplary haloalkyls include —CH 2 Cl, —CH 2 CF 3 , —CH 2 CCl 3 , perfluoroalkyl (e.g., —CF 3 ), and the like.
- Haloalkoxy means a moiety of the formula —OR, wherein R is a haloalkyl moiety as defined herein.
- An exemplary haloalkoxy is difluoromethoxy.
- Heterocycloamino means a saturated ring wherein at least one ring atom is N, NH or N-alkyl and the remaining ring atoms form an alkylene group.
- Heterocyclyl means a monovalent saturated moiety, consisting of one to three rings, incorporating one, two, or three or four heteroatoms (chosen from nitrogen, oxygen or sulfur).
- the heterocyclyl ring may be optionally substituted as defined herein.
- heterocyclyl moieties include, but are not limited to, optionally substituted piperidinyl, piperazinyl, homopiperazinyl, azepinyl, pyrrolidinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, pyridinyl, pyridazinyl, pyrimidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinuclidinyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazolylidinyl, benzothiazolidinyl, benzoazolylidinyl, dihydrofuryl, tetrahydrofuryl, dihydropyranyl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinylsulfoxide, thi
- Heterocyclylalkyl means a moiety of the formula —R—R′ wherein R is alkylene and R′ is heterocyclyl as defined herein.
- Heterocyclyloxy means a moiety of the formula —OR wherein R is heterocyclyl as defined herein.
- Heterocyclylalkoxy means a moiety of the formula —OR—R′ wherein R is alkylene and R′ is heterocyclyl as defined herein.
- Haldroxyalkoxy means a moiety of the formula —OR wherein R is hydroxyalkyl as defined herein.
- Haldroxyalkylamino means a moiety of the formula —NR—R′ wherein R is hydrogen or alkyl and R′ is hydroxyalkyl as defined herein.
- Haldroxyalkylaminoalkyl means a moiety of the formula —R—NR′-R′′ wherein R is alkylene, R′ is hydrogen or alkyl, and R′′ is hydroxyalkyl as defined herein.
- Haldroxycarbonylalkyl or “carboxyalkyl” means a group of the formula —R—(CO)—OH where R is alkylene as defined herein.
- Haldroxyalkyloxycarbonylalkyl or “hydroxyalkoxycarbonylalkyl” means a group of the formula —R—C(O)—O—R—OH wherein each R is alkylene and may be the same or different.
- “Hydroxyalkyl” means an alkyl moiety as defined herein, substituted with one or more, preferably one, two or three hydroxy groups, provided that the same carbon atom does not carry more than one hydroxy group.
- Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 2-hydroxy-1-hydroxymethylethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl
- Hydrocycloalkyl means a cycloalkyl moiety as defined herein wherein one, two or three hydrogen atoms in the cycloalkyl radical have been replaced with a hydroxy substituent. Representative examples include, but are not limited to, 2-, 3-, or 4-hydroxycyclohexyl, and the like.
- Rea or “ureido” means a group of the formula —NR′-C(O)—NR′′R′′′ wherein R′, R′′ and R′′′ each independently is hydrogen or alkyl.
- “Carbamate” means a group of the formula —O—C(O)—NR′R′′ wherein R′ and R′′ each independently is hydrogen or alkyl.
- Carboxy means a group of the formula —O—C(O)—OH.
- “Sulfonamido” means a group of the formula —SO 2 —NR′R′′ wherein R′, R′′ and R′′′ each independently is hydrogen or alkyl.
- Optionally substituted when used in association with “aryl”, phenyl”, “heteroaryl” “cycloalkyl” or “heterocyclyl”, means an aryl, phenyl, heteroaryl, cyclohexyl or heterocyclyl which is optionally substituted independently with one to four substituents, preferably one or two substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, hydroxyalkyl, halo, nitro, cyano, hydroxy, alkoxy, amino, acylamino, mono-alkylamino, di-alkylamino, haloalkyl, haloalkoxy, heteroalkyl, —COR (where R is hydrogen, alkyl, phenyl or phenylalkyl), —(CR′R′′) n —COOR (where n is an integer from 0 to 5, R′ and R′′ are independently hydrogen or alkyl,
- leaving group means the group with the meaning conventionally associated with it in synthetic organic chemistry, i.e., an atom or group displaceable under substitution reaction conditions.
- Examples of leaving groups include, but are not limited to, halogen, alkane-or arylenesulfonyloxy, such as methanesulfonyloxy, ethanesulfonyloxy, thiomethyl, benzenesulfonyloxy, tosyloxy, and thienyloxy, dihalophosphinoyloxy, optionally substituted benzyloxy, isopropyloxy, acyloxy, and the like.
- Module means a molecule that interacts with a target. The interactions include, but are not limited to, agonist, antagonist, and the like, as defined herein.
- Disease and Disease state means any disease, condition, symptom, disorder or indication.
- “Inert organic solvent” or “inert solvent” means the solvent is inert under the conditions of the reaction being described in conjunction therewith, including for example, benzene, toluene, acetonitrile, tetrahydrofuran, N,N-dimethylformamide, chloroform, methylene chloride or dichloromethane, dichloroethane, diethyl ether, ethyl acetate, acetone, methyl ethyl ketone, methanol, ethanol, propanol, isopropanol, tert-butanol, dioxane, pyridine, and the like.
- the solvents used in the reactions of the present invention are inert solvents.
- “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.
- “Pharmaceutically acceptable salts” of a compound means salts that are pharmaceutically acceptable, as defined herein, and that possess the desired pharmacological activity of the parent compound. Such salts include:
- acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxynaphtoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, tartaric acid, p-toluenesulfonic acid, trimethylacetic acid, and the like; or
- Acceptable organic bases include diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine, and the like.
- Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide.
- the preferred pharmaceutically acceptable salts are the salts formed from acetic acid, hydrochloric acid, sulphuric acid, methanesulfonic acid, maleic acid, phosphoric acid, tartaric acid, citric acid, sodium, potassium, calcium, zinc, and magnesium.
- Protecting group means the group which selectively blocks one reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry. Certain processes of this invention rely upon the protective groups to block reactive nitrogen and/or oxygen atoms present in the reactants.
- the terms “amino-protecting group” and “nitrogen protecting group” are used interchangeably herein and refer to those organic groups intended to protect the nitrogen atom against undesirable reactions during synthetic procedures.
- Exemplary nitrogen protecting groups include, but are not limited to, trifluoroacetyl, acetamido, benzyl (Bn), benzyloxycarbonyl (carbobenzyloxy, CBZ), p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, tert-butoxycarbonyl (BOC), and the like.
- Bn benzyloxycarbonyl
- CBZ benzyloxycarbonyl
- p-methoxybenzyloxycarbonyl p-nitrobenzyloxycarbonyl
- tert-butoxycarbonyl BOC
- Solidvates means solvent additions forms that contain either stoichiometric or non stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate, when the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one of the substances in which the water retains its molecular state as H 2 O, such combination being able to form one or more hydrate.
- Subject means mammals and non-mammals. Mammals means any member of the mammalia class including, but not limited to, humans; non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, and guinea pigs; and the like. Examples of non-mammals include, but are not limited to, birds, and the like. The term “subject” does not denote a particular age or sex.
- “Disorders of the urinary tract” or “uropathy” used interchangeably with “symptoms of the urinary tract” means the pathologic changes in the urinary tract.
- urinary tract disorders include, but are not limited to, incontinence, benign prostatic hypertrophy (BPH), prostatitis, detrusor hyperreflexia, outlet obstruction, urinary frequency, nocturia, urinary urgency, overactive bladder, pelvic hypersensitivity, urge incontinence, urethritis, prostatodynia, cystitis, idiophatic bladder hypersensitivity, and the like.
- Disease states associated with the urinary tract or “urinary tract disease states” or “uropathy” used interchangeably with “symptoms of the urinary tract” mean the pathologic changes in the urinary tract, or dysfunction of urinary bladder smooth muscle or its innervation causing disordered urinary storage or voiding. Symptoms of the urinary tract include, but are not limited to, overactive bladder (also known as detrusor hyperactivity), outlet obstruction, outlet insufficiency, and pelvic hypersensitivity.
- “Overactive bladder” or “detrusor hyperactivity” includes, but is not limited to, the changes symptomatically manifested as urgency, frequency, altered bladder capacity, incontinence, micturition threshold, unstable bladder contractions, sphincteric spasticity, detrusor hyperreflexia (neurogenic bladder), detrusor instability, and the like.
- Outlet obstruction includes, but is not limited to, benign prostatic hypertrophy (BPH), urethral stricture disease, tumors, low flow rates, difficulty in initiating urination, urgency, suprapubic pain, and the like.
- BPH benign prostatic hypertrophy
- urethral stricture disease tumors
- low flow rates difficulty in initiating urination
- urgency urgency
- suprapubic pain and the like.
- Outlet insufficiency includes, but is not limited to, urethral hypermobility, intrinsic sphincteric deficiency, mixed incontinence, stress incontinence, and the like.
- Pelvic Hypersensitivity includes, but is not limited to, pelvic pain, interstitial (cell) cystitis, prostatodynia, prostatitis, vulvadynia, urethritis, orchidalgia, overactive bladder, and the like.
- Respiratory disorder or “respiratory disease” refers to, without limitation, chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, and the like.
- COPD chronic obstructive pulmonary disease
- GI disorder or disease refers to, without limitation, Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), biliary colic and other biliary disorders, renal colic, diarrhea-dominant IBS, pain associated with GI distension, and the like.
- IBS Irritable Bowel Syndrome
- IBD Inflammatory Bowel Disease
- biliary colic and other biliary disorders renal colic, diarrhea-dominant IBS, pain associated with GI distension, and the like.
- “Therapeutically effective amount” means an amount of a compound that, when administered to a subject for treating a disease state, is sufficient to effect such treatment for the disease state.
- the “therapeutically effective amount” will vary depending on the compound, disease state being treated, the severity or the disease treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors.
- treating when referring to a chemical reaction means adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture
- the invention provides methods for treating a respiratory disease or a gastrointestinal disease mediated by a P2X 3 or P2X 2/3 receptor antagonist, said method comprising administering to a subject in need thereof an effective amount of a compound of formula (I):
- X is: —CH 2 —; —O—; —C(O)—; —CHOH—; —S(O) n —; or —NR c — wherein n is from 0 to 2 and R c is hydrogen or alkyl;
- Y is: hydrogen; or —NR d R e wherein one of R d and R e is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalky; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl;
- D is an optional oxygen
- R 1 is: alkyl; alkenyl; cycloalkyl; cycloalkenyl; halo; haloalkyl; hydroxyalkyl; or alkoxy;
- R 2 , R 3 , R 4 and R 5 each independently is: hydrogen; alkyl; alkenyl; amino; aminosulfonyl; halo; amido; haloalkyl; alkoxy; hydroxy; haloalkoxy; nitro; hydroxyalkyl; alkoxyalkyl; hydroxyalkoxy; alkynylalkoxy; alkylsulfonyl; arylsulfonyl; cyano; aryl; heteroaryl; heterocyclyl; heterocyclylalkoxy; aryloxy; heteroaryloxy; aralkyloxy; heteroaralkyloxy; optionally substituted phenoxy; —(CH 2 ) m —(Z) n —(CO)—R f or —(CH 2 ) m —(Z) n —SO 2 —(NR g ) n —R f where m and n each independently is 0 or 1, Z is O or NR
- R 6 is: hydrogen; alkyl; halo; haloalkyl; amino; or alkoxy; and
- R 7 and R 8 is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalky; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- the respiratory disease may be chronic obstructive pulmonary disease (COPD), asthma, or bronchospasm.
- COPD chronic obstructive pulmonary disease
- asthma asthma
- bronchospasm a chronic obstructive pulmonary disease
- the gastrointestinal disease may be Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), biliary colic and other biliary disorders, renal colic, diarrhea-dominant IBS, or pain associated with GI distension.
- IBS Irritable Bowel Syndrome
- IBD Inflammatory Bowel Disease
- biliary colic and other biliary disorders renal colic, diarrhea-dominant IBS, or pain associated with GI distension.
- the disease is a respiratory disease selected from chronic obstructive pulmonary disease (COPD), asthma, and bronchospasm.
- COPD chronic obstructive pulmonary disease
- the disease is a gastrointestinal disease selected from Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), biliary colic, renal colic, diarrhea-dominant IBS, and pain associated with GI distension.
- IBS Irritable Bowel Syndrome
- IBD Inflammatory Bowel Disease
- biliary colic biliary colic
- renal colic biliary colic
- diarrhea-dominant IBS and pain associated with GI distension.
- Y is —NR d R e .
- R 5 and R 6 are hydrogen.
- R 2 is hydrogen
- X is —CH 2 — or —O—.
- X is O.
- D is absent.
- R 1 is alkyl, alkenyl or cycloalkyl.
- R 1 is ethyl, cyclopropyl, isopropenyl or isopropyl. More preferably R 1 is isopropyl.
- one of R 7 and R 8 is hydrogen, and the other is: alkyl, cycloalkyl; cycloalkylalkyl; haloalkyl; hydroxyalky; alkoxyalkyl; alkylsulfonylalkyl; acetyl; alkylsulfonyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- one of R 7 and R 8 is hydrogen and the other is alkyl, hydroxyalkyl or haloalkyl.
- one of R d and R e is hydrogen, and the other is: alkyl, cycloalkyl; cycloalkylalkyl; haloalkyl; hydroxyalky; alkoxyalkyl; alkylsulfonylalkyl; acetyl; alkylsulfonyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- one of R d and R e is hydrogen and the other is alkyl, hydroxyalkyl or haloalkyl.
- R 3 and R 4 each independently is halo, alkoxy, aminosulfonyl; hydroxy; haloalkoxy or alkylsulfonyl.
- R 3 is halo, alkoxy, hydroxy, haloalkoxy or hydroxy.
- R 3 is methoxy, hydroxy, fluoro, or chloro. More preferably R 3 is methoxy. In certain embodiments R 3 is hydroxy.
- R 4 is halo, alkoxy, alkylsulfonyl or heteroaryl.
- R 4 is methoxy, iodo, methanesulfonyl or heteroaryl. More preferably R 4 is methoxy, bromo, chloro or iodo. In specific embodiments R 4 may be methoxy, while in other embodiments R 4 may be iodo.
- R 7 , R 8 , R d and R e are hydrogen.
- R 4 is heteroaryl.
- the heteroaryl may be, in certain embodiments, tetrazolyl, pyrazolyl, oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl, isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl, or pyrrolyl.
- the heteroaryl may be tetrazol-5-yl, pyrazol-1-yl, 3-methylpyrazol-1-yl, oxazol-2-yl, oxazol-5-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, thiophen-3-yl, 5-chloro-thiophen-2-yl, 1-methyl-imidazol-2-yl, imidazol-1-yl, pyrazol-3-yl, 2-methyl-thiazol-4-yl, furan-2-yl, 3,5-dimethyl-pyrazol-1-yl, 4,5-dihydrooxazol-2-yl, isoxazol-5-yl, [1,2,4]-oxadiazol-3-yl, benzo[b]thiophen-3-yl, oxazol-4-yl, furan-3-yl, 4-methyl-thiophen-2-yl, thiazol
- R 3 and R 4 together with the atoms to which they are attached may form a five or six-membered ring that optionally includes one or two heteroatoms selected from O, S and N.
- R 3 and R 4 together with the atoms to which they are attached may form: a five membered aromatic with one nitrogen, i.e.
- a pyrrol ring a five membered aromatic with two nitrogens, i.e., a pyrazol or imidazol ring; a five membered aromatic with one nitrogen and one oxygen, i.e., an oxazole or isoxazole ring; a five membered aromatic with one nitrogen and one sulfur, i.e., a thiazole or isothiazole ring; a five membered aromatic ring with one oxygen, i.e., a furanyl ring; or a five membered aromatic with one sulfur, i.e., a thiophenyl ring.
- R 2 and R 3 together with the atoms to which they are attached may form a five or six-membered ring that optionally includes one or two heteroatoms selected from O, S and N.
- R 3 and R 4 together with the atoms to which they are attached may form: a five membered aromatic with one nitrogen, i.e.
- a pyrrol ring a five membered aromatic with two nitrogens, i.e., a pyrazol or imidazol ring; a five membered aromatic with one nitrogen and one oxygen, i.e., an oxazole or isoxazole ring; a five membered aromatic with one nitrogen and one sulfur, i.e., a thiazole or isothiazole ring; a five membered aromatic with one oxygen, i.e., a furanyl ring; or a five membered aromatic with one sulfur, i.e., a thiophenyl ring.
- X is —O—
- R 1 is alkyl, alkenyl, cycloalkyl, or halo
- R 2 is hydrogen
- R 3 is alkoxy, hydroxy or halo
- R 4 is alkoxy, halo, alkenyl, or heteroaryl selected from tetrazolyl, pyrazolyl, oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl, isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl and pyrrolyl
- R 5 and R 6 are hydrogen.
- X is —O—
- R 1 is alkyl, alkenyl, cycloalkyl, or halo
- R 2 is hydrogen
- R 3 is alkoxy, hydroxy or halo
- R 4 is alkoxy, halo, aminosulfonyl, or alkenyl
- R 5 and R 6 are hydrogen.
- X is —O—
- R 1 is alkyl, alkenyl, cycloalkyl, or halo
- R 2 is hydrogen
- R 3 is alkoxy, hydroxy or halo
- R 4 is heteroaryl selected from tetrazolyl, pyrazolyl, oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl, isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl and pyrrolyl
- R 5 and R 6 are hydrogen.
- X is —O—
- R 1 is alkyl, alkenyl, cycloalkyl, or halo
- R 2 is hydrogen
- R 3 is alkoxy, hydroxy or halo
- R 4 is alkoxy, halo, aminosulfonyl, or alkenyl
- R 5 and R 6 are hydrogen
- R 7 and R 8 are hydrogen
- one of R a and R b is hydrogen and the other is hydrogen, alkyl, hydroxyalkyl or haloalkyl.
- X is —O—
- R 1 is alkyl, alkenyl, cycloalkyl, or halo
- R 2 is hydrogen
- R 3 is alkoxy, hydroxy or halo
- R 4 is heteroaryl selected from tetrazolyl, pyrazolyl, oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl, isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl and pyrrolyl
- R 5 and R 6 are hydrogen
- R 7 and R 8 are hydrogen
- one of R a and R b is hydrogen and the other is hydrogen, alkyl, acetyl, hydroxyalkyl or haloalkyl.
- X is —O— or —CH 2 —
- R 1 is isopropyl, isopropenyl, cyclopropyl or iodo
- R 2 is hydrogen
- R 3 is alkoxy, hydroxy or halo
- R 4 is alkoxy, aminosulfonyl, or halo
- R 5 and R 6 are hydrogen.
- X is —O— or —CH 2 —
- R 1 is isopropyl, isopropenyl, cyclopropyl or iodo
- R 2 is hydrogen
- R 3 is alkoxy, hydroxy or halo
- R 4 is alkoxy, aminosulfonyl, or halo
- R 5 and R 6 are hydrogen
- R 7 and R 8 are hydrogen
- one of R a and R b is hydrogen and the other is hydrogen, alkyl, hydroxyalkyl or haloalkyl.
- X is —O— or —CH 2 —
- R 1 is isopropyl or iodo
- R 2 is hydrogen
- R 3 is methoxy, hydroxy, chloro, bromo or iodo
- R 4 is methoxy, aminosulfonyl, chloro, bromo or iodo
- R 5 and R 6 are hydrogen.
- X is —O— or —CH 2 —
- R 1 is isopropyl or iodo
- R 2 is hydrogen
- R 3 is methoxy, hydroxy, chloro, bromo or iodo
- R 4 methoxy, aminosulfonyl, chloro, bromo or iodo
- R 5 and R 6 are hydrogen
- R 7 and R 8 are hydrogen
- one of R a and R b is hydrogen and the other is hydrogen, alkyl, hydroxyalkyl or haloalkyl.
- X is —O— or —CH 2 —
- R 1 is isopropyl
- R 2 is hydrogen
- R 3 is methoxy, hydroxy, chloro, bromo or iodo
- R 4 is methoxy, aminosulfonyl, chloro, bromo or iodo
- R 5 and R 6 are hydrogen.
- X is —O— or —CH 2 —
- R 1 is isopropyl
- R 2 is hydrogen
- R 3 is methoxy, hydroxy, chloro, bromo or iodo
- R 4 methoxy, aminosulfonyl, chloro, bromo or iodo
- R 5 and R 6 are hydrogen
- R 7 and R 8 are hydrogen
- one of R a and R b is hydrogen and the other is hydrogen, alkyl, hydroxyalkyl or haloalkyl.
- the invention provides methods for treating a respiratory disease or a gastrointestinal disease mediated by a P2X 3 or P2X 2/3 receptor antagonist, said method comprising administering to a subject in need thereof an effective amount of a compound of formula (II):
- X is: —CH 2 —; or —O—;
- R 1 is: alkyl; alkenyl; cycloalkyl; cycloalkenyl; or halo;
- R 3 and R 4 each independently is: alkyl; alkenyl; amino; aminosulfonyl; halo; amido; haloalkyl; alkoxy; hydroxy; haloalkoxy; nitro; hydroxyalkyl; alkoxyalkyl; hydroxyalkoxy; alkynylalkoxy; alkylsulfonyl; arylsulfonyl; cyano; aryl; heteroaryl; heterocyclyl; heterocyclylalkoxy; aryloxy; heteroaryloxy; aralkyloxy; heteroaralkyloxy; optionally substituted phenoxy; —(CH 2 ) m —(Z) n —(CO)—R f or —(CH 2 ) m —(Z) n —SO 2 —(NR g ) n —R f where m and n each independently is 0 or 1, Z is O or NR g , R f is hydrogen,
- R 7 and R 8 is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalkyl; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl; and
- R d and R e is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalkyl; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- R 1 is alkyl, alkenyl or cycloalkyl.
- R 1 is ethyl, cyclopropyl, isopropenyl or isopropyl. More preferably R 1 is isopropyl.
- one of R 7 and R 8 is hydrogen, and the other is: alkyl, cycloalkyl; cycloalkylalkyl; haloalkyl; hydroxyalky; alkoxyalkyl; alkylsulfonylalkyl; acetyl; alkylsulfonyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- one of R 7 and R 8 is hydrogen and the other is alkyl, hydroxyalkyl or haloalkyl.
- one of R d and R 3 is hydrogen, and the other is: alkyl, cycloalkyl; cycloalkylalkyl; haloalkyl; hydroxyalky; alkoxyalkyl; alkylsulfonylalkyl; acetyl; alkylsulfonyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- one of R d and R e is hydrogen and the other is alkyl, hydroxyalkyl or haloalkyl.
- R 3 and R 4 each independently is halo, alkoxy, haloalkoxy, aminosulfonyl, hydroxy or alkylsulfonyl.
- R 3 is halo, alkoxy, haloalkoxy or hydroxy.
- R 3 is methoxy, fluoro, or chloro. More preferably R 3 is methoxy. In certain embodiments R 3 is hydroxy.
- R 4 is halo, alkoxy, alkylsulfonyl or heteroaryl.
- R 4 is methoxy, iodo, methanesulfonyl or heteroaryl. More preferably R 4 is methoxy, bromo, chloro or iodo. In specific embodiments R 4 may be methoxy, while in other embodiments R 4 may be iodo.
- R 7 , R 8 , R d and R e are hydrogen.
- R 4 is heteroaryl.
- the heteroaryl may be, in certain embodiments, tetrazolyl, pyrazolyl, oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl, isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl, or pyrrolyl.
- the heteroaryl may be tetrazol-5-yl, pyrazol-1-yl, 3-methylpyrazol-1-yl, oxazol-2-yl, oxazol-5-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, thiophen-3-yl, 5-chloro-thiophen-2-yl, 1-methyl-imidazol-2-yl, imidazol-1-yl, pyrazol-3-yl, 2-methyl-thiazol-4-yl, furan-2-yl, 3,5-dimethyl-pyrazol-1-yl, 4,5-dihydrooxazol-2-yl, isoxazol-5-yl, [1,2,4]-oxadiazol-3-yl, benzo[b]thiophen-3-yl, oxazol-4-yl, furan-3-yl, 4-methyl-thiophen-2-yl, thiazol
- R 3 and R 4 together with the atoms to which they are attached may form a five or six-membered ring that optionally includes one or two heteroatoms selected from O, S and N.
- R 3 and R 4 together with the atoms to which they are attached may form: a five membered aromatic with one nitrogen, i.e.
- a pyrrol ring a five membered aromatic with two nitrogens, i.e., a pyrazol or imidazol ring; a five membered aromatic with one nitrogen and one oxygen, i.e., an oxazole or isoxazole ring; a five membered aromatic with one nitrogen and one sulfur, i.e., a thiazole or isothiazole ring; a five membered aromatic with one oxygen, i.e., a furanyl ring; or a five membered aromatic with one sulfur, i.e., a thiophenyl ring.
- X is —O—
- R 1 is alkyl, alkenyl, cycloalkyl, or halo
- R 3 is alkoxy, hydroxy or halo
- R 4 is alkoxy, halo, alkenyl, or heteroaryl selected from tetrazolyl, pyrazolyl, oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl, isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl and pyrrolyl.
- X is —O—
- R 1 is alkyl, alkenyl, cycloalkyl, or halo
- R 3 is alkoxy, hydroxy or halo
- R 4 is alkoxy, aminosulfonyl, halo, or alkenyl.
- X is —O—
- R 1 is alkyl, alkenyl, cycloalkyl, or halo
- R 3 is alkoxy, hydroxy or halo
- R 4 is heteroaryl selected from tetrazolyl, pyrazolyl, oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl, isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl and pyrrolyl.
- X is —O—
- R 1 is alkyl, alkenyl, cycloalkyl, or halo
- R 3 is alkoxy, hydroxy or halo
- R 4 is alkoxy, aminosulfonyl, halo, or alkenyl
- R 7 and R 8 are hydrogen
- one of R a and R b is hydrogen and the other is hydrogen, alkyl, hydroxyalkyl or haloalkyl.
- X is —O—
- R 1 is alkyl, alkenyl, cycloalkyl, or halo
- R 3 is alkoxy, hydroxy or halo
- R 4 is heteroaryl selected from tetrazolyl, pyrazolyl, oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl, isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl and pyrrolyl
- R 7 and R 8 are hydrogen
- one of R a and R b is hydrogen and the other is hydrogen, alkyl, acetyl, hydroxyalkyl or haloalkyl.
- X is —O— or —CH 2 —
- R 1 is isopropyl, isopropenyl, cyclopropyl or iodo
- R 3 is alkoxy, hydroxy or halo
- R 4 is alkoxy, aminosulfonyl, or halo.
- X is —O— or —CH 2 —
- R 1 is isopropyl, isopropenyl, cyclopropyl or iodo
- R 3 is alkoxy, hydroxy or halo
- R 4 is alkoxy, aminosulfonyl, or halo
- R 7 and R 8 are hydrogen
- one of R a and R b is hydrogen and the other is hydrogen, alkyl, hydroxyalkyl or haloalkyl.
- X is —O— or —CH 2 —
- R 1 is isopropyl or iodo
- R 3 is methoxy, hydroxy, chloro, bromo or iodo
- R 4 is methoxy, aminosulfonyl, chloro, bromo or iodo.
- X is —O— or —CH 2 —
- R 1 is isopropyl or iodo
- R 3 is methoxy, hydroxy, chloro, bromo or iodo
- R 4 methoxy, aminosulfonyl, chloro, bromo or iodo
- R 7 and R 8 are hydrogen
- one of R a and R b is hydrogen and the other is hydrogen, alkyl, hydroxyalkyl or haloalkyl.
- X is —O— or —CH 2 —
- R 1 is isopropyl
- R 3 is methoxy, hydroxy, chloro, bromo or iodo
- R 4 is methoxy, aminosulfonyl, chloro, bromo or iodo.
- X is —O— or —CH 2 —
- R 1 is isopropyl
- R 3 is methoxy, hydroxy, chloro, bromo or iodo
- R 4 methoxy, aminosulfonyl, chloro, bromo or iodo
- R 7 and R 8 are hydrogen
- one of R a and R b is hydrogen and the other is hydrogen, alkyl, hydroxyalkyl or haloalkyl.
- the invention provides methods for treating a respiratory disease or a gastrointestinal disease mediated by a P2X 3 or P2X 2/3 receptor antagonist, said method comprising administering to a subject in need thereof an effective amount of a compound of formula (III):
- R 1 is: isopropyl; isopropenyl; cyclopropyl; or iodo;
- R 3 and R 4 each independently is: alkyl; alkenyl; amino; aminosulfonyl; halo; amido; haloalkyl; alkoxy; hydroxy; haloalkoxy; nitro; hydroxyalkyl; alkoxyalkyl; hydroxyalkoxy; alkynylalkoxy; alkylsulfonyl; arylsulfonyl; cyano; aryl; heteroaryl; heterocyclyl; heterocyclylalkoxy; aryloxy; heteroaryloxy; aralkyloxy; heteroaralkyloxy; optionally substituted phenoxy; —(CH 2 ) m —(Z) n —(CO)—R f or —(CH 2 ) m —(Z) n —SO 2 —(NR g ) n —R f where m and n each independently is 0 or 1, Z is O or NR g , R f is hydrogen,
- R 7 and R 8 is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalkyl; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl; and
- R d and R e is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalkyl; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- the invention provides methods for treating a respiratory or gastrointestinal disease mediated by a P2X 3 or P2X 2/3 receptor antagonist, said method comprising administering to a subject in need thereof an effective amount of a compound of formula (IV):
- R 1 is: alkyl; alkenyl; cycloalkyl; cycloalkenyl or halo;
- R 3 and R 4 each independently is: alkyl; alkenyl; amino; aminosulfonyl; halo; amido; haloalkyl; alkoxy; hydroxy; haloalkoxy; nitro; hydroxyalkyl; alkoxyalkyl; hydroxyalkoxy; alkynylalkoxy; alkylsulfonyl; arylsulfonyl; cyano; aryl; heteroaryl; heterocyclyl; heterocyclylalkoxy; aryloxy; heteroaryloxy; aralkyloxy; heteroaralkyloxy; optionally substituted phenoxy; —(CH 2 ) m —(Z) n —(CO)—R f or —(CH 2 ) m —(Z), —SO 2 —(NR g ) n —R f where m and n each independently is 0 or 1, Z is O or NR g , R f is hydrogen, alky
- R 7 and R 8 is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalkyl; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl; and
- R d and R e is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalkyl; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- R 1 is alkyl, alkenyl, cycloalkyl or halo.
- R 1 is ethyl, cyclopropyl, isopropenyl, isopropyl or iodo. More preferably R 1 is isopropyl or iodo.
- one of R 7 and R 8 is hydrogen, and the other is: alkyl, cycloalkyl; cycloalkylalkyl; haloalkyl; hydroxyalky; alkoxyalkyl; alkylsulfonylalkyl; acetyl; alkylsulfonyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- one of R 7 and R 8 is hydrogen and the other is alkyl, hydroxyalkyl or haloalkyl.
- one of R d and R e is hydrogen, and the other is: alkyl, cycloalkyl; cycloalkylalkyl; haloalkyl; hydroxyalky; alkoxyalkyl; alkylsulfonylalkyl; acetyl; alkylsulfonyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- one of R d and R e is hydrogen and the other is alkyl, hydroxyalkyl or haloalkyl.
- R 3 and R 4 each independently is halo, alkoxy, aminosulfonyl, haloalkoxy or alkylsulfonyl.
- R 3 is halo, alkoxy, haloalkoxy or hydroxy.
- R 3 is methoxy, fluoro, or chloro. More preferably R 3 is methoxy. In certain embodiments R 3 is hydroxy.
- R 4 is halo, alkoxy, aminosulfonyl, alkylsulfonyl or heteroaryl.
- R 4 is methoxy, iodo, methanesulfonyl, aminosulfonyl, or heteroaryl. More preferably R 4 is methoxy, aminosulfonyl, bromo, chloro or iodo. In specific embodiments R 4 may be methoxy, aminosulfonyl, while in other embodiments R 4 may be iodo.
- R 7 , R 8 , R d and R e are hydrogen.
- R 4 is heteroaryl.
- the heteroaryl may be, in certain embodiments, tetrazolyl, pyrazolyl, oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl, isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl, or pyrrolyl.
- the heteroaryl may be tetrazol-5-yl, pyrazol-1-yl, 3-methylpyrazol-1-yl, oxazol-2-yl, oxazol-5-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, thiophen-3-yl, 5-chloro-thiophen-2-yl, 1-methyl-imidazol-2-yl, imidazol-1-yl, pyrazol-3-yl, 2-methyl-thiazol-4-yl, furan-2-yl, 3,5-dimethyl-pyrazol-1-yl, 4,5-dihydrooxazol-2-yl, isoxazol-5-yl, [1,2,4]-oxadiazol-3-yl, benzo[b]thiophen-3-yl, oxazol-4-yl, furan-3-yl, 4-methyl-thiophen-2-yl, thiazol
- R 3 and R 4 together with the atoms to which they are attached may form a five or six-membered ring that optionally includes one or two heteroatoms selected from O, S and N.
- R 3 and R 4 together with the atoms to which they are attached may form: a five membered aromatic with one nitrogen, i.e.
- a pyrrol ring a five membered aromatic with two nitrogens, i.e., a pyrazol or imidazol ring; a five membered aromatic with one nitrogen and one oxygen, i.e., an oxazole or isoxazole ring; a five membered aromatic with one nitrogen and one sulfur, i.e., a thiazole or isothiazole ring; a five membered aromatic with one oxygen, i.e., a furanyl ring; or a five membered aromatic with one sulfur, i.e., a thiophenyl ring.
- the invention provides methods for treating a respiratory or gastrointestinal disease mediated by a P2X 3 or P2X 2/3 receptor antagonist, said method comprising administering to a subject in need thereof an effective amount of a compound of formula (V):
- R 3 and R 4 each independently is: alkyl; alkenyl; amino; aminosulfonyl; halo; amido; haloalkyl; alkoxy; hydroxy; haloalkoxy; nitro; hydroxyalkyl; alkoxyalkyl; hydroxyalkoxy; alkynylalkoxy; alkylsulfonyl; arylsulfonyl; cyano; aryl; heteroaryl; heterocyclyl; heterocyclylalkoxy; aryloxy; heteroaryloxy; aralkyloxy; heteroaralkyloxy; optionally substituted phenoxy; —(CH 2 ) m —(Z) n —(CO)—R f or —(CH 2 ) m —(Z) n —SO 2 —(NR g ) n —R f where m and n each independently is 0 or 1, Z is O or NR g , R f is hydrogen,
- R 7 and R 8 is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalkyl; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl; and
- R d and R e is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalkyl; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- the subject methods may utilize compounds of the formula (VI):
- R 3 and R 4 each independently is: alkyl; alkenyl; amino; aminosulfonyl; halo; amido; haloalkyl; alkoxy; hydroxy; haloalkoxy; nitro; hydroxyalkyl; alkoxyalkyl; hydroxyalkoxy; alkynylalkoxy; alkylsulfonyl; arylsulfonyl; cyano; aryl; heteroaryl; heterocyclyl; heterocyclylalkoxy; aryloxy; heteroaryloxy; aralkyloxy; heteroaralkyloxy; optionally substituted phenoxy; —(CH 2 ) m —(Z) n —(CO)—R f or —(CH 2 ) m —(Z) n —SO 2 —(NR g ) n —R f where m and n each independently is 0 or 1, Z is O or NR g , R f is hydrogen,
- R 7 and R 8 is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalkyl; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl; and
- R d and R e is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalkyl; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- one of R 7 and R 8 is hydrogen, and the other is: alkyl, cycloalkyl; cycloalkylalkyl; haloalkyl; hydroxyalky; alkoxyalkyl; alkylsulfonylalkyl; acetyl; alkylsulfonyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- one of R 7 and R 8 is hydrogen and the other is alkyl, hydroxyalkyl or haloalkyl.
- one of R d and R e is hydrogen, and the other is: alkyl, cycloalkyl; cycloalkylalkyl; haloalkyl; hydroxyalky; alkoxyalkyl; alkylsulfonylalkyl; acetyl; alkylsulfonyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- one of R d and R e is hydrogen and the other is alkyl, hydroxyalkyl or haloalkyl.
- R 3 and R 4 each independently is halo, aminosulfonyl, hydroxy, alkoxy, haloalkoxy or alkylsulfonyl.
- R 3 is halo, alkoxy, haloalkoxy or hydroxy.
- R 3 is methoxy, fluoro, or chloro. More preferably R 3 is methoxy. In certain embodiments R 3 is hydroxy.
- R 4 is halo, alkoxy, aminosulfonyl, alkylsulfonyl or heteroaryl.
- R 4 is methoxy, aminosulfonyl, iodo, methanesulfonyl or heteroaryl. More preferably R 4 is methoxy, aminosulfonyl, bromo, chloro or iodo. In specific embodiments R 4 may be methoxy, while in other embodiments R 4 may be iodo. In certain embodiments R 4 is aminosulfonyl.
- R 7 , R 8 , R d and R e are hydrogen.
- R 4 is heteroaryl.
- the heteroaryl may be, in certain embodiments, tetrazolyl, pyrazolyl, oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl, isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl, or pyrrolyl.
- the heteroaryl may be tetrazol-5-yl, pyrazol-1-yl, 3-methylpyrazol-1-yl, oxazol-2-yl, oxazol-5-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, thiophen-3-yl, 5-chloro-thiophen-2-yl, 1-methyl-imidazol-2-yl, imidazol-1-yl, pyrazol-3-yl, 2-methyl-thiazol-4-yl, furan-2-yl, 3,5-dimethyl-pyrazol-1-yl, 4,5-dihydrooxazol-2-yl, isoxazol-5-yl, [1,2,4]-oxadiazol-3-yl, benzo[b]thiophen-3-yl, oxazol-4-yl, furan-3-yl, 4-methyl-thiophen-2-yl, thiazol
- R 3 and R 4 together with the atoms to which they are attached may form a five or six-membered ring that optionally includes one or two heteroatoms selected from O, S and N.
- R 3 and R 4 together with the atoms to which they are attached may form: a five membered aromatic with one nitrogen, i.e.
- a pyrrol ring a five membered aromatic with two nitrogens, i.e., a pyrazol or imidazol ring; a five membered aromatic with one nitrogen and one oxygen, i.e., an oxazole or isoxazole ring; a five membered aromatic with one nitrogen and one sulfur, i.e., a thiazole or isothiazole ring; a five membered aromatic with one oxygen, i.e., a furanyl ring; or a five membered aromatic with one sulfur, i.e., a thiophenyl ring.
- the methods of the invention may use administration of a compound or compounds of the formula (VII):
- X is: —CH 2 —; or —O—;
- R 1 is: alkyl; alkenyl; cycloalkyl; cycloalkenyl; or halo;
- R 2 is: hydrogen; alkyl; alkenyl; amino; aminosulfonyl; halo; amido; haloalkyl; alkoxy; hydroxy; haloalkoxy; nitro; hydroxyalkyl; alkoxyalkyl; hydroxyalkoxy; alkynylalkoxy; alkylsulfonyl; arylsulfonyl; cyano; aryl; heteroaryl; heterocyclyl; heterocyclylalkoxy; aryloxy; heteroaryloxy; aralkyloxy; heteroaralkyloxy; optionally substituted phenoxy; or —(CH 2 ) m —(Z) n —(CO)—R f or —(CH 2 ) m —(Z) n —SO 2 —(NR g ) n —R f where m and n each independently is 0 or 1, Z is O or NR g , R f is hydrogen, alky
- R 7 and R 8 is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalkyl; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl;
- R d and R e is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalkyl; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl;
- Q is CR 9 , one of A and E is O, S or NR 10 and the other is CR 9 or N; or
- Q is N, one of A and E is NR 10 and the other is CR 9 ;
- each R 9 is independently hydrogen, alkyl, halo or alkoxy
- A is NR 10
- Q and E are CR 9 .
- E is NR 10
- a and Q are CR 9 .
- Q is NR 10
- a and E are CR 9 .
- A is O, E is N, and Q is CR 9 .
- A is N, E is O, and Q is CR 9 .
- A is S, E is N, and Q is CR 9 .
- A is N, E is S, and Q is CR 9 .
- E is S, and A and Q are CR 9 .
- E is O, and A and Q are CR 9 .
- A is S, and E and Q are CR 9 .
- A is O, and E and Q are CR 9 .
- A is NR 10 , Q is N, and E is CR 9 .
- E is NR 10
- Q is N
- A is CR 9 .
- R 2 is hydrogen
- X is —CH 2 — or —O—.
- X is O.
- R 1 is alkyl, alkenyl or cycloalkyl.
- R 1 is ethyl, cyclopropyl, isopropenyl or isopropyl. More preferably R 1 is isopropyl.
- one of R 7 and R 8 is hydrogen, and the other is: alkyl, cycloalkyl; cycloalkylalkyl; haloalkyl; hydroxyalky; alkoxyalkyl; alkylsulfonylalkyl; acetyl; alkylsulfonyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- one of R 7 and R 8 is hydrogen and the other is alkyl, hydroxyalkyl or haloalkyl.
- one of R d and R e is hydrogen, and the other is: alkyl, cycloalkyl; cycloalkylalkyl; haloalkyl; hydroxyalky; alkoxyalkyl; alkylsulfonylalkyl; acetyl; alkylsulfonyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- one of R d and R e is hydrogen and the other is alkyl, hydroxyalkyl or haloalkyl.
- R 7 , R 8 , R d and R e are hydrogen.
- the subject methods may be based on use of compounds of the formula (VIII):
- X is: —CH 2 —; or —O—;
- R 1 is: alkyl; alkenyl; cycloalkyl; cycloalkenyl; or halo;
- R 4 is: hydrogen; alkyl; alkenyl; amino; aminosulfonyl; halo; amido; haloalkyl; alkoxy; hydroxy; haloalkoxy; nitro; hydroxyalkyl; alkoxyalkyl; hydroxyalkoxy; alkynylalkoxy; alkylsulfonyl; arylsulfonyl; cyano; aryl; heteroaryl; heterocyclyl; heterocyclylalkoxy; aryloxy; heteroaryloxy; aralkyloxy; heteroaralkyloxy; optionally substituted phenoxy; or —(CH 2 ) m —(Z) n —(CO)—R f or —(CH 2 ) m —(Z) n —SO 2 —(NR g ) n —R f where m and n each independently is 0 or 1, Z is O or NR g , R f is hydrogen, alky
- R 7 and R 8 is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalkyl; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl;
- R d and R e is hydrogen, and the other is: hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; haloalkyl; haloalkoxy; hydroxyalkyl; alkoxyalkyl; acetyl; alkylsulfonyl; alkylsulfonylalkyl; aminocarbonyloxyalkyl; hydroxycarbonylalkyl; hydroxyalkyloxycarbonylalkyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl;
- Q is CR 9 , one of A and E is O, S or NR 10 and the other is CR 9 or N; or
- Q is N, one of A and E is NR 10 and the other is CR 9 ;
- each R 9 is independently hydrogen, alkyl, halo or alkoxy
- R 10 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, —(CH 2 ) m —(Z) n —(CO)—R f , or —(CH 2 ) m —(Z) n —SO 2 —(NR g ) n —R f .
- A is NR 10
- Q and E are CR 9 .
- E is NR 10
- a and Q are CR 9 .
- Q is NR 10
- a and E are CR 9 .
- A is O
- E is N
- Q is CR 9 .
- A is N, E is O, and Q is CR 9 .
- A is S, E is N, and Q is CR 9 .
- A is N
- E is S
- Q is CR 9 .
- E is S, and A and Q are CR 9 .
- E is O
- a and Q are CR 9 .
- A is S, and E and Q are CR 9 .
- A is O, and E and Q are CR 9 .
- A is NR 10 , Q is N, and E is CR 9 .
- E is NR 10
- Q is N
- A is CR 9 .
- X is —CH 2 — or —O—.
- X is O.
- R 1 is alkyl, alkenyl or cycloalkyl.
- R 1 is ethyl, cyclopropyl, isopropenyl or isopropyl. More preferably R 1 is isopropyl.
- one of R 7 and R 8 is hydrogen, and the other is: alkyl, cycloalkyl; cycloalkylalkyl; haloalkyl; hydroxyalky; alkoxyalkyl; alkylsulfonylalkyl; acetyl; alkylsulfonyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- one of R 7 and R 8 is hydrogen and the other is alkyl, hydroxyalkyl or haloalkyl.
- one of R d and R e is hydrogen, and the other is: alkyl, cycloalkyl; cycloalkylalkyl; haloalkyl; hydroxyalky; alkoxyalkyl; alkylsulfonylalkyl; acetyl; alkylsulfonyl; aryl; aralkyl; arylsulfonyl; heteroaryl; heteroarylalkyl; heteroarylsulfonyl; heterocyclyl; or heterocyclylalkyl.
- one of R d and R e is hydrogen and the other is alkyl, hydroxyalkyl or haloalkyl.
- R 7 , R 8 , R d and R e are hydrogen.
- R 4 is halo, alkoxy, haloalkoxy or alkylsulfonyl.
- R 4 is halo, alkoxy, alkylsulfonyl or heteroaryl.
- R 4 is methoxy, iodo, methanesulfonyl or heteroaryl. More preferably R 4 is methoxy, bromo, chloro or iodo. In specific embodiments R 4 may be methoxy, while in other embodiments R 4 may be iodo.
- R 4 is heteroaryl.
- the heteroaryl may be, in certain embodiments, tetrazolyl, pyrazolyl, oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl, isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl, or pyrrolyl.
- the heteroaryl may be tetrazol-5-yl, pyrazol-1-yl, 3-methylpyrazol-1-yl, oxazol-2-yl, oxazol-5-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, thiophen-3-yl, 5-chloro-thiophen-2-yl, 1-methyl-imidazol-2-yl, imidazol-1-yl, pyrazol-3-yl, 2-methyl-thiazol-4-yl, furan-2-yl, 3,5-dimethyl-pyrazol-1-yl, 4,5-dihydrooxazol-2-yl, isoxazol-5-yl, [1,2,4]-oxadiazol-3-yl, benzo[b]thiophen-3-yl, oxazol-4-yl, furan-3-yl, 4-methyl-thiophen-2-yl, thiazol
- any of R 7 , R 8 , R d or R e are heterocyclyl or a group that includes a heterocyclyl moiety
- such heterocyclyl or heterocyclyl moiety may be piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothiopyranyl, or 1,1-dioxotetrahydrothiopyranyl.
- heterocyclyl or heterocyclyl moiety may be piperidin-4-yl, 1-methyl-piperidine-4-yl, 1-methanesulfonyl-piperidin-4-yl, tetrahydropyran-4-yl, tetrahydrothiopyran-4-yl, or 1,1-dioxotrahydrothiopyran-4-yl.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R c , R d , R e , R f , R g , or R h is alkyl or contains an alkyl moiety, such alkyl is preferably lower alkyl, i.e. C 1 -C 6 alkyl, and more preferably C 1 -C 4 alkyl.
- the starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis ; Wiley & Sons: New York, 1991, Volumes 1-15; Rodd's Chemistry of Carbon Compounds , Elsevier Science Publishers, 1989, Volumes 1-5 and Supplementals; and Organic Reactions , Wiley & Sons: New York, 1991, Volumes 1-40.
- the following synthetic reaction schemes are merely illustrative of some methods by which the compounds of the present invention can be synthesized, and various modifications to these synthetic reaction schemes can be made and will be suggested to one skilled in the art having referred to the disclosure contained in this Application.
- the starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.
- the reactions described herein preferably are conducted under an inert atmosphere at atmospheric pressure at a reaction temperature range of from about ⁇ 78° C. to about 150° C., more preferably from about 0° C. to about 125° C., and most preferably and conveniently at about room (or ambient) temperature, e.g., about 20° C.
- Scheme A illustrates one synthetic procedure usable to prepare specific compounds of formula (I) wherein X is methylene, Y is —NR d R e , and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R d , and R e are as defined herein.
- benzaldehyde a is alkylated with the Grignard reagent derived from 4-chloro-5-iodo-2-methylsulfanyl-pyrimidine b or like iodopyrimidine to provide an alpha-hydroxy benzyl pyrimidine c.
- the iodopyrimidine used in this step may be prepared according to the procedure described by T. Sakamoto, et al., Chem. Pharm. Bull., 34 1986, p. 2719. Numerous substituted benzaldehydes a are commercially available or are readily prepared by techniques well known to those skilled in the art.
- a “masked aldehyde”, such as an imine or oxazoline, may be used to allow introduction of desired functionalities to benzaldehyde a, after which the masked aldehyde is deprotected to provide the free aldehyde group.
- Aldehyde protection schemes of this sort are shown in the experimental examples below.
- step 1 may be carried out in the presence of an alkyl magnesium bromide under dry polar aprotic solvent conditions.
- step 2 alpha-hydroxy benzyl pyrimidine c is reduced to provide benzyl pyrimidine d.
- the reduction of step 2 may be achieved using triethylsilane and trifluoroacetic acid under polar solvent conditions.
- step 3 a first amination by reaction of amine e with benzyl pyrimidine d yields benzyl aminopyrimidine f.
- Amine e may comprise any suitable primary or secondary amine having functionalities R 7 or R 8 in accordance with the invention.
- Amine e may comprise, for example, ammonia, methylamine, ethylamine, isopropylamine, aniline, benzylamine, phenylethylamine, cyclopropylamine, dimethylamine, aziridine, pyrrlolidine, piperidine, or the like.
- the amination of step 3 may be carried out by heating benzyl pyrimidine d in the presence of excess amine e under sealed conditions.
- step 4 an oxidation of the methylsulfanyl group of benzyl aminopyrimidine f is carried out to afford amino methanesulfonyl benzylpyrimidine g.
- the oxidation of step 4 may be carried out using metachloroperbenzoic acid (mCPBA), OXONE®, or like oxidizing agent under mild, polar solvent conditions.
- a second amination occurs in step 6 in which amino methanesulfonyl benzylpyrimidine g is treated with amine h to displace the methanesulfonyl group and provide diamino benzylpyrimidine i.
- the diamino benzylpyrimidine i is a compound of formula (I) and is usable in the methods of the invention.
- the amination of step 6 may be achieved by heating amino methanesulfonyl benzylpyrimidine g in the presence of excess amine h under mild pressure and polar solvent conditions.
- pyrimidine reagents may be used in place of iodopyrimidine b in step 1.
- benzaldehyde a may be treated with 5-lithio-2,6-dimethoxypyrimidine (Mathson, R. J. et al., JOC 55(10) 1990 3410-12) to form a dimethoxy benzyl pyrimidine alcohol which is subsequently oxidized with MnO 2 .
- the resultant ketone can then be animated to displace the methoxy groups to yield a diamino benzylpyrimidine in accordance with the invention.
- Scheme B illustrates another synthetic procedure usable to prepare specific compounds of formula (I) above, wherein X is O, Y is —NR d R e , R 7 and R 8 are hydrogen, and R 1 , R 2 , R 3 , R 4 , R 5 , R d , and R e are as defined herein.
- step 1 of Scheme B an O-alkylation is carried out by reaction of phenol j with a haloacetonitrile such as iodoacetonitrile k, to afford cyano ether l.
- a haloacetonitrile such as iodoacetonitrile k
- Numerous substituted phenols j are either commercially available or may be prepared by techniques well known in the art for use in step 1.
- the substituted benzaldehydes a of Scheme A above may be converted to the corresponding phenols j via Baeyer-Villiger oxidation using peracid such as mCPBA, as illustrated in the experimental examples below.
- the alkylation of step 1 may be effected in the presence of mild base under polar aprotic solvent conditions.
- a cyano enol ether compound n is formed by treatment of cyano ether l with a strong base such as sodium hydride, followed by introduction of ester m to form an enolate (not shown), that in turn is alkylated by addition of iodomethane or other alkyl halide.
- a strong base such as sodium hydride
- step 3 cyano enol ether n is reacted with guanidine compound o in the presence of base, under polar aprotic conditions, to yield diaminopyrimidine (VI).
- the diaminopyrimidine (VI) is a compound of formula (I) usable in the methods of the invention.
- Scheme C Yet another procedure usable for preparation of the subject compounds is shown in Scheme C, wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein.
- Scheme C represents the well-known synthesis of “ormetoprim” and “trimethoprim” antibacterials. This synthetic procedure is reported by Manchand et al., Journal of Organic Chemistry 1992, 57, 3531-3535.
- Diamino pyrimidine r is a compound of formula (I) in which X is —CH 2 —, Y is —NH 2 and R 6 , R 7 and R 8 are hydrogen.
- the compounds of the invention are usable for the treatment of a wide range of genitorurinary diseases, conditions and disorders, including urinary tract disease states associated with bladder outlet obstruction and urinary incontinence conditions such as reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benign prostatic hypertrophy (BPH), prostatitis, detrusor hyperreflexia, urinary frequency, nocturia, urinary urgency, overactive bladder, pelvic hypersensitivity, urethritis, prostatitits, pelvic pain syndrome, prostatodynia, cystitis, and idiophatic bladder hypersensitivity, and other symptoms related to overactive bladder.
- urinary tract disease states associated with bladder outlet obstruction and urinary incontinence conditions such as reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benign prostatic hypertrophy (BPH), prostatitis, detrusor hyperreflexia, urinary frequency, nocturia,
- the compounds of the invention are expected to find utility as analgesics in the treatment of diseases and conditions associated with pain from a wide variety of causes, including, but not limited to, inflammatory pain, surgical pain, visceral pain, dental pain, premenstrual pain, central pain, pain due to burns, migraine or cluster headaches, nerve injury, neuritis, neuralgias, poisoning, ischemic injury, interstitial cystitis, cancer pain, viral, parasitic or bacterial infection, post-traumatic injuries (including fractures and sports injuries), and pain associated with functional bowel disorders such as irritable bowel syndrome.
- causes including, but not limited to, inflammatory pain, surgical pain, visceral pain, dental pain, premenstrual pain, central pain, pain due to burns, migraine or cluster headaches, nerve injury, neuritis, neuralgias, poisoning, ischemic injury, interstitial cystitis, cancer pain, viral, parasitic or bacterial infection, post-traumatic injuries (including fractures and sports injuries), and pain associated with functional bowel disorders such as
- compounds of the invention are useful for treating respiratory disorders, including chronic obstructive pulmonary disorder (COPD), asthma, bronchospasm, and the like.
- COPD chronic obstructive pulmonary disorder
- compounds of the invention are useful for treating gastrointestinal disorders, including Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), biliary colic and other biliary disorders, renal colic, diarrhea-dominant IBS, pain associated with GI distension, and the like.
- IBS Irritable Bowel Syndrome
- IBD Inflammatory Bowel Disease
- biliary colic and other biliary disorders renal colic
- renal colic diarrhea-dominant IBS
- pain associated with GI distension and the like.
- the invention includes pharmaceutical compositions comprising at least one compound of the present invention, or an individual isomer, racemic or non-racemic mixture of isomers or a pharmaceutically acceptable salt or solvate thereof, together with at least one pharmaceutically acceptable carrier, and optionally other therapeutic and/or prophylactic ingredients.
- the compounds of the invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Suitable dosage ranges are typically 1-500 mg daily, preferably 1-100 mg daily, and most preferably 1-30 mg daily, depending upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, the indication towards which the administration is directed, and the preferences and experience of the medical practitioner involved.
- One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this Application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease.
- Compounds of the invention may be administered as pharmaceutical formulations including those suitable for oral (including buccal and sub-lingual), rectal, nasal, topical, pulmonary, vaginal, or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insulation.
- the preferred manner of administration is generally oral using a convenient daily dosage regimen which can be adjusted according to the degree of affliction.
- a compound or compounds of the invention, together with one or more conventional adjuvants, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages.
- the pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
- compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use.
- Formulations containing about one (1) milligram of active ingredient or, more broadly, about 0.01 to about one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
- the compounds of the invention may be formulated in a wide variety of oral administration dosage forms.
- the pharmaceutical compositions and dosage forms may comprise a compound or compounds of the present invention or pharmaceutically acceptable salts thereof as the active component.
- the pharmaceutically acceptable carriers may be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- a solid carrier may be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- the carrier In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component.
- the active component In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain from about one (1) to about seventy (70) percent of the active compound.
- Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
- the term “preparation” is intended to include the formulation of the active compound with encapsulating material as carrier, providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it.
- cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges may be as solid forms suitable for oral administration.
- liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations.
- Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia.
- Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents.
- Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.
- Solid form preparations include solutions, suspensions, and emulsions, and may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- the compounds of the invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
- the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol.
- oily or nonaqueous carriers, diluents, solvents or vehicles examples include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
- the compounds of the invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch.
- Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
- Lotions may be formulated with an aqueous or oily base and will in general also containing one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
- Formulations suitable for topical administration in the mouth include lozenges comprising active agents in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatine and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- the compounds of the invention may be formulated for administration as suppositories.
- a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.
- the compounds of the invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- the subject compounds may be formulated for nasal administration.
- the solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray.
- the formulations may be provided in a single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.
- the compounds of the invention may be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration.
- the compound will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
- the active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas.
- CFC chlorofluorocarbon
- the aerosol may conveniently also contain a surfactant such as lecithin.
- the dose of drug may be controlled by a metered valve.
- the active ingredients may be provided in a form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP).
- a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP).
- the powder carrier will form a gel in the nasal cavity.
- the powder composition may be presented in unit dose form for example in capsules or cartridges of e.g., gelatine or blister packs from which the powder may be administered by means of an inhaler.
- formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient.
- the compounds of the present invention can be formulated in transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the compound is necessary and when patient compliance with a treatment regimen is crucial.
- Compounds in transdermal delivery systems are frequently attached to an skin-adhesive solid support.
- the compound of interest can also be combined with a penetration enhancer, e.g., Azone (1-dodecylazacycloheptan-2-one).
- Sustained release delivery systems are inserted subcutaneously into the subdermal layer by surgery or injection.
- the subdermal implants encapsulate the compound in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polylactic acid.
- the pharmaceutical preparations are preferably in unit dosage forms.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- Step 8 (2,4-Diamino-pyrimidin-5-yl)-[4,5-dimethoxy-2-(1-methyl-2-phenyl-ethyl)-phenyl]-methanone
- Example 1 Using the procedure of Example 1 described above, but replacing 2-bromo-1-phenyl propane in step 1 with 2-bromopropane or other alkyl bromides, and replacing ammonia in step 8 with various alkyl or benzyl amines, afforded a variety of compounds under essential the same reaction conditions. Additional compounds are prepared using the procedure outlined in Example 1 are shown in Table 1.
- the 4-chloro-5-iodo-2-methylsulfanyl-pyrimidine used in this step was prepared according to the procedure described by T. Sakamoto, et al., Chem. Pharm. Bull., 34 1986, p. 2719.
- step 4 Using the procedure of step 4 from Example 2 described above, 5-chloro-2-isopropyl-4-methoxy-benzaldehyde (3.203 g, 15.1 mmol) afforded 5-chloro-2-isopropyl-4-methoxy-phenol (1.768 g, 58%) as s clear oil.
- 1,1-Carbonyldiimidazole (0.97 g, 6 mmol) was added to a solution of 2-[4-Amino-5-(5-chloro-2-isopropyl-4-methoxy-phenoxy)-pyrimidin-2-ylamino]-(R)-propan-1-ol from Example 4 (0.22 g, 0.6 mmol) in 20 mL of THF at room temperature. The mixture was stirred for 2 hours and methylamine (3 mL, 2M/THF, 0.6 mmol) was added. The reaction mixture was stirred overnight and concentrated under reduced pressure, diluted with water (75 mL), and extracted with EtOAc (2 ⁇ 75 mL).
- step 2 3-(4,5-dimethoxy-2-methyl-phenyl)-2-methoxymethyl-acrylonitrile and sodium methoxide were dissolved in dry DMSO and stirred for 3.5 hours at 85° C. under nitrogen. Guanidine carbonate was then added to the stirring solution, after which the temperature was raised to 125° C. for three hours, during which methanol removed via a Dean-Stark trap. The solution was cooled to room temperature, diluted with water, and the crude filtrate was recrystallized in DMF to yield 5-(4,5-dimethoxy-2-methyl-benzyl)-pyrimidine-2,4-diamine as a white solid. Mp: 232° C. Mass Spec (M+H): 275.
- step 1 of this Example was prepared from 1- ⁇ 2-[(5-benzyloxy)-4-(1-methylethyl)-2-nitrophenyl]ethenyl ⁇ -pyrrolidine according to the procedure reported by Leonardi et al., “Synthesis and Pharmacological Evaluation of New Indole Derivatives Structurally Related to Thymoxamine”, Eur. J. Med. Chem . (1994), 29, 551-559. The methylation of step 3 below also follows the procedure described by Leonardi et al.
- 5-(2-Cyclopropyl-4,5-dimethoxy-phenoxy)-pyrimidine-2,4-diamine was prepared from 4-cyclopropyl-1,2-dimethoxy-benzene following the procedure of step 1 and steps 3-7 of Example 2 above.
- reaction mixture was partitioned between ethyl acetate and water.
- the combined organic phase was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- the residue was purified by silica gel chromatography (2% ethyl acetate in hexane) to yield 1-chloro-4-cyclopropyl-2-methoxy-benzene as yellow oily residue (0.81 g, 67%).
- 5-(5-Chloro-2-cyclopropyl-4-methoxy-phenoxy)-pyrimidine-2,4-diamine was prepared from 4-cyclopropyl-1,2-dimethoxy-benzene following the procedure of step 1 and steps 3-7 of Example 2 above.
- the crude oil was purified via flash chromatography (gradient: 95:5 to 4:1 hexane/ethyl acetate) to afford 3-amino-2-isopropyl-5-nitro-phenol (10.03 g, 81%) as a yellow solid and 3-amino-2-isopropyl-3-nitro-phenol (1.32 g, 11%) as a yellow oil.
- step 1 8-Bromo-2,3-dihydro-benzo[1,4]dioxine-6-carboxaldehyde (115.63 g, 64 mmol)) and cycolhexylamine (7.02 g, 71 mmol) gave 8-Bromo-2,3-dihydro-benzo[1,4]dioxine-6-ylmethylene)-cyclohexyl-amine (24.2 g) as a viscous oil which was used in the following step without purification.
- n-butyllithium 36 ml, 90 mmol, 2.5 M in hexanes
- trimethyl borate 13.6 ml, 120 mmol
- Step 9 5-(7-Iodo-5-isopropyl-2,3-dihydro-benzo[1.4]dioxin-6-yloxy)-pyrimidine-2,4-diamine and 5-(7,8-Diiodo-5-isopropyl-2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-pyrimidine-2,4-diamine
- N′-[5-[5-(3-Dimethylamino-acryloyl)-2-isopropyl-4-methoxy-phenoxy]-4-(dimethylamino-methyleneamino)-pyrimidin-2-yl]-N,N-dimethyl-formamidine from step 1 was dissolved in methanol (1 mL) and ammonium hydroxide (1 mL).
- Step 2 N-[2-Amino-5-(2-isopropyl-4-methoxy-5-[1,2,4]oxadiazol-3-yl-phenoxy)-pyrimidin-4-yl]formamide, N-[4-amino-5-(2-isopropyl-4-methoxy-5-[1,2,4]oxadiazol-3-yl-phenoxy)-pyrimidin-2-yl]formamide and N-[4-formylamino-5-(2-isopropyl-4-methoxy-5-[1,2,4]oxadiazol-3-yl-phenoxy)-pyrimidin-2-yl]-formamide
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/509,921 US8008313B2 (en) | 2005-09-01 | 2006-08-25 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
US13/186,078 US8524725B2 (en) | 2005-09-01 | 2011-07-19 | Methods of using diaminopyrimidine as P2X3 and P2X⅔ receptor modulators for treatment of respiratory and gastrointestinal diseases |
US15/170,666 US20160271131A1 (en) | 2005-09-01 | 2016-06-01 | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
US16/028,365 US20180311240A1 (en) | 2005-09-01 | 2018-07-05 | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
US17/032,489 US20210008071A1 (en) | 2005-09-01 | 2020-09-25 | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71354805P | 2005-09-01 | 2005-09-01 | |
US11/509,921 US8008313B2 (en) | 2005-09-01 | 2006-08-25 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/186,078 Continuation US8524725B2 (en) | 2005-09-01 | 2011-07-19 | Methods of using diaminopyrimidine as P2X3 and P2X⅔ receptor modulators for treatment of respiratory and gastrointestinal diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
US20070049609A1 US20070049609A1 (en) | 2007-03-01 |
US8008313B2 true US8008313B2 (en) | 2011-08-30 |
Family
ID=37492274
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/509,921 Active 2029-10-02 US8008313B2 (en) | 2005-09-01 | 2006-08-25 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
US13/186,078 Active US8524725B2 (en) | 2005-09-01 | 2011-07-19 | Methods of using diaminopyrimidine as P2X3 and P2X⅔ receptor modulators for treatment of respiratory and gastrointestinal diseases |
US13/866,212 Abandoned US20130225570A1 (en) | 2005-09-01 | 2013-04-19 | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
US15/170,666 Abandoned US20160271131A1 (en) | 2005-09-01 | 2016-06-01 | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
US16/028,365 Abandoned US20180311240A1 (en) | 2005-09-01 | 2018-07-05 | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
US17/032,489 Abandoned US20210008071A1 (en) | 2005-09-01 | 2020-09-25 | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/186,078 Active US8524725B2 (en) | 2005-09-01 | 2011-07-19 | Methods of using diaminopyrimidine as P2X3 and P2X⅔ receptor modulators for treatment of respiratory and gastrointestinal diseases |
US13/866,212 Abandoned US20130225570A1 (en) | 2005-09-01 | 2013-04-19 | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
US15/170,666 Abandoned US20160271131A1 (en) | 2005-09-01 | 2016-06-01 | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
US16/028,365 Abandoned US20180311240A1 (en) | 2005-09-01 | 2018-07-05 | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
US17/032,489 Abandoned US20210008071A1 (en) | 2005-09-01 | 2020-09-25 | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
Country Status (15)
Country | Link |
---|---|
US (6) | US8008313B2 (ja) |
EP (1) | EP1924264B9 (ja) |
JP (1) | JP4850914B2 (ja) |
KR (1) | KR101012926B1 (ja) |
CN (1) | CN101300012B (ja) |
AU (1) | AU2006286601B2 (ja) |
BR (1) | BRPI0615040A2 (ja) |
CA (1) | CA2620034C (ja) |
DK (1) | DK1924264T5 (ja) |
ES (1) | ES2439454T3 (ja) |
IL (1) | IL189499A (ja) |
MX (1) | MX2008002733A (ja) |
PL (1) | PL1924264T3 (ja) |
SI (1) | SI1924264T1 (ja) |
WO (1) | WO2007025925A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130225570A1 (en) * | 2005-09-01 | 2013-08-29 | Roche Palo Alto Llc | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
US20140045871A1 (en) * | 2006-10-04 | 2014-02-13 | Roche Palo Alto Llc | Process for synthesis of phenoxy diaminopyrimidine derivatives |
US9284279B2 (en) | 2013-08-23 | 2016-03-15 | Afferent Pharmaceuticals, Inc. | Substituted pyrimidines for treatment of acute cough, chronic cough and urge to cough |
US20170096404A1 (en) * | 2004-03-05 | 2017-04-06 | Roche Palo Alto Llc | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
US20200108065A1 (en) * | 2014-07-03 | 2020-04-09 | Afferent Pharmaceuticals, Inc. | Methods and compositions for treating diseases and conditions |
US11260056B2 (en) * | 2015-09-29 | 2022-03-01 | Afferent Pharmaceuticals, Inc. | Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR053710A1 (es) * | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
WO2007024863A2 (en) | 2005-08-22 | 2007-03-01 | Melior Discovery, Inc. | Methods and formulations for modulating lyn kinase activity and treating related disorders |
EP1924565B1 (en) * | 2005-09-01 | 2016-09-14 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p3x2/3 modulators |
EP2076514A1 (en) * | 2006-10-12 | 2009-07-08 | Xenon Pharmaceuticals Inc. | Spiro (furo ý3, 2-c¨pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
EP2073806B1 (en) | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
US8101644B2 (en) | 2007-03-30 | 2012-01-24 | Shionogi & Co., Ltd. | Pyrrolinone derivative and pharmaceutical composition comprising the same |
AU2008279242A1 (en) * | 2007-07-23 | 2009-01-29 | Melior Discovery, Inc. | Methods of activating IRS-1 and AKT |
AU2008319308B2 (en) | 2007-10-31 | 2013-01-31 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
WO2009110985A2 (en) | 2008-02-29 | 2009-09-11 | Renovis, Inc. | Amide compounds, compositions and uses thereof |
US8552184B2 (en) | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
TW201016702A (en) * | 2008-09-25 | 2010-05-01 | Shionogi & Co | Novel pyrrolinone derivative and pharmaceutical composition comprising the same |
CN103664973B (zh) * | 2008-10-17 | 2017-04-19 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
US8101647B2 (en) * | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
JP5592388B2 (ja) | 2008-10-31 | 2014-09-17 | メルク・シャープ・アンド・ドーム・コーポレーション | 疼痛治療用のp2x3受容体アンタゴニスト技術分野 |
KR101422901B1 (ko) | 2009-02-13 | 2014-07-23 | 시오노기 앤드 컴파니, 리미티드 | 신규 트라이아진 유도체 및 그것을 함유하는 의약 조성물 |
EP2411001B1 (en) | 2009-03-23 | 2018-01-17 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
EP2410857B1 (en) | 2009-03-23 | 2014-01-29 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
PE20170202A1 (es) * | 2009-10-14 | 2017-03-24 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol |
MX343215B (es) | 2010-02-26 | 2016-10-27 | Xenon Pharmaceuticals Inc | Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos. |
US20130158055A1 (en) | 2010-05-28 | 2013-06-20 | Andrew G. Reaume | Prevention Of Pancreatic Beta Cell Degeneration |
AU2011290261B2 (en) | 2010-08-10 | 2014-11-06 | Shionogi & Co., Ltd. | Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity |
EP2604260B1 (en) | 2010-08-10 | 2017-05-10 | Shionogi&Co., Ltd. | Novel heterocyclic derivatives and pharmaceutical composition containing same |
JP6124351B2 (ja) | 2012-02-09 | 2017-05-10 | 塩野義製薬株式会社 | 複素環および炭素環誘導体 |
MX2014012266A (es) | 2012-04-12 | 2014-12-05 | Xenon Pharmaceuticals Inc | Sintesis asimetricas para compuestos espiro-oxindol utiles como agentes terapeuticos. |
TWI637949B (zh) | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
CN104447574A (zh) * | 2014-12-26 | 2015-03-25 | 苏州步跃医药科技有限公司 | 一种奥美普林的合成方法 |
WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
AU2017233841B9 (en) * | 2016-03-14 | 2021-09-09 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
US10662162B2 (en) | 2016-03-25 | 2020-05-26 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
US10100060B2 (en) | 2016-06-16 | 2018-10-16 | Xenon Pharmaceuticals Inc. | Asymmetric synthesis of funapide |
KR20220148928A (ko) * | 2016-12-20 | 2022-11-07 | 애퍼런트 파마슈티컬스 인크. | P2x3 길항제의 결정질 염 및 다형체 |
SG11201909406VA (en) | 2017-04-10 | 2019-11-28 | Melior Pharmaceuticals I Inc | Treatment of adipocytes |
CN109761910B (zh) * | 2018-12-04 | 2021-11-19 | 华中农业大学 | 一种艾地普林的合成方法 |
MA56020A (fr) * | 2019-05-31 | 2022-04-06 | Chiesi Farm Spa | Dérivés de pyridopyrimidines utilisés en tant qu'inhibiteurs de p2x3 |
US20220332714A1 (en) * | 2019-06-06 | 2022-10-20 | Beijing Tide Pharmaceutical Co., Ltd. | P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition containing same, and use thereof |
JP7492005B2 (ja) * | 2019-11-29 | 2024-05-28 | 武漢朗来科技発展有限公司 | ベンゼン環含有化合物及びその応用 |
WO2021127210A1 (en) * | 2019-12-18 | 2021-06-24 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998045294A1 (en) | 1997-04-09 | 1998-10-15 | Astra Pharmaceuticals Ltd. | Compounds |
US5874420A (en) | 1995-12-26 | 1999-02-23 | Allegheny University Of The Health Sciences | Process for regulating vagal tone |
WO2003040339A2 (en) | 2001-11-09 | 2003-05-15 | Algos Therapeutics, Inc. | Antisense modulation of purinoreceptor p2x¿3? |
US20050209260A1 (en) * | 2004-03-05 | 2005-09-22 | Roche Palo Alto Llc | Diaminopyrimidines as P2X3 and P2X2/3 antagonists |
US20060029548A1 (en) * | 2004-07-22 | 2006-02-09 | Amir Pelleg | Methods of diagnosing, monitoring and treating pulmonary diseases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6583148B1 (en) * | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
CN101296907B (zh) * | 2005-09-01 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3调节剂的二氨基嘧啶类 |
EP1924565B1 (en) * | 2005-09-01 | 2016-09-14 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p3x2/3 modulators |
JP4850914B2 (ja) * | 2005-09-01 | 2012-01-11 | エフ.ホフマン−ラ ロシュ アーゲー | P2x3およびp2x2/3モジュレーターとしてのジアミノピリミジン |
JP4850913B2 (ja) * | 2005-09-01 | 2012-01-11 | エフ.ホフマン−ラ ロシュ アーゲー | P2x3及びp2x2/3調節因子としてのジアミノピリジン |
-
2006
- 2006-08-23 JP JP2008528482A patent/JP4850914B2/ja active Active
- 2006-08-23 MX MX2008002733A patent/MX2008002733A/es active IP Right Grant
- 2006-08-23 DK DK06778331.6T patent/DK1924264T5/en active
- 2006-08-23 WO PCT/EP2006/065606 patent/WO2007025925A1/en active Application Filing
- 2006-08-23 CA CA2620034A patent/CA2620034C/en active Active
- 2006-08-23 BR BRPI0615040-3A patent/BRPI0615040A2/pt not_active Application Discontinuation
- 2006-08-23 KR KR1020087007681A patent/KR101012926B1/ko active IP Right Grant
- 2006-08-23 ES ES06778331.6T patent/ES2439454T3/es active Active
- 2006-08-23 EP EP06778331.6A patent/EP1924264B9/en active Active
- 2006-08-23 SI SI200631683T patent/SI1924264T1/sl unknown
- 2006-08-23 CN CN2006800405247A patent/CN101300012B/zh active Active
- 2006-08-23 AU AU2006286601A patent/AU2006286601B2/en active Active
- 2006-08-23 PL PL06778331T patent/PL1924264T3/pl unknown
- 2006-08-25 US US11/509,921 patent/US8008313B2/en active Active
-
2008
- 2008-02-13 IL IL189499A patent/IL189499A/en active IP Right Grant
-
2011
- 2011-07-19 US US13/186,078 patent/US8524725B2/en active Active
-
2013
- 2013-04-19 US US13/866,212 patent/US20130225570A1/en not_active Abandoned
-
2016
- 2016-06-01 US US15/170,666 patent/US20160271131A1/en not_active Abandoned
-
2018
- 2018-07-05 US US16/028,365 patent/US20180311240A1/en not_active Abandoned
-
2020
- 2020-09-25 US US17/032,489 patent/US20210008071A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874420A (en) | 1995-12-26 | 1999-02-23 | Allegheny University Of The Health Sciences | Process for regulating vagal tone |
WO1998045294A1 (en) | 1997-04-09 | 1998-10-15 | Astra Pharmaceuticals Ltd. | Compounds |
WO2003040339A2 (en) | 2001-11-09 | 2003-05-15 | Algos Therapeutics, Inc. | Antisense modulation of purinoreceptor p2x¿3? |
US20050209260A1 (en) * | 2004-03-05 | 2005-09-22 | Roche Palo Alto Llc | Diaminopyrimidines as P2X3 and P2X2/3 antagonists |
WO2005095359A1 (en) | 2004-03-05 | 2005-10-13 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
US20060029548A1 (en) * | 2004-07-22 | 2006-02-09 | Amir Pelleg | Methods of diagnosing, monitoring and treating pulmonary diseases |
Non-Patent Citations (2)
Title |
---|
Galligan, J. J. "Enteric P2X Receptors as Potential Targets for Drug Treatment of the Irritable Bowel Syndrome," British J. Pharmacology, 2004 vol. 141 (8), p. 1294-1302. |
MedlinePlus, "Asthma", MedlinePlus, May 21, 2009, downloaded from "http://www.nlm.nih.gov/medlineplus/ency/article/000141.htm" on Oct. 22, 2009, pp. 1-4 of 4. * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190270713A1 (en) * | 2004-03-05 | 2019-09-05 | Roche Palo Alto Llc | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
US20240158356A1 (en) * | 2004-03-05 | 2024-05-16 | Roche Palo Alto Llc | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
US20230100975A1 (en) * | 2004-03-05 | 2023-03-30 | Roche Palo Alto Llc | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
US20200115347A1 (en) * | 2004-03-05 | 2020-04-16 | Roche Palo Alto Llc | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
US20170096404A1 (en) * | 2004-03-05 | 2017-04-06 | Roche Palo Alto Llc | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
US20210008071A1 (en) * | 2005-09-01 | 2021-01-14 | Roche Palo Alto Llc | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
US20130225570A1 (en) * | 2005-09-01 | 2013-08-29 | Roche Palo Alto Llc | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
US20180311240A1 (en) * | 2005-09-01 | 2018-11-01 | Roche Palo Alto Llc | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases |
US8524725B2 (en) * | 2005-09-01 | 2013-09-03 | Roche Palo Alto Llc | Methods of using diaminopyrimidine as P2X3 and P2X⅔ receptor modulators for treatment of respiratory and gastrointestinal diseases |
US9643934B2 (en) * | 2006-10-04 | 2017-05-09 | Roche Palo Alto Llc | Process for synthesis of phenoxy diaminopyrimidine derivatives |
US20140045871A1 (en) * | 2006-10-04 | 2014-02-13 | Roche Palo Alto Llc | Process for synthesis of phenoxy diaminopyrimidine derivatives |
US9284279B2 (en) | 2013-08-23 | 2016-03-15 | Afferent Pharmaceuticals, Inc. | Substituted pyrimidines for treatment of acute cough, chronic cough and urge to cough |
US9724346B2 (en) | 2013-08-23 | 2017-08-08 | Afferent Pharmaceuticals Inc. | Substituted pyrimidines for treatment of a cough selected from chronic pathological cough, sub-acute pathological cough, acute pathological cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough |
EP3865134A1 (en) | 2013-08-23 | 2021-08-18 | Afferent Pharmaceuticals Inc. | Methods of using diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases |
US10206922B2 (en) | 2013-08-23 | 2019-02-19 | Afferent Pharmaceuticals, Inc. | Substituted pyrimidines for treatment of chronic cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough |
US20200108065A1 (en) * | 2014-07-03 | 2020-04-09 | Afferent Pharmaceuticals, Inc. | Methods and compositions for treating diseases and conditions |
EP3981406A1 (en) | 2014-07-03 | 2022-04-13 | Afferent Pharmaceuticals Inc. | Methods and compositions for treating diseases and conditions |
US11260056B2 (en) * | 2015-09-29 | 2022-03-01 | Afferent Pharmaceuticals, Inc. | Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough |
EP4215182A1 (en) | 2015-09-29 | 2023-07-26 | Afferent Pharmaceuticals Inc. | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
Also Published As
Publication number | Publication date |
---|---|
KR20080049802A (ko) | 2008-06-04 |
US20160271131A1 (en) | 2016-09-22 |
IL189499A (en) | 2013-05-30 |
US20210008071A1 (en) | 2021-01-14 |
SI1924264T1 (sl) | 2013-12-31 |
CA2620034A1 (en) | 2007-03-08 |
EP1924264A1 (en) | 2008-05-28 |
JP2009507000A (ja) | 2009-02-19 |
US20120122859A1 (en) | 2012-05-17 |
KR101012926B1 (ko) | 2011-02-09 |
WO2007025925A1 (en) | 2007-03-08 |
EP1924264B1 (en) | 2013-09-18 |
ES2439454T9 (es) | 2014-03-07 |
US20070049609A1 (en) | 2007-03-01 |
CN101300012B (zh) | 2011-09-14 |
AU2006286601B2 (en) | 2012-07-05 |
ES2439454T3 (es) | 2014-01-23 |
CA2620034C (en) | 2013-10-01 |
DK1924264T5 (en) | 2014-03-24 |
AU2006286601A1 (en) | 2007-03-08 |
US20130225570A1 (en) | 2013-08-29 |
PL1924264T3 (pl) | 2014-03-31 |
US20180311240A1 (en) | 2018-11-01 |
CN101300012A (zh) | 2008-11-05 |
MX2008002733A (es) | 2008-03-26 |
EP1924264B9 (en) | 2014-02-19 |
BRPI0615040A2 (pt) | 2011-04-26 |
JP4850914B2 (ja) | 2012-01-11 |
DK1924264T3 (da) | 2013-10-21 |
IL189499A0 (en) | 2008-08-07 |
US8524725B2 (en) | 2013-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8008313B2 (en) | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | |
US20240158356A1 (en) | Diaminopyrimidines as p2x3 and p2x2/3 antagonists | |
Broka et al. | Diaminopyrimidines as P2X3 and P2X2/3 antagonists | |
AU2012200211B2 (en) | Diaminopyrimidines as P2X3 and P2X2/3 antagonists | |
MXPA06009857A (en) | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ROCHE PALO ALTO LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BROKA, CHRIS ALLEN;CARTER, DAVID SCOTT;DILLON, MICHAEL PATRICK;AND OTHERS;SIGNING DATES FROM 20060929 TO 20061017;REEL/FRAME:018464/0010 Owner name: ROCHE PALO ALTO LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BROKA, CHRIS ALLEN;CARTER, DAVID SCOTT;DILLON, MICHAEL PATRICK;AND OTHERS;REEL/FRAME:018464/0010;SIGNING DATES FROM 20060929 TO 20061017 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |